AU2016316202B2 - Molecular constructs for preventing the formation of blood clot and/or treating thrombosis - Google Patents

Molecular constructs for preventing the formation of blood clot and/or treating thrombosis Download PDF

Info

Publication number
AU2016316202B2
AU2016316202B2 AU2016316202A AU2016316202A AU2016316202B2 AU 2016316202 B2 AU2016316202 B2 AU 2016316202B2 AU 2016316202 A AU2016316202 A AU 2016316202A AU 2016316202 A AU2016316202 A AU 2016316202A AU 2016316202 B2 AU2016316202 B2 AU 2016316202B2
Authority
AU
Australia
Prior art keywords
gly
ser
leu
lys
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016316202A
Other versions
AU2016316202A8 (en
AU2016316202A1 (en
Inventor
Tse-Wen Chang
Hsing-Mao CHU
Chun-Yu Lin
Wei-Ting TIAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunwork Inc
Original Assignee
Immunwork Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2016/071184 external-priority patent/WO2016112870A1/en
Application filed by Immunwork Inc filed Critical Immunwork Inc
Publication of AU2016316202A1 publication Critical patent/AU2016316202A1/en
Publication of AU2016316202A8 publication Critical patent/AU2016316202A8/en
Application granted granted Critical
Publication of AU2016316202B2 publication Critical patent/AU2016316202B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.

Description

BACKGROUND OF THE INVENTION [0001] 1. Field of the Invention [0002] The present disclosure relates to the field of pharmaceuticals; more particularly, to multi-functional molecular constructs, e.g., those having targeting and effector elements for delivering the effector (e.g., therapeutic drug) to targeted sites.
[0003] 2. Description of the Related Art [0004] The continual advancement of a broad array of methodologies for screening and selecting monoclonal antibodies (mAbs) for targeted antigens has helped the development of a good number of therapeutic antibodies for many diseases that were regarded as untreatable just a few years ago. According to Therapeutic Antibody Database, approximately 2,800 antibodies have been studied or are being planned for studies in human clinical trials, and approximately 80 antibodies have been approved by governmental drug regulatory agencies for clinical uses. The large amount of data on the therapeutic effects of antibodies has provided information concerning the pharmacological mechanisms how antibodies act as therapeutics.
[0005] One major pharmacologic mechanism for antibodies acting as therapeutics is that, antibodies can neutralize or trap disease-causing mediators, which may be cytokines or immune components present in the blood circulation, interstitial space, or in the lymph nodes. The neutralizing activity inhibits the interaction of the disease-causing mediators with their receptors. It should be noted that fusion proteins of the soluble receptors or the extracellular portions of receptors of cytokines and the Fc portion of IgG, which act by neutralizing the cytokines or immune factors in a similar fashion as neutralizing antibodies, have also been developed as therapeutic agents.
[0006] Several therapeutic antibodies that have been approved for clinical applications or subjected to clinical developments mediate their pharmacologic effects by binding to
WO 2017/036255
PCT/CN2016/090296 receptors, thereby blocking the interaction of the receptors with their ligands. For those antibody drugs, Fc-mediated mechanisms, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-mediated cytolysis (CMC), are not the intended mechanisms for the antibodies.
[0007] Some therapeutic antibodies bind to certain surface antigens on target cells and render Fc-mediated functions and other mechanisms on the target cells. The most important Fc-mediated mechanisms are antibody-dependent cellular cytotoxicity (ADCC) and complement-mediated cytolysis (CMC), which both will cause the lysis of the antibody-bound target cells. Some antibodies binding to certain cell surface antigens can induce apoptosis of the bound target cells.
[0008] The concept and methodology for preparing antibodies with dual specificities germinated more than three decades ago. In recent year, the advancement in recombinant antibody engineering methodologies and the drive to develop improved medicine has stimulated the development bi-specific antibodies adopting a large variety of structural configurations.
[0009] For example, the bi-valent or multivalent antibodies may contain two or more antigen-binding sites. A number of methods have been reported for preparing multivalent antibodies by covalently linking three or four Fab fragments via a connecting structure. For example, antibodies have been engineered to express tandem three or four Fab repeats.
[0010] Several methods for producing multivalent antibodies by employing synthetic crosslinkers to associate, chemically, different antibodies or binding fragments have been disclosed. One approach involves chemically cross-linking three, four, and more separately Fab fragments using different linkers. Another method to produce a construct with multiple Fabs that are assembled to one-dimensional DNA scaffold was provided. Those various multivalent Ab constructs designed for binding to target molecules differ among one another in size, half-lives, flexibility in conformation, and ability to modulate the immune system. In view of the foregoing, several reports have been made for preparing molecular constructs with a fixed number of effector elements or with two or more different kinds of functional elements (e.g., at least one targeting element and at least one effector element). However, it is often difficult to build a molecular construct with a particular
WO 2017/036255
PCT/CN2016/090296 combination of the targeting and effector elements either using chemical synthesis or recombinant technology. Accordingly, there exists a need in the related art to provide novel molecular platforms to build a more versatile molecule suitable for covering applications in a wide range of diseases.
SUMMARY [0011] < I > Peptide Core-Based Multi-Arm Linkers [0012] in the first aspect, the present disclosure is directed to a I inker unit that has at least two different functional elements linked thereto. For example, the linker unit may have linked thereto two different effector elements, one targeting element and one effector element, or one effector element and a polyethylene glycol (PEG) chain for prolonging the circulation time of the linker unit. The present linker unit is designed to have at least two different functional groups such that the functional elements can be linked thereto by reacting with the respective functional groups. Accordingly, the present linker unit can serve as a platform for preparing a molecular construct with two or more functional elements.
[0013] According to various embodiments of the present disclosure, the linker unit comprises a center core and a plurality of linking arms. The center core is a polypeptide core comprising (1) a plurality of lysine (K) resides, in which each K residue and a next K residue are separated by a filler sequence comprising glycine (G) and serine (S) residues, and the number of K residues ranges from 2 to 15; or (2) the sequence of (Xaa-K)n, where Xaa is a PEGylated amino acid having 2 to 12 repeats of ethylene glycol (EG) unit, and n is an integral from 2 to 15. Optionally, the filler sequence consists of 2 to 20 amino acid residues. In various embodiments, the filler sequence may have the sequence of GS, GGS, GSG, or SEQ ID NOs: 1-16. According to some embodiments of the present disclosure, the center core comprises 2-15 units of the sequence of G1.5SK; preferably, the center core comprises the sequence of (GSK)2-15. Each of the linking arms is linked to the K residues of the center core via forming an amide linkage between the K residue and the linking arm. The linking arm linked to the center core has a maleimide, an N-hydroxysuccinimidyl (NHS) group, an azide group, an alkyne group, a tetrazine group, a cyclooctene group, or a cyclooctyne group at its free-terminus. Also, the amino acid
WO 2017/036255
PCT/CN2016/090296 residue at the N- or C-terminus of the center core has an azide group or an alkyne group;
alternatively or additionally, the amino acid residue at the N- or C-terminus of the center core is a cysteine (C) residue, in which the thiol group of the amino acid residue is linked with a coupling arm having an azide group, an alkyne group, a tetrazine group, a cyclooctene group, or a cyclooctyne group at the free terminus of the coupling arm.
[0014] According to various embodiments of the present disclosure, the linker unit further comprises a plurality of first elements. In some embodiments, each of the first elements is linked to one of the linking arms via forming an amide bound between the linking arm and the first element. In other embodiments, each of the first elements is linked to one of the linking arms via thiol-maleimide reaction, copper catalyzed azide-alkyne cycloaddition (CuAAC) reaction, strained-promoted azide-alkyne click chemistry (SPAAC) reaction, or inverse electron demand Diels-Alder (iEDDA) reaction occurred between the linking arm and the first element.
[0015] According to some embodiments of the present disclosure, when the plurality of first elements are respectively linked to the plurality of linking arms via CuAAC or SPAAC reaction, then the amino acid residue at the N- or C-terminus of the center core is a cysteine residue, and the free terminus of the coupling arm is the tetrazine or the cyclooctene group. According to other embodiments of the present disclosure, when the plurality of first elements are respectively linked to the plurality of linking arms via iEDDA reaction, then the amino acid residue at the N- or C-terminus of the center core has the azide or the alkyne group, or the amino acid residue at the N- or C-terminus of the center core is a cysteine residue, and the free terminus of the coupling arm is the azide, the alkyne, or the cyclooctyne group.
[0016] In some embodiments, the linking arm is a PEG chain, preferably having 2 to 20 repeats of EG units. In other embodiments, the coupling linking arm is a PEG chain, preferably having 2 to 12 repeats of EG units.
[0017] Regarding amino acid residues having the azide group, non-limiting examples of said amino acid residues include L-azidohomoalanine (AHA), 4-azido-L-phenylalanine,
4-azido-D-phenylalanine, 3-azido-L-alanine, 3-azido-D-aianine, 4-azido-L-homoalanine, 4-azido-D-homoaianine, 5-azido-L-ornithine, 5-azido-d-ornithine, 6-azido-L-lysine, and
WO 2017/036255
PCT/CN2016/090296
6-azido-D-lysine. As to the amino acid residues having the alkyne group, illustrative examples thereof include L-homopropargylglycine (L-HPG), D-homopropargylglycine (D-HPG), and beta-homopropargylglycine (β-HPG).
[0018] When the amino acid residues at the N- or C-terminus of the center core is the cysteine residue, the cyclooctene group at the free terminus of the coupling arm may be, a trans-cyclooctene (TOO) group, while the cyclooctyne group at the free terminus of the coupling arm may be a dibenzocyclooctyne (DBCO), difluorinated cyclooctyne (DIFO), bicyclononyne (BON), or dibenzocyclooctyne (DICO) group. Alternatively, the tetrazine group at the free terminus of the coupling arm includes, but is not limited to, 1,2,3,4-tetrazine, 1,2,3,5-tetrazine, and 1,2,4,5-tetrazine, and derivatives thereof, such as, 6-methyl tetrazine.
[0019] According to various optional embodiments of the present disclosure, the first element is an effector element suitable for eliciting an intended effect (e.g., a therapeutic effect) in a subject. Alternatively, the first element may be a targeting element for directing the linker unit to the site of interest. According to the embodiments of the present disclosure, the first element is a single-chain variable fragment (scFv) specific for fibrin.
[0020] Optionally, the linker unit further comprises a second element that is different from the first elements. In some embodiments, the second element has an azide or alkyne group, so that it is linked to the center core or the coupling arm by coupling with the corresponding alkyne or azide group of the center core or the coupling arm via CuAAC reaction. Alternatively, in some embodiments, the second element having an azide or cyclooctyne group is linked to the center core or the coupling arm by coupling with the corresponding cyclooctyne or azide group of the center core or the coupling arm via SPAAC reaction. Still alternatively, in certain embodiments, the second element having a tetrazine or cyclooctene group is linked to the center core or the coupling arm by coupling with the corresponding cyclooctene or tetrazine group of the center core or the coupling arm via iEDDA reaction. According to the embodiments of the present disclosure, the second element is a tissue plasminogen activator or an inhibitor of Factor Xa or thrombin. Non-limiting examples of the tissue plasminogen activators include, alteplase, reteplase, tenecteplase, and lanoteplase. The inhibitor of Factor Xa is selected from the group
WO 2017/036255
PCT/CN2016/090296 consisting of, apixaban, edoxaban, and rivaroxaban. The inhibitor of thrombin can be argatroban or melagatran.
[0021] in certain embodiments, the linker unit further comprises an optional third element that is different from the first and second elements. In the case where the second element is directly linked to the center core, the other terminus (i.e., the free terminus that is not linked with the second element) of the center core is optionally a cysteine residue, which can be used to introduce an optional third element. Specifically, the thiol group of the cysteine residue is reacted with a maleimide group of a PEG chain; and the thus-linked PEG chain is designated as the coupling arm, which has a tetrazine group or a cyclooctene group at its free terminus. Accordingly, the third element is then linked to the coupling arm via iEDDA reaction. Preferably, the third element is an element for improving the pharmacokinetic property of the linker unit. One example of the element for improving the pharmacokinetic property is a long PEG chain having a molecular weight of about 20,000 to 50,000 Daltons.
[0022] < II > Uses of Peptide Core-Based Multi-Arm Linkers [0023] The linker unit according to the first aspect of the present disclosure may find its utility in clinical medicine for the treatment of various diseases. Hence, the second aspect of the present disclosure is directed to a method for treating these diseases. According to various embodiments of the present disclosure, the method for treating a particular disease includes the step of administering to the subject in need thereof a therapeutically effective amount of the linker unit according to the above-mentioned aspect and embodiments of the present disclosure. As could be appreciated, said linker unit may be administered in a pharmaceutical formulation, which comprises a pharmaceutically-acceptable excipient suitable for the intended or desired administration route, in addition to the present linker unit.
[0024] According to some embodiments of the present disclosure, the present linker unit is useful in preventing the formation of blood clot. In these embodiments, the first element is an scFv specific for fibrin, and the second element is the inhibitor of Factor Xa or thrombin. The inhibitor of Factor Xa is selected from the group consisting of, apixaban, edoxaban, and rivaroxaban. The inhibitor of thrombin can be argatroban or melagatran.
WO 2017/036255
PCT/CN2016/090296 [0025] According to other embodiments of the present disclosure, the linker units suitable for treating thrombosis comprise an scFv specific for fibrin as the first element, and a tissue plasminogen activator as the second element. Non-limiting examples of the tissue plasminogen activators include, alteplase, reteplase, tenecteplase, and lanoteplase.
[0026] < III > Molecular Constructs with Targeting and Effector Moieties [0027] in the third aspect, the present disciosure is directed to a molecular construct comprising two linker units coupling to each other either directly or indirectly, in which the core of one linker unit is configured to be linked with at least one targeting element while the core of the other linker unit is configured to be linked with at least one effector element. The present molecular construct is advantageous in that the two linker units are coupled to each other via an IEDDA reaction, a SPAAC reaction, or a CuAAC reaction. This design allows for a facile synthesis of a molecular construct with a complex structure. According to the principles and spirits of the present disclosure, the two linker units respectively carrying different numbers and/or types of functional elements can be independently prepared, and then conjugated together. In this way, it becomes feasible for a skilled artisan to construct libraries of molecular constructs respectively carrying different functional elements, and then select and combine two molecular constructs (or linker units) from the libraries to generate a desired constructs, depending on the needs and/or intended applications. Moreover, the number of functional elements per linker unit may be controlled by adjusting the number of specific functional group(s) of the core.
[0028] According to one embodiment of the present disclosure, the molecular construct comprises a first linker unit and a second linker unit. Specifically, the first linker unit comprises (1) a first center core, (2) one or more linking arms (hereinafter, the first linking arms) linked to the first center core, (3) one or more elements (hereinafter, the first elements) linked to the first linking arm(s), and (4) optionally a coupling arm (hereinafter, the first coupling arm) linked to the first center core; the second linker unit comprises (1) a second center core, (2) one or more linking arms (hereinafter, the second linking arms) linked to the second center core, (3) one or more elements (hereinafter, the second elements) linked to the second linking arm(s), and (4) optionally a coupling arm (hereinafter, the second coupling arm) linked to the second center core. The first and second linker units are
WO 2017/036255
PCT/CN2016/090296 coupled to each other via iEDDA, SPAAC, or CuAAC reaction occurred between any of the followings: the first and second center cores, the first coupling arm and the second center core, the first and second coupling arms, or the first center core and the second coupling arm.
[0029] According to the embodiments of the present disclosure, both the first and second center cores have a plurality of amine groups. Each of the linking arms is linked to the center core via forming an amide bond therebetween, for example, between the N-hydroxysuccinimidyl (NHS) group and the amine group. After being linked to the center core, the linking arm thus has an NHS, a maleimide, an azide, an alkyne, a tetrazine, a cyclooctene, or a cyclooctyne group at the free terminus thereof.
[0030] In the presence of the NHS group, the first element and the second element are respectively linked to the first and second linking arms via forming an amide bond between the element (i.e., the first element and the second element) and the linking arm (i.e., the first linking arm or the second linking arm). In the case where the linking arm has a maleimide, an azide, an alkyne, a tetrazine, a cyclooctene, or a cyclooctyne group at its free terminus, the first element and the second element are respectively linked to the first and second linking arms via the thiol-maleimide, CuAAC, iEDDA, or SPAAC reaction occurred between the element (i.e., the first element and the second element) and the linking arm (i.e., the first linking arm or the second linking arm).
[0031] According to some embodiments of the present disclosure, each of the linking arms is a PEG chain having 2-20 repeats of EG units. According to other embodiments of the present disclosure, each of the coupling arms is a PEG chain having 2-12 repeats of EG units.
[0032] According to various embodiments of the present disclosure, each of the first and second center cores may be a compound core or a polypeptide core. In some examples, both the first and second center cores are compounds cores of the same or different compound(s). in certain preferred embodiments, both the first and second center cores are polypeptide cores having the same or different sequence(s). Alternatively, one of the two cores is a compound core, while the other is a polypeptide core.
WO 2017/036255
PCT/CN2016/090296 [0033] Non-limiting examples of the compound suitable for use as the present compound core include, benzene-1,3,5-triamine, 2-(aminomethyl)-2-methylpropane-1,3-diamine, tris(2-aminoethyl)-amine, benzene-1,2,4,5-tetraamine, 3,3',5,5’-tetraamine-1,1 ’-biphenyl, tetrakis-(2-aminoethyl)methane, tetrakis(ethylamine)-hydrazine, Ν,Ν,Ν',Ν’,-tetrakis(aminoethyl)-ethylenediamine, benzene-1,2,3,4,5,6-hexaamine, 1-N,1-N,3-N,3-N,5-N,5-Nhexakis-(methylamine)-benzene-1,3,5-triamine, 1 -N, 1 -N,2-N,2-N,4-N,4-N,5-N,5-N-octakis(methylamine)-benzene-l ,2,4,5-triamine, and N, N-bis[(1 -amino-3,3-diaminoethyl)pentyljmethane-diamine.
[0034] In the case where the center core is a compound core, the coupling arm is linked to one of the plurality of amine groups of the center core by forming an amide bond between the coupling arm and the center core. Meanwhile, the free terminus of the coupling arm has an azide, an alkyne, a cyclooctene, a cyclooctyne, or a tetrazine group.
[0035] According to some embodiments of the present disclosure, the polypeptide suitable for use as the present polypeptide core comprises a plurality of lysine (K) residues; optionally, 2 to 15 K residues. Also, each K residue and the next K residue are separated by a filler sequence comprising glycine (G) and serine (S) residues; optionally, the filler sequence consists of 2 to 20 amino acid residues. In various embodiments, the filler sequence may have the sequence of GS, GGS, GSG, or SEQ ID NOs: 1-16. In some embodiments, the polypeptide comprises 2-15 units of the sequence of Gi_5SK, for example, (GSK)2-15. Alternatively, the polypeptide core may comprise the sequence of (Xaa-K)n, where Xaa is a PEGylated amino acid having 2 to 12 repeats of ethylene glycol (EG) unit, and n is an integral from 2 to 15.
[0036] In the case where the center core is a polypeptide core, it may comprise a cysteine residue at its N- or C-terminus. In these instances, the coupling arm is linked to the cysteine residue of the center core via the thiol-maleimide reaction. The coupling arm linked to the cysteine residue has an azide, an alkyne, a cyclooctene, a cyclooctyne, or a tetrazine group at the free-terminus thereof.
[0037] The first and second linker units may be coupled via various configurations, which are described in detail below, depending on the presence or absence of the first and second coupling arms. For a linker unit having a compound core, it is preferable that it is linked
WO 2017/036255
PCT/CN2016/090296 with another linker unit via a coupling arm (i.e., the first or second coupling arm), while for a linker unit having a polypeptide core, the need for a coupling arm becomes optional.
[0038] When the first and second linker units respectively comprise the coupling arms, then one of the coupling arms (say, for example, the first coupling arm) has a tetrazine group at the free-terminus thereof, and the other coupling arm (in this case, the second coupling arm) has a cyclooctene group at the free-terminus thereof, such that the two linker units are coupled via the iEDDA reaction occurred between the two coupling arms (i.e., the first and second coupling arms). Preferably, the tetrazine group is 1,2,3,4-tetrazine, 1,2,3,5-tetrazine, and 1,2,4,5-tetrazine, or derivatives thereof, such as, 6-methyl tetrazine; and the cyclooctene group Is TCO. The same rule also applies in the case where the free termini of both coupling arms respectively have an azide group and an alkyne group; in this instance, the two linker units are coupled via the CuAAC reaction occurred between the two coupling arms (I.e., the first and second coupling arms). Alternatively, one of the coupling arms (for example, the first coupling arm) has an azide group, and the other coupling arm (in this case, the second coupling arm) has a cyclooctyne group (preferably, DBCO, DIFO, BCN, or DICO); accordingly, the two coupling arm can be coupled via the SPAAC reaction. These configurations may occur between two linker units, where both units have either compound cores or polypeptide cores, as well as in situations where one linker unit has a compound core, while the other has a polypeptide core.
[0039] When only one linker unit has the coupling arm (as an example, the first linker unit with the first coupling arm), the center core of the other linker unit (for example, the second center core) is a polypeptide core. In this case, the first amino acid residue at the N- or C-terminus of one of the second center core is an amino acid residue having an azide group or an alkyne group. In some embodiments, the amino acid residue having the azide or alkyne group would undergo CuAAC reaction with the corresponding alkyne or azide group of the first coupling arm of the first linker unit, thereby coupling the first and second linker units. Alternatively, the first amino acid residue at the N- or C-terminus of one of the second center core is an amino acid residue having an azide group, which can be linked to the coupling arm of the first linker unit having a cyclooctyne group (preferably, DBCO, DIFO, BCN, or DICO) at the free-terminus via the SPAAC reaction. This configuration may occur io
WO 2017/036255
PCT/CN2016/090296 between two linker units, where both units have polypeptide cores, or in situations where one linker unit has a compound core, while the other has a polypeptide core.
[0040] It is also possible that the first and second linker units are coupled without the presence of any coupling arms (that is, the first and second coupling arms). In other words, the first and second coupling arms are directly linked with each other. This configuration mostly occurs between two polypeptide cores. Specifically, one of the two center cores (say, for example, the first center core) has an amino acid residue having an azide group at the N- or C-terminus thereof, while the other center core (such as the second center core) has an amino acid residue having an alkyne group at the N- or C-terminus thereof. In this way, the azide group of the first center core reacts with the alkyne group of the second center core, thereby coupling the first and second linker units.
[0041] Non-limiting examples of amino acid residues having the azide group include, L-azidohomoalanine (AHA), 4-azido-L-phenylalanine, 4-azido-D-phenylalanine, 3-azido-L-alanine, 3-azido-D-alanine, 4-azido-L-homoalanine, 4-azido-D-homoalanine,
5-azido-L-ornithine, 5-azido-d-ornithine, 6-azido-L-lysine, and 6-azido-D-lysine. Illustrative examples of amino acid residues having the alkyne group include, but are not limited to, L-homopropargylglycine (L-HPG), D-homopropargylglycine (D-HPG), and beta-homopropargylglycine (β-HPG).
[0042] According to some embodiments of the present disclosure, one of the first and second linker units of the molecular construct further comprises an additional linking arm (hereinafter, the third linking arm) linked to the first or the second linker unit.
[0043] Like the first and second linking arms, the third linking arm is configured to be linked with an element either via forming an amide bond therebetween, or via the thiol— maleimide, CuAAC, iEDDA, or SPAAC reaction. In some embodiments, the additional element is a second targeting element or a second effector element, which Is used to enhance the targeting or therapeutic effect of the present molecular construct. Alternatively, a long PEG chain having a molecular weight of about 20,000 to 50,000 Daltons can be used us the additional element so as to enhance the stability of the present molecular construct.
WO 2017/036255
PCT/CN2016/090296 [0044] In other embodiments, the present molecular construct further comprises a third linker unit. The third linker unit comprises (1) a third center core, (2) one or more linking arms (hereinafter, the third linking arms) linked to the third center core, (3) one or more elements (hereinafter, the third elements) linked to the third linking arm(s), and (4) optionally a coupling arm (hereinafter, the third coupling arm) linked to the third center core. In this case, the third linker unit is linked to the first or the second linker unit via CuAAC reaction, iEDDA reaction, or SPAAC reaction occurred between any of the followings: the first or the second coupling arm and the third coupling arm, the first or the second center core and the third coupling arm, the first or the second center coupling arm and the third center core, or the first or the second center core and the third center core.
[0045] Regarding the third linking arm of the third linker unit, it may have an NHS, a maleimide, an azide, an alkyne, a cyclooctene, a cyclooctyne, or a tetrazine group at the free terminus thereof. Accordingly, the third linking arm may be directly linked to the third element either via forming an amide bond therebetween, or via the thiol-maleimide, CuAAC, iEDDA, or SPAAC reaction.
[0046] According to various embodiments of the present disclosure, the first, second, and optionally, the third center core may be the same or different.
[0047] < IV > Uses of Molecular Constructs with Targeting and Effector Moieties [0048] The molecular construct according to the third aspect of the present disclosure may find its utility In clinical medicine for the treatment of diseases. Hence, the fourth aspect of the present disclosure is directed to a method for treating diseases. According to various embodiments of the present disclosure, the method for treating a particular disease includes the step of administering to the subject in need thereof a molecular construct according to the third aspect of the present disclosure and embodiments thereof in a therapeutically effective amount. As could be appreciated, said molecular construct may be administered in a pharmaceutical formulation, which comprises a pharmaceutically-acceptable excipient suitable for the intended or desired administration route, in addition to the present molecular construct.
[0049] Various illustrative combinations of the first and second elements of the present
WO 2017/036255
PCT/CN2016/090296 molecular construct for treating some particular diseases are disclosed below for facilitating the understanding of some embodiments of the present disclosure.
[0050] According to some embodiments of the present disclosure, the present linker unit is useful in preventing the formation of blood clot. In these embodiments, the first element is an scFv specific for fibrin, and the second element is the inhibitor of Factor Xa or thrombin. The inhibitor of Factor Xa is selected from the group consisting of, apixaban, edoxaban, and rivaroxaban. The inhibitor of thrombin can be argatroban or melagatran.
[0051] According to other embodiments of the present disclosure, the linker units suitable for treating thrombosis comprise an scFv specific for fibrin as the first element, and a tissue plasminogen activator as the second element. Non-limiting examples of the tissue plasminogen activators include, alteplase, reteplase, tenecteplase, and lanoteplase.
[0052] < V > Fc-based Molecular Construct for Preventing the Formation of Blood
Clot and Treating Thrombosis and Uses thereof [0053] In the fifth aspect, the present disclosure is directed to a fragment crystailizable (Fc)-based molecular construct that has at least one targeting element and at least one effector element linked, directly or indirectly, to a CH2-CH3 domain of an immunoglobulin. Targeting and effector elements of the present Fc-based molecular constructs are specifically selected such that these Fc-based molecular constructs are suitable for use in the formation of blood clots and the treatment of thrombosis, or for use in the manufacture of a medicament for such uses. As could be appreciated, methods for preventing the formation of blood clots and for treating thrombosis using such Fc-based molecular constructs also fall within the aspect of the present disclosure.
[0054] According to certain embodiments of the present disclosure, the Fc-based molecular construct comprises a pair of CH2-CH3 segments of an IgG.Fc, a pair of effector elements, and a pair of targeting elements. The pair of effector element is a tissue plasminogen activator or a drug bundle comprising a plurality of molecules of an inhibitor of Factor Xa or an inhibitor of thrombin, while the pair targeting elements is an antibody fragment specific for fibrin.
WO 2017/036255
PCT/CN2016/090296 [0055] In the case where the effector element is the tissue plasminogen activator (e.g., alteplase, reteplase, tenecteplase, and lanoteplase), then the pair of effector elements is linked to the N-termini of the pair of CH2-CH3 segments, and the pair of targeting elements is linked to the C-termini of the pair of CH2-CH3 segments, or vice versa. Alternatively, when the effector element is a drug bundle, then the pair of effector elements is linked to the C-termini of the pair of CH2-CH3 segments, and the pair of targeting elements is linked to the N-termini of the pair of CH2-CH3 segments.
[0056] In certain embodiments, the pair of CH2-CH3 segments is derived from human IgG heavy chain γ4 or human IgG heavy chain γ1.
[0057] In some examples, the pair of the targeting elements takes a Fab configuration (i.e., consisting of the Vh-CH1 domain and the Vl-Ck domain); this Fab fragment is linked to the N-termini of the first and second heavy chains, so that the Fc-based molecular construct adopts an IgG configuration. In these cases, the pair of effector elements is linked to the C-termini of the pair of CH2-CH3 segments.
[0058] According to some optional embodiments, the effector elements are drug bundles based on linker units. Such drug bundles are advantageous at least in that they can be manufactured separately before being conjugated to the antibody molecules, thus avoiding subjecting drug molecules under harsh chemical conditions for the direct conjugation with the antibody molecules. According to various embodiments of the present disclosure, the drug bundle comprises a plurality of inhibitors associated with blood clotting, such as Factor Xa inhibitors (e.g., apixaban, edoxaban, and rivaroxaban) and thrombin inhibitors (e.g., argatroban and melagatran). As an example, rather than a limitation, these Fc-based molecular constructs are useful in the prevention of blood clotting.
[0059] According to certain embodiments, the present Fc-based molecular construct further comprises a peptide extension and a coupling arm. Specifically, the peptide extension has the sequence of (G2-4S)2-8C and is linked to the C-terminus of one of the pair of CH2-CH3 segments. In such cases, the coupling arm is linked to the C-terminus of the peptide extension via thiol-maleimide reaction occurred therebetween. Also, before being conjugated with the drug bundle, the free terminus of the coupling arm (that is, the terminus that is not linked to the cysteine residue) is modified with an alkyne, azide, strained alkyne,
WO 2017/036255
PCT/CN2016/090296 or tetrazine group, so that the drug bundle is linked thereto via inverse electron demand
Diels-Alder (iEDDA) reaction or the strain-promoted azide-alkyne click chemistry (SPAAC) reaction or Copper(l)-catalyzed alkyne-azide cycloaddition (CuAAC) reaction occurred therebetween.
[0060] According to some optional embodiments, the drug bundle comprises a center core and a plurality of linking arms. The center core may be a compound having a plurality of amine groups or a polypeptide comprising a plurality of lysine (K) residues, according to various embodiments of the present disclosure. Each of the linking arms has one terminus that is linked to the center core by reacting with the amine groups of the compound core or the K residues of the polypeptide core. The linking arm also carries a maleimide group at the free terminus thereof, wherein each of the molecules (e.g., molecules of inhibitors associated with blood clotting) is linked to the center core through the linking arm by reacting with the maleimide group.
[0061] In the case where the center core is the polypeptide core, then the amino acid residue at the N- or C-terminus of the center core is a cysteine residue or has an azide group or an alkyne group.
[0062] For polypeptide cores with a terminal amino acid residue having the azide group or the alkyne group, the drug bundle may be linked to the peptide extension via the CuAAC reaction occurred between said terminal residue and the C-terminus of the peptide extension.
[0063] Methods for preventing blood clot formation and/or treating thrombosis in a subject in need thereof comprise the step of administering to the subject an effective amount of the molecular construct of this aspect.
BRIEF DESCRIPTION OF THE DRAWINGS [0064] The present description will be better understood from the following detailed description read in light of the accompanying drawings briefly discussed below.
[0065] Figure 1A to Figure 1K are schematic diagrams illustrating linker units according to certain embodiments of the present disclosure.
WO 2017/036255
PCT/CN2016/090296 [0066] Figure 2 is a schematic diagram illustrating a linker unit having a compound core.
[0067] Figure 3A to Figure 3D are schematic diagrams illustrating T-E molecular constructs according to some embodiments of the present disclosure.
[0068] Figure 4 is a schematic diagram that illustrates libraries for constructing molecular constructs according to some embodiments of the present disclosure.
[0069] Figure 5A and Figure 5B are schematic diagrams that illustrate molecular constructs according to some embodiments of the present disclosure.
[0070] Figure 6 is a schematic diagram that illustrates a molecular construct according to some embodiments of the present disclosure.
[0071] Figure 7A and Figure 7B are schematic diagrams illustrating molecular constructs according to various embodiments of the present disclosure.
[0072] Figures 8A to 8C are schematic diagrams illustrating Fc-based molecular constructs according to various embodiments of the present disclosure.
[0073] Figures 9A and 9B are schematic diagrams illustrating Fc-based molecular constructs according to various embodiments of the present disclosure.
[0074] Figure 10 shows the mass spectrometry MALDI-TOF result of a peptide core-based linker-unit carrying one linking arm with TCO group and five PEG6 linking arms with maleimide groups, according to one working example of the present disclosure.
[0075] Figure 11 shows the mass spectrometry MALDI-TOF result of the apixaban-PEG3-S-S-PEG3-apixaban synthetized according to one working example of the present disclosure.
[0076] Figure 12 shows the mass spectrometry MALDI-TOF result of the argatroban-PEG3-S-S-PEG3-argatroban synthetized according to one working example of the present disclosure.
WO 2017/036255
PCT/CN2016/090296 [77] Figures 13A, 13B, and 13C respectively show the results of SDS-PAGE, MALDI-TOF and ELISA analysis of purified 102-10 scFv specific for human fibrin, according to one working example of the present disclosure.
[78] Figure 14A and Figure 14B respectively show the results of phage titer analysis and single colony ELISA analysis of phage-displayed scFvs specific for human fibrin, according to one working example of the present disclosure.
[79] Figure 15A and Figure 15B respectively show the results of SDS-PAGE and MALDI-TOF analysis of purified reteplase, according to one working example of the present disclosure.
[80] Figure 16 shows the result of mass spectrometric analysis of TCO-conjugated reteplase, according to one working example of the present disclosure.
[81] Figure 17 shows the result of SDS-PAGE analysis of a targeting linker-unit with one free tetrazine functional group and a set of three scFvs specific for human fibrin, according to one working example of the present disclosure.
[82] Figure 18 shows the MS result on a single linker-unit molecular construct with three scFvs specific for human fibrin (as targeting elements) and one reteplase molecule (as the effector element), according to one working example of the present disclosure.
[83] Figure 19 shows the result of inhibition assay of apixaban-PEG3-SH molecule, according to one working example of the present disclosure.
[84] Figure 20 shows the result of SDS-PAGE analysis of purified recombinant 2-chain (reteplase)-hlgG4.Fc fusion protein, according to one working example of the present disclosure.
[85] Figure 21 shows the result of SDS-PAGE analysis of purified recombinant 2-chain (reteplase)-hlgG4.Fc-(scFv a fibrin) fusion protein, according to one working example of the present disclosure.
RECTIFIED SHEET (RULE 91) ISA/CN
WO 2017/036255
PCT/CN2016/090296 [0077] Figures 13A, 13B, and 13C respectively show the results of SDS-PAGE, MALDI-TOF and ELISA analysis of purified 102-10 scFv specific for human fibrin, according to one working example of the present disclosure.
[0078] Figure 14A and Figure 14B respectively show the results of phage titer analysis and single colony ELISA analysis of phage-displayed scFvs specific for human fibrin, according to one working example of the present disclosure.
[0079] Figure 15A and Figure 15B respectively show the results of SDS-PAGE and MALDI-TOF analysis of purified reteplase, according to one working example of the present disclosure.
[0080] Figure 16 shows the result of mass spectrometric analysis of TCO-conjugated reteplase, according to one working example of the present disclosure.
[0081] Figure 17A and Figure 17B respectively show the results of SDS-PAGE analysis and mass spectrometric analysis of a targeting linker-unit with one free tetrazine functional group and a set of three scFvs specific for human fibrin, according to one working example of the present disclosure.
[0082] Figure 18 shows the MS result on a single linker-unit molecular construct with three scFvs specific for human fibrin (as targeting elements) and one reteplase molecule (as the effector element), according to one working example of the present disclosure.
[0083] Figure 19 shows the result of inhibition assay of apixaban-PEG3-SH molecule, according to one working example of the present disclosure.
[0084] Figure 20 shows the result of SDS-PAGE analysis of purified recombinant 2-chain (reteplase)-hlgG4.Fc fusion protein, according to one working example of the present disclosure.
[0085] Figure 21 shows the result of SDS-PAGE analysis of purified recombinant 2-chain (reteplase)-hlgG4.Fc-(scFv a fibrin) fusion protein, according to one working example of the present disclosure.
WO 2017/036255
PCT/CN2016/090296 [0086] Figure 22 shows the result of SDS-PAGE analysis of purified recombinant 2-chain (reteplase)-(scFv a fibrin) fusion protein, according to one working example of the present disclosure.
[0087] Figure 23 shows the result of SDS-PAGE analysis of purified recombinant 2-chain (TNK-tPA)-lgG4.Fc fusion protein, according to one working example of the present disclosure.
[0088] Figure 24 shows the assay results of protease activity of recombinant 2-chain (reteplase)-hlgG4.Fc, 2-chain (reteplase)-hlgG4.Fc-(scFv a fibrin) and (reteplase)-(scFv a fibrin), according to one working example of the present disclosure.
[0089] In accordance with common practice, the various described features/elements are not drawn to scale but instead are drawn to best illustrate specific features/elements relevant to the present invention. Also, like reference numerals and designations in the various drawings are used to indicate like elements/parts, where possible.
DESCRIPTION [0090] The detailed description provided below in connection with the appended drawings is intended as a description of the present examples and is not intended to represent the only forms in which the present example may be constructed or utilized. The description sets forth the functions of the example and the sequence of steps for constructing and operating the example. However, the same or equivalent functions and sequences may be accomplished by different examples.
[0091] For convenience, certain terms employed in the specification, examples and appended claims are collected here. Unless otherwise defined herein, scientific and technical terminologies employed in the present disclosure shall have the meanings that are commonly understood and used by one of ordinary skill in the art.
[0092] Unless otherwise required by context, it will be understood that singular terms shall include plural forms of the same and plural terms shall include the singular. Specifically, as used herein and in the claims, the singular forms “a” and “an” include the plural reference unless the context clearly indicated otherwise. Also, as used herein and in the claims, the
WO 2017/036255
PCT/CN2016/090296 terms “at least one” and “one or more” have the same meaning and include one, two, three, or more. Furthermore, the phrases “at least one of A, B, and C”, “at least one of A, B, or C” and “at least one of A, B and/or C,” as use throughout this specification and the appended claims, are intended to cover A alone, B alone, C alone, A and B together, B and C together,
A and C together, as well as A, B, and C together.
[0093] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in the respective testing measurements. Also, as used herein, the term “about” generally means within 10%, 5%, 1%, or 0.5% of a given value or range. Alternatively, the term “about” means within an acceptable standard error of the mean when considered by one of ordinary skill in the art. Other than in the operating/working examples, or unless otherwise expressly specified, all of the numerical ranges, amounts, values and percentages such as those for quantities of materials, durations of times, temperatures, operating conditions, ratios of amounts, and the likes thereof disclosed herein should be understood as modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the present disclosure and attached claims are approximations that can vary as desired. At the very least, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Ranges can be expressed herein as from one endpoint to another endpoint or between two endpoints. All ranges disclosed herein are inclusive of the endpoints, unless specified otherwise.
[0094] This present disclosure pertains generally to molecular constructs, in which each molecular construct comprises a targeting element (T) and an effector element (E), and these molecular constructs are sometimes referred to as “T-E molecules”, “T-E pharmaceuticals” or “T-E drugs” in this document.
[0095] As used herein, the term “targeting element” refers to the portion of a molecular construct that directly or indirectly binds to a target of interest (e.g., a receptor on a cell surface or a protein in a tissue) thereby facilitates the transportation of the present
WO 2017/036255
PCT/CN2016/090296 molecular construct into the interested target. In some example, the targeting element may direct the molecular construct to the proximity of the target cell. In other cases, the targeting element specifically binds to a molecule present on the target cell surface or to a second molecule that specifically binds a molecule present on the cell surface. In some cases, the targeting element may be internalized along with the present molecular construct once it is bound to the interested target, hence is relocated into the cytosol of the target cell. A targeting element may be an antibody or a ligand for a cell surface receptor, or it may be a molecule that binds such antibody or ligand, thereby indirectly targeting the present molecular construct to the target site (e.g., the surface of the cell of choice). The localization of the effector (therapeutic agent) in the diseased site will be enhanced or favored with the present molecular constructs as compared to the therapeutic without a targeting function. The localization is a matter of degree or relative proportion; it is not meant for absolute or total localization of the effector to the diseased site.
[0096] According to the present invention, the term “effector element” refers to the portion of a molecular construct that elicits a biological activity (e.g., inducing immune responses, exerting cytotoxic effects and the like) or other functional activity (e.g., recruiting other hapten tagged therapeutic molecules), once the molecular construct is directed to its target site. The “effect” can be therapeutic or diagnostic. The effector elements encompass those that bind to cells and/or extracellular immunoregulatory factors. The effector element comprises agents such as proteins, nucleic acids, lipids, carbohydrates, glycopeptides, drug moieties (both small molecule drug and biologies), compounds, elements, and isotopes, and fragments thereof.
[0097] Although the terms, first, second, third, etc., may be used herein to describe various elements, components, regions, and/or sections, these elements (as well as components, regions, and/or sections) are not to be limited by these terms. Also, the use of such ordinal numbers does not imply a sequence or order unless clearly indicated by the context. Rather, these terms are simply used to distinguish one element from another. Thus, a first element, discussed below, could be termed a second element without departing from the teachings of the exemplary embodiments.
WO 2017/036255
PCT/CN2016/090296 [0098] Here, the terms “link,” “couple,” and “conjugates” are used interchangeably to refer to any means of connecting two components either via direct linkage or via indirect linkage between two components.
[0099] The term “polypeptide” as used herein refers to a polymer having at least two amino acid residues. Typically, the polypeptide comprises amino acid residues ranging in length from 2 to about 200 residues; preferably, 2 to 50 residues. Where an amino acid sequence is provided herein, L-, D-, or beta amino acid versions of the sequence are also contemplated. Polypeptides also include amino acid polymers in which one or more amino acid residues are an artificial chemical analogue of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers. In addition, the term applies to amino acids joined by a peptide linkage or by other, “modified linkages,” e.g., where the peptide bond is replaced by an α-ester, a β-ester, a thioamide, phosphoramide, carbomate, hydroxylate, and the like.
[0100] In certain embodiments, conservative substitutions of the amino acids comprising any of the sequences described herein are contemplated. In various embodiments, one, two, three, four, or five different residues are substituted. The term “conservative substitution” is used to reflect amino acid substitutions that do not substantially alter the activity (e.g., biological or functional activity and/or specificity) of the molecule. Typically, conservative amino acid substitutions involve substitution one amino acid for another amino acid with similar chemical properties (e.g., charge or hydrophobicity). Certain conservative substitutions include “analog substitutions” where a standard amino acid is replaced by a non-standard (e.g., rare, synthetic, etc.) amino acid differing minimally from the parental residue. Amino acid analogs are considered to be derived synthetically from the standard amino acids without sufficient change to the structure of the parent, are isomers, or are metabolite precursors.
[0101] In certain embodiments, polypeptides comprising at least 80%, preferably at least 85% or 90%, and more preferably at least 95% or 98% sequence identity with any of the sequences described herein are also contemplated.
[0102] Percentage (%) amino acid sequence identity with respect to the polypeptide sequences identified herein is defined as the percentage of polypeptide residues in a
WO 2017/036255
PCT/CN2016/090296 candidate sequence that are identical with the amino acid residues in the specific polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percentage sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, sequence comparison between two polypeptide sequences was carried out by computer program Blastp (protein-protein BLAST) provided online by Nation Center for Biotechnology Information (NCBI). The percentage amino acid sequence identity of a given polypeptide sequence A to a given polypeptide sequence B (which can alternatively be phrased as a given polypeptide sequence A that has a certain % amino acid sequence identity to a given polypeptide sequence B) is calculated by the formula as follows:
— xl00%
Y where X is the number of amino acid residues scored as identical matches by the sequence alignment program BLAST in that program's alignment of A and B, and where Y is the total number of amino acid residues in A or B, whichever is shorter.
[0103] The term “PEGylated amino acid” as used herein refers to a polyethylene glycol (PEG) chain with one amino group and one carboxyl group. Generally, the PEGylated amino acid has the formula of ΝΗ2-(0Η20Η20)η-000Η. In the present disclosure, the value of n ranges from 1 to 20; preferably, ranging from 2 to 12.
[0104] As used herein, the term “terminus” with respect to a polypeptide refers to an amino acid residue at the N- or C- end of the polypeptide. With regard to a polymer, the term “terminus” refers to a constitutional unit of the polymer (e.g., the polyethylene glycol of the present disclosure) that is positioned at the end of the polymeric backbone. In the present specification and claims, the term “free terminus” is used to mean the terminal amino acid residue or constitutional unit is not chemically bound to any other molecular.
WO 2017/036255
PCT/CN2016/090296 [0105] The term “antigen” or “Ag” as used herein is defined as a molecule that elicits an immune response. This immune response may involve a secretory, humoral, and/or cellular antigen-specific response. In the present disclosure, the term “antigen” can be any of a protein, a polypeptide (including mutants or biologically active fragments thereof), a polysaccharide, a glycoprotein, a glycolipid, a nucleic acid, or a combination thereof.
[0106] In the present specification and claims, the term “antibody” is used in the broadest sense and covers fully assembled antibodies, antibody fragments that bind with antigens, such as antigen-binding fragment (Fab/Fab’), F(ab’)2 fragment (having two antigen-binding Fab portions linked together by disulfide bonds), variable fragment (Fv), single chain variable fragment (scFv), bi-specific single-chain variable fragment (bi-scFv), nanobodies, unibodies and diabodies. “Antibody fragments” comprise a portion of an intact antibody, preferably the antigen-binding region or variable region of the intact antibody. Typically, an “antibody” refers to a protein consisting of one or more polypeptides substantially encoded by immunoglobulin genes or fragments of immunoglobulin genes. The well-known immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD, and IgE, respectively. Atypical immunoglobulin (antibody) structural unit is known to comprise a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, with each pair having one “light” chain (about 25 kDa) and one “heavy” chain (about 50-70 kDa). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) refer to these light and heavy chains, respectively. According to embodiments of the present disclosure, the antibody fragment can be produced by modifying the nature antibody or by de novo synthesis using recombinant DNA methodologies. In certain embodiments of the present disclosure, the antibody and/or antibody fragment can be bispecific, and can be in various configurations. For example, bispecific antibodies may comprise two different antigen binding sites (variable regions). In various embodiments, bispecific antibodies can be produced by hybridoma technique or
WO 2017/036255
PCT/CN2016/090296 recombinant DNA technique. In certain embodiments, bispecific antibodies have binding specificities for at least two different epitopes.
[0107] The term “specifically binds” as used herein, refers to the ability of an antibody or an antigen-binding fragment thereof, to bind to an antigen with a dissociation constant (Kd) of no more than about 1 χ10“6 M, 1 χ10“7 M, 1 χ10“8 M, 1 χ10“9 M, 1 χ10“10 M, 1 χ10“11 M, 1 χ10“12 M, and/or to bind to an antigen with an affinity that is at least two-folds greater than its affinity to a nonspecific antigen.
[0108] The term “treatment” as used herein includes preventative (e.g., prophylactic), curative or palliative treatment; and “treating” as used herein also includes preventative (e.g., prophylactic), curative or palliative treatment. In particular, the term “treating” as used herein refers to the application or administration of the present molecular construct or a pharmaceutical composition comprising the same to a subject, who has a medical condition a symptom associated with the medical condition, a disease or disorder secondary to the medical condition, or a predisposition toward the medical condition, with the purpose to partially or completely alleviate, ameliorate, relieve, delay onset of, inhibit progression of, reduce severity of, and/or reduce incidence of one or more symptoms or features of said particular disease, disorder, and/or condition. Treatment may be administered to a subject who does not exhibit signs of a disease, disorder, and/or condition, and/or to a subject who exhibits only early signs of a disease, disorder and/or condition, for the purpose of decreasing the risk of developing pathology associated with the disease, disorder and/or condition.
[0109] The term “effective amount” as used herein refers to the quantity of the present molecular construct that is sufficient to yield a desired therapeutic response. An effective amount of an agent is not required to cure a disease or condition but will provide a treatment for a disease or condition such that the onset of the disease or condition is delayed, hindered or prevented, or the disease or condition symptoms are ameliorated. The effective amount may be divided into one, two, or more doses in a suitable form to be administered at one, two or more times throughout a designated time period. The specific effective or sufficient amount will vary with such factors as particular condition being treated, the physical condition of the patient (e.g., the patient's body mass, age, or gender), the type
WO 2017/036255
PCT/CN2016/090296 of subject being treated, the duration of the treatment, the nature of concurrent therapy (if any), and the specific formulations employed and the structure of the compounds or its derivatives. Effective amount may be expressed, for example, as the total mass of active component (e.g., in grams, milligrams or micrograms) or a ratio of mass of active component to body mass, e.g., as milligrams per kilogram (mg/kg).
[0110] The terms “application” and “administration” are used interchangeably herein to mean the application of a molecular construct or a pharmaceutical composition of the present invention to a subject in need of a treatment thereof.
[0111] The terms “subject” and “patient” are used interchangeably herein and are intended to mean an animal including the human species that is treatable by the molecular construct, pharmaceutical composition, and/or method of the present invention. The term “subject” or “patient” intended to refer to both the male and female gender unless one gender is specifically indicated. Accordingly, the term “subject” or “patient” comprises any mammal, which may benefit from the treatment method of the present disclosure. Examples of a “subject” or “patient” include, but are not limited to, a human, rat, mouse, guinea pig, monkey, pig, goat, cow, horse, dog, cat, bird and fowl. In an exemplary embodiment, the patient is a human. The term “mammal” refers to all members of the class Mammalia, including humans, primates, domestic and farm animals, such as rabbit, pig, sheep, and cattle; as well as zoo, sports or pet animals; and rodents, such as mouse and rat. The term “non-human mammal” refers to all members of the class Mammalis except human.
[0112] The present disclosure is based, at least on the construction of the T-E pharmaceuticals that can be delivered to target cells, target tissues or organs at increased proportions relative to the blood circulation, lymphoid system, and other cells, tissues or organs. When this is achieved, the therapeutic effect of the pharmaceuticals is increased, while the scope and severity of the side effects and toxicity is decreased. It is also possible that a therapeutic effector is administered at a lower dosage in the form of a T-E molecule, than in a form without a targeting component. Therefore, the therapeutic effector can be administered at lower dosages without losing potency, while lowering side effects and toxicity.
WO 2017/036255
PCT/CN2016/090296 [0113] Diseases that can benefit from better drug targeting [0114] Drugs used for many diseases can be improved for better efficacy and safety, if they can be targeted to the disease sites, i.e., if they can be localized or partitioned to the disease sites more favorably than the normal tissues or organs. Certain antibody drugs, which target infectious microorganisms or their toxic products, can be improved, if they are empowered with the ability to recruit immunocytes, which phagocytose and clear the antibody-bound particles. Following are primary examples of diseases, in which drugs can be improved if they can be preferentially distributed to the disease sites or cells or if they can recruit phagocytic immunocytes.
[0115] Disease/Condition associated with Blood Clot [0116] There are two main aspects of pharmaceutical needs in dealing with the pathological problems of blood clotting (or coagulation): one aspect is to prevent or inhibit pathological blood clots to form or to grow in size once a nucleus of clot is formed, and the other aspect is to dissolve already-formed pathological clots timely. In both aspects, there are batteries of pharmaceutical products available clinically. Research aiming at developing still better products is continuing actively and a number of products are in clinical trials.
[0117] Patients suffered from various complications (e.g., those resulted from cardiovascular, endocrine, or other bodily regulatory conditions, surgical, the use of medicine, and other factor) have the tendency to develop blood clots. The clots may cause hemorrhagic strokes, head trauma, myocardial infarction, pulmonary embolism, or deep vein thrombosis, which often lead to serious, life threatening clinical conditions.
[0118] Coagulation involves a cascade of protease-catalyzed events, which amplify in sequence. Toward the later steps, Factor Xa cleaves prothrombin to thrombin, and thrombin cleaves fibrinogen to fibrin, which in combination with platelets forms the meshwork of a clot. The dissolution of the blood clot involves plasmin, which is generated from plasminogen via one of several of enzymes, including tissue plasminogen activator.
[0119] A. The use of T-E molecules for preventing the formation of a blood clot
WO 2017/036255
PCT/CN2016/090296 [0120] A large number of indirect inhibitors of Factor Xa have been developed and used. For many decades, the inhibitors are primarily heparin, which is a mixture of naturally occurring polysaccharides of glycosaminoglycan of varying molecular weights from 5 to 30 kDa, low-molecular weight heparin, and heparinoid compounds. Those substances bind to heparin-binding proteins, including anti-thrombin, thus potentiating those substances to inhibit Factor Xa, thereby inhibiting the clot formation. Tissue factor pathway inhibitor (TFPI), a single-chain serum protein of 34,000-40,000 Daltons depending on the degree of proteolysis, can inhibit Factor Xa. However, it is not produced by recombinant DNA technology as a therapeutic.
[0121] A number of direct inhibitors of thrombin have also been developed and used clinically. Naturally recovered hirudin from medical leeches and recombinant hirudin, which bind to thrombin, were used for many years before they were discontinued because of the introduction of other better medicines.
[0122] More recently, several small molecules that are direct inhibitors of Factor Xa, or thrombin have been developed and approved for clinical uses in preventing coagulation in several clinical indications. In one set of clinical applications, these small molecules are direct inhibitors of Factor Xa, and may be apixaban, edoxaban, or rivaroxaban. In another set of applications, these small molecules are direct inhibitors of thrombin, and may be argatroban or dabigatran. Ximelagatran, a direct thrombin inhibitor, has favorable kinetics and may be administered in very small doses; however, it has been withdrawn from the market due to hepatoxicity problems. It is noted that Ximelagatran is a pro-drug, and the orally taken ximelagatran is converted in the liver to melagatran, which is the active form that binds to and inhibits thrombin. It is very possible that the reduced dosage of melagatran relative to that of ximelagatran and the avoidance of conversion of ximelagatran in the live can avoid the hepatoxicity seen with ximelagatran.
[0123] We rationalize that an effective approach to deal with clot formation is to inhibit a nucleus of a clot from growing into a pathological clot. Therefore, if an increased amount of Factor Xa inhibitor or thrombin inhibitor or both are brought to the clot nucleus, the clot will be prevented from growing in size and becoming pathological. We can use IgG or scFv of an anti-fibrin antibody to carry a drug bundle of an inhibitor of Factor Xa or an
WO 2017/036255
PCT/CN2016/090296 inhibitor of thrombin or combined bundles of both kinds of inhibitors to the newly formed nucleus of clot. Both the Factor Xa inhibitor molecules (such as, apixaban, edoxaban, and rivaroxaban) and the thrombin inhibitor molecules (such as, argatroban and melagatran) have an NH2 group for conjugation with a linker unit proposed in the present disclosure.
[0124] Because the Factor Xa inhibitor and/or thrombin inhibitor are carried to the site of the clot by an anti-fibrin antibody, smaller amounts of the inhibitors than those used without anti-fibrin targeting will be required. Furthermore, because the blood stream flows in the blood vessels, the concentration effects of the carried inhibitors surrounding the clot will be significant only when the nucleus of the clot has grown to a certain size. Therefore, the physiologically required blood coagulation to mend minute internal wounds will not be affected. Thus, the targeting of Factor Xa and thrombin inhibitors by an anti-fibrin antibody to the clot should be therapeutically more effective, while reducing side effects of internal bleeding.
[0125] According to embodiments of the present disclosure, T-E molecules in the joint-linker configuration contain scFv specific for fibrin as targeting elements and a Factor Xa inhibitor (apixaban, edoxaban, or rivaroxaban) or thrombin inhibitor (argatroban and melagatran) or both as effector elements.
[0126] (B) The use of T-E molecules to speed up the dissolution of blood clots [0127] To administer proper medications for dissolving pathological clots in a timely, tightly controlled fashion has been a very important pharmaceutical challenge. The development of several forms of recombinant human tissue plasminogen activator (tPA), including alteplase, reteplase, tenecteplase, and lanoteplase, has solved a significant part of the thrombosis problems. However, the use of tPA in many cases either is not sufficient to dissolve the clots or causes serious internal bleeding, or both. The controlled use of dosages and administration schedule of tPA is still an area of active research. The clinical studies comparing the several forms of recombinant tPA are also very active. From the wealth of published literature on tPA and its variants and their medical uses, it is apparent that the various properties of tPA, including the affinity in binding to fibrin, its half-life, the susceptibility to breakdown by liver cells, and the resistance to plasminogen activator inhibitor all play part in the desired properties of the tPAfor a particular clinical condition.
WO 2017/036255
PCT/CN2016/090296 [0128] The molecular structure of intact tPA is complex, comprising several structural domains with discrete functions or activities, although not all of these domains are required for a thrombolytic product suitable for use in dissolving blood clots. A full-length tPA molecule (alteplase) with 527 amino acid residues contains, (i) a fibronectin finger domain that binds to fibrin, (2) an epidermal growth factor domain that binds to hepatocytes and facilitates tPA’s clearance, (3) a Kringle 1 domain that binds to hepatic endothelial cells and facilitates tPA’ clearance, (4) a Kringle 2 domain that binds to fibrin and activates the serine protease, and (5) a protease domain that cleaves the plasminogen and is inhibited by plasminogen activator inhibitor type 1 (PAI-1). Alteplase, tenecteplase, and lanoteplase are produced in mammalian cells, CHO cells, and reteplase is produced in bacteria.
[0129] Reteplase, which is 355 residues in length, does not contain the fibronectin finger, epidermal growth factor domain, and Kringle 1 domain. Reteplase is produced in bacteria, and therefore it does not contain the posttranslational carbohydrate modification. While reteplase has a lower affinity for fibrin and its protease is not activated to the extent as in alteplase, reteplase has a plasma half-life of 14-18 minutes; in contrast, the half-life period of alteplase only lasts 3-4 minutes in plasma. Reteplase is administered to patients in boli, while alteplase is administered in a bolus followed by an infusion.
[0130] Tenecteplase has the entire length of 527 amino acid residues of alteplase, but has mutations at three sites. Threonine at 103 is replaced by asparagine to allow glycosylation modification, and asparagine at 117 is replaced by glutamine to eliminate glycosylation. These mutations inhibit the clearance of the molecule by liver cells. In addition, the four residues at 296-299 (i.e., lysine-histidine-arginine-arginine) are replaced by four alanine residues, thus increasing the resistance to PAI-1 by 80 times. Tenecteplase has a plasma half-life of 18 minutes.
[0131] In lanoteplase, the fibronectin finger and the epidermal growth factor domain are deleted and the asparagine at 117 is replaced by glutamine. The plasma half-life of lanoteplase is increased to 45 minutes, which improves administration procedures.
[0132] In various clinical trials, the overall therapeutic efficacies of the four forms of tPA are about equal, and each seems to fit better than others do in particular clinical conditions.
WO 2017/036255
PCT/CN2016/090296 [0133] In the present invention, it is rationalized that a moderate increase in binding strength to fibrin and a moderate increase of plasma half-life over those exhibited by reteplase will increase the therapeutic properties of reteplase. These molecular constructs will allow more specificity for binding to clots and hence allowing lower doses and fewer side effects. If they cannot fit to all clinical conditions pertaining to dissolving blood clots, they can be applied to some of the conditions. Thus, a preferred embodiment of the present invention for an improved tPA for dissolving blood clots is that 1 -3 scFv of an anti-fibrin antibody are employed as targeting elements and 1-2 copies reteplase are employed as effector elements in a joint-linkers configuration. In an alternative construct, reteplase is conjugated to the linker-unit via its C-terminal in order that the N-terminal Kringle 2 domain is flexible in contacting fibrin meshwork in the clot. The C-terminal is extended with a linker, such as (GGGGS)2 and a cysteine residue. In still another embodiment, an Fc-fusion protein construct linking a tPA or its fragment and scFv specific for fibrin may also be applicable for facilitating the dissolution of pathological clots.
[0134] PARTI Multi-Arm Linkers for Treating Specific Diseases [0135] l-(i) Peptide Core for Use in Multi-arm Linker [0136] The first aspect of the present disclosure pertains to a linker unit that comprises, (1) a center core that comprises 2-15 lysine (K) residues, and (2) 2-15 linking arms respectively linked to the K residues of the center core. The present center core is characterized in having or being linked with an azide group, an alkyne group, a tetrazine group, or a strained alkyne group at its N- or C-terminus.
[0137] In the preparation of the present linker unit, a PEG chain having a N-hydroxysuccinimidyl (NHS) group at one terminus and a functional group (e.g., an NHS, a maieimide, an azide, an alkyne, a tetrazine, or a strained alkyne group) at the other terminus is linked to the K residue of the center core by forming an amide bond between the NHS group of the PEG chain and the amine group of the K residue. In the present disclosure, the PEG chain linked to the K residue is referred to as a linking arm, which has a functional group at the free-terminus thereof.
[0138] According to the embodiments of the present disclosure, the center core is a
WO 2017/036255
PCT/CN2016/090296 polypeptide that has 8-120 amino acid residues in length and comprises 2 to 15 lysine (K) residues, in which each K residue and the next K residue are separated by a filler sequence.
[0139] According to embodiments of the present disclosure, the filler sequence comprises glycine (G) and serine (S) residues; preferably, the filler sequence consists of 2-15 residues selected from G, S, and a combination thereof. For example, the filler sequence can be,
GS,
GGS,
GSG,
GGGS (SEQ ID NO: 1),
GSGS (SEQ ID NO: 2),
GGSG (SEQ ID NO: 3),
GSGGS (SEQ ID NO: 4),
SGGSG (SEQ ID NO: 5),
GGGGS (SEQ ID NO: 6),
GGSGGS (SEQ ID NO: 7),
GGSGGSG (SEQ ID NO: 8),
SGSGGSGS (SEQ ID NO: 9),
GSGGSGSGS (SEQ ID NO: 10),
SGGSGGSGSG (SEQ ID NO: 11),
GGSGGSGGSGS (SEQ ID NO: 12), SGGSGGSGSGGS (SEQ ID NO: 13), GGGGSGGSGGGGS (SEQ ID NO: 14), GGGSGSGSGSGGGS (SEQ ID NO: 15), or SGSGGGGGSGGSGSG (SEQ ID NO: 16).
[0140] The filler sequence placed between two lysine residues may be variations of glycine and serine residues in somewhat random sequences and/or lengths. Longer fillers may be used for a polypeptide with fewer lysine residues, and shorter fillers for a polypeptide with more lysine residues. Hydrophilic amino acid residues, such as aspartic acid and histidine, may be inserted into the filler sequences together with glycine and serine. As alternatives for filler sequences made up with glycine and serine residues, filler
WO 2017/036255
PCT/CN2016/090296 sequences may also be adopted from flexible, soluble loops in common human serum proteins, such as albumin and immunoglobulins.
[0141] Basically, the filler sequences between lysine residues cover peptides with glycine and serine residues. However, they can alternatively be peptides composed of amino acids excluding one with amine group in its side chain. Those amino acids are predominantly, but not necessarily entirely hydrophilic amino acids. The amino acids are not necessarily naturally occurring amino acids.
[0142] According to certain preferred embodiments of the present disclosure, the center core comprises 2-15 units of the sequence of G1-5SK. Alternatively, the polypeptide comprises the sequence of (GSK)2_i5; that is, the polypeptide comprises at least two consecutive units of the sequence of GSK. For example, the present center core may comprises the amino acid sequence of the following,
Ac-CGGSGGSGGSKGSGSK (SEQ ID NO: 17), Ac-CGGSGGSGGSKGSGSKGSK (SEQ ID NO: 18), or Ac-CGSKGSKGSKGSKGSKGSKGSKGSKGSKGSK (SEQ ID NO: 19), in which Ac represents the acetyl group.
[0143] According to certain embodiments of the present disclosure, the center core is a polypeptide that comprises the sequence of (Xaa-K)n, in which Xaa is a PEGylated amino acid having 2 to 12 repeats of ethylene glycol (EG) unit, and n is an integral from 2 to 15.
[0144] As would be appreciated, the lysine residue of the present center core may be substituted with an amino acid, which side chain contains an amine group. For example, an α-amino acid with (CH2-)nNH2 side chain, where n=1-3 or 5; an α-amino acid with (CH(OH)-)nCH2-NH2 side chain, where n=1-5; an α-amino acid with (CH2-CH(OH)-)nCH2-NH2 side chain, where n=1-3; an α-amino acid with (CH2-CH2-O-)nCH2-NH2 side chain, where n=1-2. These amino acids are not necessarily naturally occurring amino acids.
[0145] As described above, the present center core is characterized in having or being linked with an azide group, an alkyne group, a tetrazine group, or a strained alkyne group at its N- or C-terminus. According to some embodiments of the present disclosure, the
WO 2017/036255
PCT/CN2016/090296 present center core comprises, at its N- or C-terminus, an amino acid residue having an azide group or an alkyne group. The amino acid residue having an azide group can be, L-azidohomoalanine (AHA), 4-azido-L-phenylalanine, 4-azido-D-phenylalanine, 3-azido-L-alanine, 3-azido-D-alanine, 4-azido-L-homoalanine, 4-azido-D-homoalanine, 5-azido-L-ornithine, 5-azido-d-ornithine, 6-azido-L-lysine, or 6-azido-D-lysine. For example, the present center core may have the sequence of,
Ac-(GSK)2.7-(G2.4S)i.8-Aah,
Ac-Aah-(SG2.4)i-8-(GSK)2.7,
Ac-Aah-(SG2.4)o-7-(GSK)2.6-(G2.4S)i.8-C, Ac-C-(SG2.4)0.7-(GSK)2.6-(G2.4S)i.8-Aah,
Ac-K-(Xaa2.i2-K)2.4-Xaa2_i2-AAH,
Ac-AAH-Xaa2.i 2-K-(Xaa2_i 2-K)2.4,
Ac-AAH-Xaa2.i2-K-(Xaa2.i2-K)i _3-Xaa2.i2-C, or Ac-C-Xaa2_i 2-K-(Xaa2_i 2-K)i .3-Xaa2-i 2-Aap\ in which Xaa is a PEGylated amino acid having specified repeats of EG unit, Ac represents the acetyl group, and Aah represents the AHA residue.
[0146] Exemplary amino acid having an alkyne group includes, but is not limited to, L-homopropargylglycine (L-HPG), D-homopropargylglycine (D-HPG), or beta-homopropargylglycine (β-HPG). In this case, the present center core may have the sequence of,
Ac-(GSK)2.7-(G2.4S)i.8-GHP,
Ac-GHP-(SG2.4)i.8-(GSK)2.7,
Ac-Gnn-iSG^o-riGSKj^-iG^Sjvs-C,
Ac-C-iSG^o-riGSKj^-iG^Sjvs-Gn,
Ac-K-(Xaa2-i2-K)2.4-Xaa2.i2-GHP,
Ac-GHP-Xaa2-i2-K-(Xaa2.i2-K)2.4,
Ac-GHP-Xaa2.i2-K-(Xaa2.i2-K)i _3-Xaa2.i2-C, or Ac-C-Xaa2-i2-K-(Xaa2.i2-K)i.3-Xaa2.i2-GHP, in which Xaa is a PEGylated amino acid having specified repeats of EG unit, Ac represents the acetyl group, and GHP represents the HPG residue.
[0147] It is noted that many of the amino acids containing an azide or alkyne group in their
WO 2017/036255
PCT/CN2016/090296 side chains and PEGylated amino acids are available commercially in t-boc (tert-butyloxycarbonyl)- or Fmoc (9-fluorenylmethyloxycarbonyl)-protected forms, which are readily applicable in solid-phase peptide synthesis.
[0148] According to some working examples of the present disclosure, the center core may comprise the sequence of,
Ac-GhpGGSGGSGGSKGSGSK (SEQ ID NO: 21), Ac-GhpGGSGGSGGSKGSGSKGSK (SEQ ID NO: 22), Ac-AahGGSGGSGGSKGSGSKGSK (SEQ ID NO: 23), Ac-GhpGGSGGSGGSKGSGSKGSGSC (SEQ ID NO: 24), Ac-C-Xaa2-K-Xaa2-K-Xaa2-K (SEQ ID NO: 25), or Ac-C-Xaae-K-Xaae-K-Xaae-K-Xaae-K-Xaae-K (SEQ ID NO: 26), in which Xaa is a PEGylated amino acid having specified repeats of EG unit, Ac represents the acetyl group, Aah represents the AHA residue, and GHP represents the HPG residue.
[0149] Alternatively, the present center core is linked with a coupling arm, which has a functional group (e.g., an azide group, an alkyne group, a tetrazine group, or a strained alkyne group) at the free-terminus thereof (that is, the terminus that is not linked to the center core). In these cases, the present center core comprises a cysteine residue at its N- or C-terminus. To prepare a linker unit linked with a coupling arm, a PEG chain having a maleimide group at one terminus and a functional group at the other terminus is linked to the cysteine residue of the center core via thiol-maleimide reaction occurred between the maleimide group of the PEG chain and the thiol group of the cysteine residue. In the present disclosure, the PEG chain linked to the cysteine residue of the center core is referred to as the coupling arm, which has a functional group at the free-terminus thereof.
[0150] As would be appreciated, the cysteine residue of the present center core may be substituted with an amino acid, which side chain contains a sulfhydryl group. For example, an α-amino acid with (CH(OH)-)nCH2-SH side chain, where n=1-5; an α-amino acid with (CH2-CH(OH)-)nCH2-SH side chain, where n=1-3; an α-amino acid with (CH2-CH2-O-)nCH2-SH side chain, where n=1-2. The amino acid is not necessarily naturally occurring amino acids. The cysteine residue need not be placed at the N- or C-terminal of the peptide core. For example, the cysteine residue can be placed in the
WO 2017/036255
PCT/CN2016/090296 middle of the peptide, so that the lysine residues are distributed on two sides of the cysteine residue.
[0151] Preferably, the coupling arm has a tetrazine group ora strained alkyne group (e.g., a cyclooctene or cyclooctyne group) at the free-terminus thereof. These coupling arms have 2-12 EG units. According to the embodiments of the present disclosure, the tetrazine group is 1,2,3,4-tetrazine, 1,2,3,5-tetrazine, 1,2,4,5-tetrazine, or derivatives thereof. The strained alkyne group may be a cyclooctene or a cyclooctyne group. According to the working examples of the present disclosure, the cyclooctene group is a trans-cyclooctene (TOO) group; example of cyclooctyne group includes, but is not limited to, dibenzocyclooctyne (DBCO), difluorinated cyclooctyne (DIFO), bicyclononyne (BON), and dibenzocyclooctyne (DICO). According to some embodiments of the present disclosure, the tetrazine group is 6-methyl-tetrazine.
[0152] Example of the present center core configured to be linked with the coupling arm includes, but is not limited to,
Ac-(GSK)2-7-(G2-4S)i-8-C-Xaa2-i2-tetrazine, Ac-(GSK)2-7-(G2-4S)i-8-C-Xaa2-i2-strained alkyne, Ac-K-(Xaa2-i2-K)2-4-Xaa2-i2-C-Xaa2-i2-tetrazine, Ac-K-(Xaa2-i 2-K)2-4-Xaa2-i 2-C-Xaa2-i 2-strained alkyne, Tetrazine-Xaa2-i2-C(Ac)-(SG2-4)i-8-(GSK)2-7, Strained alkyne-Xaa2-i2-C(Ac)-(SG2-4)i-8-(GSK)2-7! Tetrazine-Xaa2-i2-C(Ac)-Xaa2-i2-K-(Xaa2-i2-K)2-4! and Strained alkyne-Xaa2-i2-C(Ac)-Xaa2-i2-K-(Xaa2-i2-K)2-4· [0153] Alternatively, the center core has an azide or alkyne group at one terminus and a coupling arm with tetrazine or strained alkyne group at the other terminus. Examples are the following:
Ac-Aah-(SG2-4)o-7-(GSK)2.6-(G2-4S)i -8-C-Xaa2-i2-tetrazine, Ac-AAH-(SG2-4)o-7-(GSK)2-6-(G2-4S)i-8-C-Xaa2-i2-strained alkyne, Tetrazine-Xaa2-i2-C(Ac)-(SG2-4)o-7-(GSK)2-6-(G2-4S)i-8-AAH, Strained alkyne-Xaa2-i2-C(Ac)-(SG2-4)o-7-(GSK)2-6-(G2-4S)i-8-AAH, Ac-AAH-Xaa2-i 2-K-(Xaa2-i 2-K)i -3-Xaa2-i 2-C-Xaa2-i 2-tetrazine,
WO 2017/036255
PCT/CN2016/090296
Ac-AAH-Xaa2-i2-K-(Xaa2_i2-K)!.3-Xaa2_i2-C-Xaa2_i2-strained alkyne, Tetrazine-Xaa2-i 2-C(Ac)-Xaa2-i 2-K-(Xaa2-i 2-K) 1 _3-Xaa2-i 2-Aah, Strained alkyne-Xaa2-i2-C(Ac)-Xaa2-i2-K-(Xaa2-i2-K)i.3-Xaa2-i2-AAH, Ac-GHP-(SG2-4)o-7-(GSK)2_6-(G2-4S)i-8-C-Xaa2-i2-tetrazine, Ac-GHP-(SG2-4)o-7-(GSK)2.6-(G2-4S)i-8-C-Xaa2-i2-strained alkyne, Tetrazine-Xaa2-i2-C(Ac)-(SG2.4)o-7-(GSK)2.6-(G2.4S)i .8-Ghp, Strained alkyne-Xaa2-i2-C(AC)-(SG2-4)o-7_(GSK)2-6-(G2-4S)i-8_Gp'p, Ac-G HP-Xaa2-i 2-K-(Xaa2-i 2-K) 1 _3-Xaa2-i 2-C-Xaa2-i 2-tetrazi ne, Ac-GHP-Xaa2-i 2-K-(Xaa2-i 2-K) 1 _3-Xaa2-i 2-C-Xaa2-i 2-strained alkyne, Tetrazine-Xaa2-i2-C(Ac)-Xaa2-i2-K-(Xaa2-i2-K) 1 _3-Xaa2-i2-GHP, and Strained alkyne-Xaa2.i2-C(Ac)-Xaa2.i2-K-(Xaa2.i2-K)1.3-Xaa2.i2-GHP.
[0154] The polypeptide may also be synthesized using recombinant technology by expressing designed gene segments in bacterial or mammalian host cells. It is preferable to prepare the polypeptide as recombinant proteins if the core has high numbers of lysine residues with considerable lengths. As the length of a polypeptide increases, the number of errors increases, while the purity and/or the yield of the product decrease, if solid-phase synthesis was adopted. To produce a polypeptide in bacterial or mammalian host cells, a filler sequence ranges from a few amino acid residues to 10-20 residues may be placed between two K residues. Further, since AHA and HPG are not natural amino acids encoded by the genetic codes, the N-terminal or C-terminal residue for those recombinant polypeptides is cysteine. After the recombinant proteins are expressed and purified, the terminal cysteine residue is then reacted with short bifunctional cross-linkers, which have maleimide group at one end, which reacts with SH group of cysteine residue, and alkyne, azide, tetrazine, or strained alkyne at the other end.
[0155] The synthesis of a polypeptide using PEGylated amino acids involves fewer steps than that with regular amino acids such as glycine and serine resides. In addition, PEGylated amino acids with varying lengths (i.e., numbers of repeated ethylene glycol units) may be employed, offering flexibility for solubility and spacing between adjacent amino groups of lysine residues. Other than PEGylated amino acids, the center cores may also be constructed to comprise artificial amino acids, such as D-form amino acids, homo-amino acids, N-methyl amino acids, etc. Preferably, the PEGylated amino acids with varying
WO 2017/036255
PCT/CN2016/090296 lengths of polyethylene glycol (PEG) are used to construct the center core, because the
PEG moieties contained in the amino acid molecules provide conformational flexibility and adequate spacing between conjugating groups, enhance aqueous solubility, and are generally weakly immunogenic. The synthesis of PEGylated amino acid-containing center core is similar to the procedures for the synthesis of regular polypeptides.
[0156] Optionally, for stability purpose, the present center core has an acetyl group to block the amino group at its N-terminus.
[0157] As could be appreciated, the number of the linking arms linked to the center core is mainly determined by the number of lysine resides comprised in the center core. Since there are at least two lysine residues comprised in the present center core, the present linker unit may comprise a plurality of linking arms.
[0158] Reference is now made to Figure 1 A. As illustrated, the linker unit 10A comprises a center core 11a comprising one HPG (GHP) residue and four lysine (K) residues respectively separated by filler sequences (denoted by the dots throughout the drawings). The filler sequences between the HPG residue and K residue or between any two K residues may comprise the same or different amino acid sequences. In this example, four linking arms 20a-20d are linked to the lysine residues by forming an amide linkage between the NHS group and the amine group of the lysine residue, respectively. As could be appreciated, certain features discussed above regarding the linker unit 10A or any other following linker units are common to other linker units disclosed herein, and hence some or all of these features are also applicable in the following examples, unless it is contradictory to the context of a specific embodiment. However, for the sake of brevity, these common features may not be explicitly repeated below.
[0159] Figure 1B provides a linker unit 10B according to another embodiment of the present disclosure. The center core 11 b comprises one cysteine (C) residue and six lysine (K) residues respectively separated by the filler sequences. In this example, the linker unit 10B comprises six linking arms 20a-20f that are respectively linked to the lysine residues. According to the embodiments of the present disclosure, the linking arm is a PEG chain having 2-20 repeats of EG units.
WO 2017/036255
PCT/CN2016/090296 [0160] Unlike the linker unit 10A of Figure 1A, the linker unit 1B further comprises a coupling arm 60. As discussed above, a PEG chain having a maleimide group at one end and a functional group at the other end is used to form the coupling arm 60. In this way, the coupling arm 60 is linked to the cysteine residue of the center core 11b via thiol— maleimide reaction. In this example, the functional group at the free terminus of the coupling arm 60 is a tetrazine group 72. According to the embodiments of the present disclosure, the coupling arm is a PEG chain having 2-12 repeats of EG units.
[0161] When the release of effector elements at the targeted site is required, a cleavable bond can be installed in the linking arm. Such a bond is cleaved by acid/alkaline hydrolysis, reduction/oxidation, or enzymes. One embodiment of a class of cleavable PEG chains that can be used to form the coupling arm is NHS-PEG2-2o-S-S-maleimide, where S-S is a disulfide bond that can be slowly reduced, while the NHS group is used for conjugating with the amine group of the center core, thereby linking the PEG chain onto the center core. The maleimide group at the free terminus of the linking arm may be substituted by an azide, alkyne, tetrazine, or strained alkyne group.
[0162] According to the embodiments of the present disclosure, the linking arm linked to the K residue of the center core has a functional group (i.e., a maleimide, an NHS, an azide, an alkyne, a tetrazine, or a strained alkyne group) at its free terminus. Preferably, when the free terminus of the linking arm is an azide, alkyne, or cyclooctyne group, then the amino acid residue at the N- or C-terminus of the center core is a cysteine residue, and the free terminus of the coupling arm is a tetrazine or cyciooctene group. Alternatively, when the free terminus of the linking arm is a tetrazine group or cyciooctene group, then the amino acid residue at the N- or C-terminus of the center core has an azide or alkyne group, or the amino acid residue at the N- or C-terminus of the center core is a cysteine residue, and the free terminus of the coupling arm is an azide, the alkyne, or the cyclooctyne group [0163] Depending on the functional group (i.e., a maleimide, an NHS, an azide, an alkyne, a tetrazine, or a strained alkyne group) present at the free terminus of the linking arm, it is feasible to design a functional element (such as, a targeting element, an effector element, or an element for improving the pharmacokinetic property) with a corresponding functional
WO 2017/036255
PCT/CN2016/090296 group, so that the functional element may linked to the free terminus of the linking arm via any of the following chemical reactions, (1) forming an amide bond therebetween: in this case, the linking arm has an NHS group at the free terminus, and the functional element has an amine group;
(2) the thiol-maleimide reaction: in this case, the linking arm has a maleimide group at the free terminus, and the functional element has an thiol group;
(3) the Copper(l)-catalyzed alkyne-azide cycloaddition reaction (CuAAC reaction, or the “click reaction for short): one of the free terminus of the linking arm and the functional element has an azide group, while the other has an alkyne group; the CuAAC reaction is exemplified in Scheme 1;
(4) the inverse electron demand Diels-Alder (iEDDA) reaction: one of the free terminus of the linking arm and the functional element has a tetrazine group, while the other has a cyclooctene group; the iEDDA reaction is exemplified in Scheme 2; or (5) the strained-promoted azide-alkyne click chemistry (SPAAC) reaction: one of the free terminus of the linking arm and the functional element has an azide group, while the other has an cyclooctyne group; the SPAAC reaction is exemplified in Scheme 3.
«Scheme 1 CuAAC reaction» azide alkyne
R—N=N=N
R'
Figure AU2016316202B2_D0001
copper(l) catalyzed azide-alkyne cycloaddition (CuAAC)
Figure AU2016316202B2_D0002
I
N—N
CuAAC reaction yields 1,5 di-substituted 1,2,3-triazole. The reaction [0164] The between alkyne and azide is very selective and there are no alkyne and azide groups in natural biomolecules. Furthermore, the reaction is quick and pH-insensitive. It has been suggested that instead of using copper (I), such as cuprous bromide or cuprous iodide, for catalyzing the click reaction, it is better to use a mixture of copper (II) and a reducing agent,
WO 2017/036255
PCT/CN2016/090296 such as sodium ascorbate to produce copper (I) in situ in the reaction mixture.
Alternatively, the second element can be linked to the N- or C-terminus of the present center core via a copper-free reaction, in which pentamethylcyclopentadienyl ruthenium chloride complex is used as the catalyst to catalyze the azide-alkyne cycloaddition.
«Scheme 2 iEDDA Reaction»
Tetrazine Trans-cyclooctene (TCO)
Figure AU2016316202B2_D0003
«Scheme 3 SPAAC reaction» di benzocyclooctyl (DBCO)
Figure AU2016316202B2_D0004
Figure AU2016316202B2_D0005
WO 2017/036255
PCT/CN2016/090296 [0165] For the sake of illustration, the functional elements linked to the linking arms are referred to as the first elements. As could be appreciated, the number of the first elements carried by the present linker unit depends on the number of K residues of the center core (and thus, the number of the linking arms). Accordingly, one of ordinary skill in the art may adjust the number of the first elements of the linker unit as necessary, for example, to achieve the desired targeting or therapeutic effect.
[0166] An example of a linker unit 10C having the first elements is illustrated Figure 1C. Other than the features disused hereafter, Figure 1C is quite similar to Figure 1B. First, there are five K residues in the center core 11 d, and accordingly, five linking arms 20a-20e are linked thereto, respectively. Second, the linker unit 10C has five first elements 30a-30e linked to each of the linking arms 20a-20e. As disused below, the optional tetrazine group 72 allows for the conjugation with an additional functional element, another molecular construct (see, Part II or Part III below).
[0167] In order to increase the intended or desired effect (e.g., the therapeutic effect), the present linker unit may further comprise a second element in addition to the first element. For example, the second element can be either a targeting element or an effector element. In optional embodiments of the present disclosure, the first element is an effector element, while the second element may be another effector element, which works additively or synergistically with or independently of the first element. Still optionally, the first and second elements exhibit different properties; for example, the first element is a targeting element, and the second element is an effector element, and vice versa. Alternatively, the first element is an effector element, and the second element is an element capable of improving the pharmacokinetic property of the linker unit, such as solubility, clearance, half-life, and bioavailability. The choice of a particular first element and/or second element depends on the intended application in which the present linker unit (or multi-arm linker) is to be used. Examples of these functional elements are discussed below in Part l-(iii) of this specification.
[0168] Structurally, the second element is linked to the azide, alkyne, tetrazine, or strained alkyne group at the N- or C-terminus of the center core. Specifically, the second element may be optionally conjugated with a short PEG chain (preferably having 2-12 repeats of EG
WO 2017/036255
PCT/CN2016/090296 units) and then linked to the N- or C-terminal amino acid residue having an azide group or an alkyne group (e.g., AHA residue or HPG residue). Alternatively, the second element may be optionally conjugated with the short PEG chain and then linked to the coupling arm of the center core.
[0169] According to some embodiments of the present disclosure, the center core comprises an amino acid having an azide group (e.g., the AHA residue) at its N- or C-terminus; and accordingly, a second element having an alkyne group is linked to the N- or C-terminus of the center core via the CuAAC reaction. According to other embodiments of the present disclosure, the center core comprises an amino acid having an alkyne group (e.g., the HPG residue) at its N- or C-terminus; and a second element having an azide group is thus capable of being linked to the N- or C-terminus of the center core via the CuAAC reaction.
[0170] Figure 1D provides an example of the present linker unit 10D carrying a plurality of first elements and one second element. In this example, the center core 11c comprises one HPG (GHP) residue and five lysine (K) residues. Five linking arms 20a-20e are respectively linked to the five K residues of the center core 11c; and five first elements 30a-30e are respectively linked to said five linking arms 20a-20e via the thiol-maleimide reaction. In addition to the first elements, the linker unit 10D further comprises one second element 50 that is linked to one end of a short PEG chain 62. Before being conjugated with the center core 11c, the other end of the short PEG chain 62 has an azide group. In this way, the azide group may react with the HPG residue that having an alkyne group via CuAAC reaction, so that the second element 50 is linked to the center core 11c. The solid dot 40 depicted in Figure 1D represents the chemical bond resulted from the CuAAC reaction occurred between the HPG residue and the azide group.
[0171] Alternatively, the second element is linked to the center core via a coupling arm. According to certain embodiments of the present disclosure, the coupling arm has a tetrazine group, which can be efficiently linked to a second element having a TCO group via the iEDDA reaction. According to other embodiments of the present disclosure, the coupling arm has a TCO group, which is capable of being linked to a second element having a tetrazine group via the iEDDA reaction. In the iEDDA reaction, the strained cyclooctene
WO 2017/036255
PCT/CN2016/090296 that possess remarkably decreased activation energy in contrast to terminal alkynes is employed, and thus eliminates the need of an exogenous catalyst.
[0172] Reference is now made to Figure 1E, in which the center core 11 d of the linker unit 10E comprises a terminal cysteine (C) residue and five lysine (K) residues. As depicted in Figure 1E, five linking arms 20a-20e are respectively linked to the five K residue of the center core 11 d, and then five first elements 30a-30e are respectively linked to the five linking arms 20a-20e via thiol-maleimide reactions. The cysteine residue is linked to the coupling arm 60, which, before being conjugated with the second element, comprises a tetrazine group or a TCO group at its free-terminus. In this example, a second element 50 linked with a short PEG chain 62 having a corresponding TCO or tetrazine group can be linked to the coupling arm 60 via the iEDDA reaction. The ellipse 70 as depicted in Figure 1E represents the chemical bond resulted from the iEDDA reaction occurred between the coupling arm 60 and the short PEG chain 62.
[0173] According to other embodiments of the present disclosure, before the conjugation with a second element, the coupling arm has an azide group. As such, the coupling arm can be linked to the second element having a strained alkyne group (e.g., the DBCO, DIFO, BCN, or DICO group) at the free-terminus of a short PEG chain via SPAAC reaction (see, scheme 3), and vice versa.
[0174] Reference is now made to Figure 1F, in which the linker unit 10F has a structure similar to the linker unit 10E of Figure 1E, except that the coupling arm 60 comprises an azide or a strained alkyne group (e.g., the DBCO, DIFO, BCN, or DICO group), instead of the tetrazine or TCO group. Accordingly, the second element 50 linked with a short PEG chain 62 may have a corresponding strained alkyne (e.g., DBCO, DIFO, BCN, or DICO) or azide group, so that it can be linked to the coupling arm 60 via the SPAAC reaction. The diamond 90 as depicted in Figure 1F represents the chemical bond resulted from the SPAAC reaction occurred between the coupling arm 60 and the short PEG chain 62.
[0175] Scheme 4 is an exemplary illustration of the process of preparing the present linker unit. In step 1, the center core comprising the amino acid sequence of (GSK)3 and a L-azidohomoalanine (AHA) residue at the C-terminus thereof is prepared. In step 2, three linking arms are respectively linked to the lysine (K) residues of the center core via forming
WO 2017/036255
PCT/CN2016/090296 an amide bond between the NHS group and the amine group; the linking arm linked to the center core has a maleimide (Mai) group at the free-terminus thereof. In step 3, three anti-fibrin scFvs (scFv a fibrin) as the first element are respectively linked to the linking arms via the thiol-maleimide reaction. Meanwhile, in step 4, one tPA analogue as the second element is linked with a short PEG chain that has 4 repeats of EG units and a DBCO group at the free terminus. Finally, in step 5, the second element is linked to the AHA residue of the center core via the SPAAC reaction.
«Scheme 4 Preparation of linker unit linked with two different scFvs via linking arm and C-terminal amino acid residue»
N-terminal
SPACC tPA analogue
Ac-(GSK)3-(GGGGS’XA· fibnn [0176] Scheme 5 illustrates another example of the process for preparing the present linker unit. In step 1, the center core comprising the amino acid sequence of (K-Xaa)3 and a cysteine residue at the C-terminus thereof is prepared. In step 2, a PEG chain (as the coupling arm) that has the maleimide (Mai) group at one terminus and a tetrazine group at the other terminus is linked to the cysteine residue via the thiol-maleimide reaction. Then, in step 3, three linking arm are respectively linked to the lysine (K) residues of the center core. Next, three anti-fibrin scFvs (scFv a fibrin) as the first elements are respectively linked to the linking arms via the thiol-maleimide reaction as described in step 4.
WO 2017/036255
PCT/CN2016/090296
Meanwhile, in step 5, one tPA analogue as the second element is linked with a short PEG chain that has 3 repeats of EG units and a TOO group at the free terminus. Finally, in step
6, the second element is linked to the coupling arm via the iEDDA reaction.
«Scheme 5 Preparation of linker unit linked with two different scFvs via linking arm and coupling arm»
N-terminai
Ac-(K· Xaa^fy-C k MskPEGi-tetraxine ί
Ac~(K · Xsa^a-OPEG^tetrazine
Ac~(K - Xaa^-O-PEG^tsti'azma >
* scFv a fibrin tPA analogue | + TCO-PEGg-Mai i
Figure AU2016316202B2_D0006
Figure AU2016316202B2_D0007
Figure AU2016316202B2_D0008
Ag-(K* Xaa4)3-C’PEG4—|— tPA analogue scFv a fibrin [0177] PEGylation is a process, in which a PEG chain is attached or linked to a molecule (e.g., a drug or a protein). It is known that PEGylation imparts several significant pharmacological advantages over the unmodified form, such as improved solubility, 10 increased stability, extended circulating life, and decreased proteolytic degradation.
According to one embodiment of the present disclosure, the second element is a PEG chain, which has a molecular weight of about 20,000 to 50,000 Daltons.
[0178] Figure 1G provides an alternative example of the present linker unit (linker unit 10G), in which five first elements 30 are respectively linked to the lysine residues via the
WO 2017/036255
PCT/CN2016/090296 linking arms 20, and the AHA (Aah) residue of the center core 11 e is linked with a PEG chain via the CuAAC reaction. The solid dot 40 depicted in Figure 1G represents the chemical bond resulted from the CuAAC reaction occurred between the AHA residue and the PEG chain 80.
[0179] Figure 1H provides another example of the present disclosure, in which the N-terminus of the center core 11 d is a cysteine residue that is linked to a coupling arm 60. A PEG chain 80 can be efficiently linked to the coupling arm 60 via the iEDDA reaction. The ellipse 70 of the linker unit 10H represents the chemical bond resulted from the iEDDA reaction occurred between the coupling arm 60 and the PEG chain 80.
[0180] Figure 11 provides an alternative example of the present linker unit, in which the linker unit 101 has a structure similar to the linker unit 10G of Figure 1G, except that the PEG chain 80 is linked to the coupling arm 60 via the SPAAC reaction. The diamond 90 depicted in Figure 11 represents the chemical bond resulted from the SPAAC reaction occurred between the coupling arm 60 and the PEG chain 80.
[0181] According to some embodiments of the present disclosure, in addition to the first and second elements, the present linker unit further comprises a third element. In this case, one of the N- and C-terminus of the center core is an amino acid having an azide group or an alkyne group, while the other of the N- and C-terminus of the center core is a cysteine residue. The lysine residues of the center core are respectively linked with the linking arms, each of which has a maleimide group at its free terminus; whereas the cysteine residue of the center core is linked with the coupling arm, which has a tetrazine group or a strained alkyne group at its free terminus. As described above, the first element is therefore linked to the linking arm via the thiol-maleimide reaction, and the second element is linked to the coupling arm via the iEDDA reaction. Further, a third element is linked to the terminal amino acid having an azide group or an alkyne group via the CuAAC reaction or SPAAC reaction.
[0182] Reference is now made to the linker unit 10J of Figure 1 J, in which the center core 11f has an HPG (GHP) residue at the N-terminus thereof and a cysteine residue at the C-terminus thereof. The linking arms 20 and the coupling arm 60 are respectively linked to the lysine (K) residues and the cysteine (C) residue of the center core 11 f. Further, five first
WO 2017/036255
PCT/CN2016/090296 elements 30 are respectively linked to the five linking arms 20, the second element (i.e., the PEG chain) 80 is linked to the coupling arm 60 via the short PEG chain 62, and the third element 50 is linked to the HPG residue. The solid dot 40 indicated the chemical bond resulted from the CuAAC reaction occurred between the HPG residue and the short PEG chain 62; while the ellipse 70 represents the chemical bond resulted from the iEDDA reaction occurred between the coupling arm 60 and the PEG chain 80.
[0183] Figure 1K provides another embodiment of the present disclosure, in which the linker unit 10K has the similar structure with the linker unit 10J of Figure 1 J, except that the short PEG chain 62 is linked with the HPG residue via the SPAAC reaction, instead of the iEDDA reaction. The diamond 90 in Figure 1K represents the chemical bond resulted from the SPAAC reaction occurred between the short PEG chain 62 and the HPG residue.
[0184] In the preferred embodiments of this disclosure, the linking arms have a maleimide group in the free terminus for conjugating with first elements having the sulfhydryl group via the thiol-maleimide reaction. Also, there is one cysteine residue or an amino acid residue with an azide or alkyne group at a terminus of the peptide core for attaching a coupling arm for linking a second element.
[0185] It is conceivable for those skilled in the arts that variations may be made. A conjugating group, other than maleimide, such as azide, alkyne, tetrazine, or strained alkyne may be used for the free terminus of the linking arms, for linking with first elements with a CuAAC, iEDDA, or SPAAC reaction. Also the cysteine residue (or an amino acid residue with an azide or alkyne group) of the peptide core needs not to be at the N- or C-terminus. Furthermore, two or more of such residues may be incorporated in the peptide core to attach multiple coupling arms for linking a plural of second elements.
[0186] l-(ii) Compound Core for Use in Multi-arm Linker [0187] In addition to the linker unit described in part l-(i) of the present disclosure, also disclosed herein is another linker unit that employs a compound, instead of the polypeptide, as the center core. Specifically, the compound is benzene-1,3,5-triamine, 2-(aminomethyl)-2-methylpropane-1,3-diamine, tris(2-aminoethyl)amine, benzene-1,2,4,5tetraamine, 3,3',5,5'-tetraamine-1,1'-biphenyl, tetrakis(2-aminoethyl)methane, tetrakis47
WO 2017/036255
PCT/CN2016/090296 (ethylamine)hydrazine, N,N,N',N',-tetrakis(aminoethyl)ethylenediamine, benzene1,2,3,4,5,6-hexaamine, 1 -N,1 -N,3-N,3-N,5-N,5-N-hexakis(methylamine)-benzene-1,3,5triamine, 1 -N,1 -N,2-N,2-N,4-N,4-N,5-N,5-N,-octakis(methylamine)-benzene-1,2,4,5triamine, benzene-1,2,3,4,5,6-hexaamine, or N,N-bis[(1-amino-3,3-diaminoethyl)pentyl]methanediamine. Each of these compounds has 3 or more amine groups in identical or symmetrical configuration. Therefore, when one of the amine groups of a compound is conjugated with a coupling arm, all of the molecules of the compound have the same configuration.
[0188] Similar to the mechanism of linkage described in Part l-(i) of the present disclosure, each compound listed above comprises a plurality of amine groups, and thus, a plurality of PEG chains having NHS groups can be linked to the compound via forming an amine linkage between the amine group and the NHS group; the thus-linked PEG chain is designated as linking arm, which has a functional group (e.g., an NHS, a maleimide, an azide, an alkyne, a tetrazine, a cyclooctene, or a cyclooctyne group) at the free-terminus thereof. Meanwhile, at least one of the amine groups of the compound core is linked to another PEG chain, which has an NHS group at one end, and a functional group (e.g., an azide, alkyne, tetrazine, cyclooctene, or cyclooctyne group) at the other end; the thus-linked PEG chain is designated as coupling arm, which has a functional group at the free-terminus thereof.
[0189] Accordingly, a first element can be linked to the linking arm via (1) forming an amide bond therebetween, (2) the thiol-maleimide reaction, (3) the CuAAC reaction, (4) the iEDDA reaction, or (5) SPAAC reaction. Meanwhile, the second element can be linked io the coupling arm via the CuAAC, iEDDA, or SPAAC reaction.
[0190] According to some embodiments of the present disclosure, the linking arm is a PEG chain having 2-20 repeats of EG units; and the coupling arm is a PEG chain having 2-12 repeats of EG unit.
[0191] Schemes 6 and 7 respectively depict the linkages between the center compound core and the linking arm, as well as the coupling arm. In schemes 6 and 7, “NHS” represents the NHS ester, “Mai” represents the maleimide group, “azide” represents the azide group, and “alkyne” represents the alkyne group.
WO 2017/036255
PCT/CN2016/090296 «Scheme 6 Linkage of linking and coupling arms respectively having maleimide group and azide group to center core»
NHS
J nn2
W Z HSN-
Figure AU2016316202B2_D0009
Figure AU2016316202B2_D0010
Figure AU2016316202B2_D0011
Figure AU2016316202B2_D0012
-azide «Scheme 7 Linkage of linking and coupling arms respectively having maleimide group and alkyne group to center core»
...--I NH,.....·, / \.....i.....,
....., : NHS - -fetal
............................. —NH, \-4
NH;,-- H?N •-alkyne
Figure AU2016316202B2_D0013
H . fetai
-N ......
R
H [0192] The requirement of having multiple NH2 groups exist in a symmetrical and identical orientation in the compound serving as the center core is for the following reason: when one of the NH2 group is used for connecting a bifunctional linker arm with N-hydroxysuccinimidyl 10 (NHS) ester group and alkyne, azide, tetrazine, or strained alkyne group, the product, namely, a core with a coupling arm having alkyne, azide, tetrazine or strained alkyne, is homogeneous and may be purified. Such a product can then be used to produce multi-arm linker units with all other NH2 groups connected to linking arms with maleimide or other coupling groups at the other ends. If a compound with multiple NH2 groups in
WO 2017/036255
PCT/CN2016/090296 non-symmetrical orientations, the product with one bifunctional linking arm/coupling arms is not homogeneous.
[0193] Some of those symmetrical compounds can further be modified to provide center cores with more linking arms/coupling arms. For example, tetrakis(2-aminoethyl)methane, which can be synthesized from common compounds or obtained commercially, may be used as a core for constructing linker units with four linking arms/coupling arms. Tetrakis(2-aminoethyl)methane can react with bis(sulfosuccinimidyl)suberate to yield a condensed product of two tetrakis(2-aminoethyl)methane molecules, which can be used as a core for constructing linker units having six linking arms/coupling arms. The linker units, respectively having three linking arms/coupling arms, four linking arms/coupling arms and six linking arms/coupling arms, can fulfill most of the need for constructing targeting/effector molecules with joint-linker configuration.
[0194] As would be appreciated, the numbers of the linking arm and/or the coupling arm and the element linked thereto may vary with the number of amine groups comprised in the center core. In some preferred embodiments, the numbers of the linking arm/coupling arm and the corresponding linking element linked thereto ranges from about 1-7.
[0195] Reference is now made to Figure 2, in which benzene-1,2,4,5-tetraamine having 4 amine groups is depicted. Three of the amine groups are respectively linked to the linking arms 20, and one of the amine group is linked to the coupling arm 60, which has an azide group at its free-terminus. Three first elements 30 are then respectively linked to the three linking arms 20 via the thiol-maleimide reactions, and one second element 50 is linked to the coupling arm 60 via the CuAAC reaction. The solid dot 40 as depicted in Figure 2 represents the chemical bond resulted from the CuAAC reaction occurred between the coupling arm 60 and the second element 50.
[0196] l-(iii) Functional Elements Suitable for Use in Multi-arm Linker [0197] In the case where the linker unit (or multi-arm linker) comprises only the first element but not the second and/or third element(s), the first element is an effector element that may elicit a therapeutic effect in a subject. On the other hand, when the present linker unit comprises elements in addition to first element(s), then at least one of the elements is
WO 2017/036255
PCT/CN2016/090296 an effector element, while the other may be another effector element, a targeting element, or an element capable of enhancing one or more pharmacokinetic properties of the linker unit (e.g., solubility, clearance, half-life, and bioavailability). For example, the linker unit may have two different kinds of effector element, one effector element and one targeting element or one pharmacokinetic property-enhancing element, two different kinds of targeting elements and one kind of effector element, two different kinds of effector elements and one kind of targeting element, or one kind of targeting element, one kind of effector element and one element capable of improving the pharmacokinetic property of the linker unit.
[0198] According to some embodiments of the present disclosure, the present linker unit is useful in preventing the formation of blood clot. In these embodiments, the present linker unit comprises the first element of an scFv specific for fibrin as the targeting element, and the second element of Factor Xa inhibitors or thrombin inhibitors as the effector element. Preferably, the inhibitor of Factor Xa is selected from the group consisting of, apixaban, edoxaban, and rivaroxaban; and the inhibitor of thrombin is argatroban or melagatran.
[0199] Linker units for use in the treatment of thrombosis may comprise the first element of an scFv specific for fibrin as the targeting element, and the second element of tissue plasminogen activators (such as alteplase, reteplase, tenecteplase and lanoteplase) used as the effector element.
[0200] l-(iv) Use of Multi-arm Linker [0201] The present disclosure also pertains to method for treating various diseases using the suitable linker unit. Generally, the method comprises the step of administering to a subject in need of such treatment an effective amount of the linker unit according to embodiments of the present disclosure.
[0202] Compared with previously known therapeutic constructs, the present linker unit discussed in Part I is advantageous in two points:
(1) The number of the functional elements may be adjusted in accordance with the needs and/or applications. The present linker unit may comprise two elements (i.e., the first and second elements) or three elements (i.e., the first, second, and third elements) in
WO 2017/036255
PCT/CN2016/090296 accordance with the requirements of the application (e.g., the disease being treated, the route of administration of the present linker unit, and the binding avidity and/or affinity of the antibody carried by the present linker unit). For example, when the present linker unit is directly delivered into the tissue/organ (e.g., the treatment of eye), one element acting as the effector element may be enough, thus would eliminate the need of a second element acting as the targeting element. However, when the present linker unit is delivered peripherally (e.g., oral, enteral, nasal, topical, transmucosal, intramuscular, intravenous, or intraperitoneal injection), it may be necessary for the present linker unit to simultaneously comprise a targeting element that specifically targets the present linker unit to the lesion site; and an effector element that exhibits a therapeutic effect on the lesion site. For the purpose of increasing the targeting or treatment efficacy or increasing the stability of the present linker unit, a third element (e.g., a second targeting element, a second effector element, or a PEG chain) may be further included in the present linker unit.
(2) The first element is provided in the form of a bundle. As described above, the number of the first element may vary with the number of lysine residue comprised in the center core. If the number of lysine residue in the center core ranges from 2 to 15, then at least two first elements may be comprised in each linker unit. Thus, instead of providing one single molecule (e.g., cytotoxic drug and antibody) as traditional therapeutic construct or method may render, the present linker unit is capable of providing more functional elements (either as targeting elements or as effector elements) at one time, thereby greatly improves the therapeutic effect.
[0203] In certain therapeutic applications, it is desirable to have a single copy of a targeting or effector element. For example, a single copy of a targeting element can be used to avoid unwanted effects due to overly tight binding. This consideration is relevant, when the scFv has a relatively high affinity for the targeted antigen and when the targeted antigen is a cell surface antigen on normal cells, which are not targeted diseased cells. As an example, in using scFv specific for CD3 or CD16a to recruit T cells or NK cells to kill targeted cells, such as thyroid gland cells in patients with Grave’s disease,, a single copy of the scFv specific for CD3 or CD16a is desirable, so that unwanted effects due to cross-linking of the CD3 or CD16a may be avoided. Similarly, in using scFv specific for CD32 or CD16b to recruit phagocytic neutrophils and macrophages to clear antibody-bound
WO 2017/036255
PCT/CN2016/090296 viral or bacterial particles or their products, a single copy of scFv may be desirable. Also, in using scFv specific for transferrin receptor to carry effector drug molecules to the BBB for treating CNS diseases, a single copy of scFv specific for transferrin receptor is desirable. In still another example, it is desirable to have only one copy of long-chain PEG for enhancing pharmacokinetic properties. Two or more long PEG chains may cause tangling and affect the binding properties of the targeting or effector elements.
[0204] PART II Joint-linker Molecular Constructs for Treating Specific Diseases [0205] Another aspect of the present disclosure pertains to a molecular construct comprising at least two linker units, in which one linker unit carries one or more targeting element, whereas another other linker unit carries one or more effector elements or pharmacokinetic property-enhancing elements. In the present disclosure, molecular constructs with both the targeting and effector moieties (whether a therapeutic or pharmacokinetic one) are referred to as joint-linker molecular constructs. According to various embodiments of the present disclosure, each of the linker unit comprised in such joint-linker molecular constructs may be either a peptide core-based or a compound core-based multi-arm linkers discussed above in Part I of the present disclosure. According to certain embodiments of the present disclosure, at least one of the linker units of the present molecular construct comprises the polypeptide core. Preferably, at least two linker units of the present molecular construct comprise the polypeptide cores. More preferably, all the linker units of present molecular construct respectively comprise the polypeptide cores.
[0206] //-(7) Structure of Joint-linker Molecular Construct [0207] According to some embodiments of the present disclosure, the molecular construct comprises two linker units, and the linker units are coupled to each other via either the CuAAC reaction (using copper or pentamethylcyclopentadienyl ruthenium chloride complex as catalyst), the SPAAC reaction, or the iEDDA reaction. In the embodiments, one of the linker units is linked with a plurality of first elements, which act as the targeting elements, and the other of the linker units is linked with a plurality of second elements, which act as the effector elements.
WO 2017/036255
PCT/CN2016/090296 [0208] According to other embodiments of the present disclosure, the molecular construct comprises three linker units, in which the first and second linker units are coupled to each other via the iEDDA reaction, and then, the third linker unit is coupled to the first or second linker unit via the CuAAC reaction. Alternatively, the first and second linker units are coupled to each other via the iEDDA reaction, and the third linker unit is coupled to the first or second linker unit via the SPAAC reaction. In the embodiments, the first, second, and third linker units respectively carry a plurality of first, second, and third elements, in which the first, second, and third elements are different. According to one embodiment, two of the three elements (i.e., the first, second, and third elements) are targeting elements, and one of the three elements is an effector element. According to another embodiment, two of the three elements are effector elements, and one of the three elements is a targeting element. According to still another embodiment, one of the three elements is a targeting element, another of the three elements is an effector element, and the other of the three elements is an element capable of improving the pharmacokinetic property of the molecular construct, such as solubility, clearance, half-life, and bioavailability.
[0209] Reference is first made to Figures 3A-3D, which respectively depicts the linkage between the two linker units. Figure 3A depicts a molecular construct comprising two linker units (100A, 200A), which are coupled to each other via the iEDDA reaction. The first linker unit 100A comprises a first center core 110a, a linking arm 120 (as the first linking arm), and a coupling arm 130a (as the first coupling arm), in which the linking and coupling arms are respectively linked to the first center core 110a at one ends. Similarly, the second linker unit 200A comprises a second center core 210a, a linking arm 220 (as the second linking arm), and a coupling arm 230a (as the second coupling arm), in which the linking and coupling arms are respectively linked to the second center core 210a at one ends. One of the coupling arms 130a, 230a has a tetrazine group at its free terminus, while the other of the coupling arms 130a, and 230a has a TCO group. Specifically, if the coupling arm 130a has a tetrazine group 152 at its free terminus (i.e., the terminus not connected to the first center core 110a), then the coupling arm 230a would have a TCO group 154 at its free terminus (i.e., the terminus not connected to the second center core 210a), and vice versa. Accordingly, the two linker units (100A, 200A) are coupled to each other via the iEDDA reaction occurred between the respective free ends of the coupling arms 130a, 230a. The
WO 2017/036255
PCT/CN2016/090296 ellipse 156 as depicted in Figure 3A represents the chemical bond resulted from the iEDDA reaction occurred between the coupling arms 130a, 230a.
[0210] In the depicted embodiment, each of the linking arms 120, 220 has a maleimide group at its free terminus. Accordingly, a first targeting element 140 and a first effector element 240, each has a thiol group are respectively linked to the linking arms 120, 220 via the thiol-maleimide reaction.
[0211] According to one embodiment, both the first and second center cores 110a, 210a depicted in Figure 3A are polypeptide cores. According to another embodiment, both the first and second center cores 110a, 210a depicted in Figure 3A are compound cores. According to still another embodiment, one of the first and second center cores 110a, 210a depicted in Figure 3A is a polypeptide core, while the other of the first and second center cores 110a, 210a depicted in Figure 3A is a compound core.
[0212] Figure 3B provides an alternative embodiment of the present disclosure, in which both the first and second center cores 110b, 210b are polypeptide cores, and are respectively linked to a first targeting element 140 and a first effector element 240 via the linking arms 120, 220. The unique feature in this embodiment is that, one of the center cores 110b, 210b comprises an amino acid residue having an azide group (e.g., the AHA residue) at it N- or C-terminus, while the other of the center cores 110b, 210b comprises an amino acid residue having an alkyne group (e.g., the HPG residue) at it N- or C-terminus, such configuration allows the center cores 110a, 210a to be directly linked to each other, that is, without connecting through any coupling arms as that depicted in Figure 3A. Specifically, if the center core 110b comprises the amino acid residue having the azide group 162 at its N- or C-terminus, then the center core 210b would comprises the amino acid residue having the alkyne group 164 at its N- or C-terminus, and vice versa. Accordingly, the linker units 100B, 200B can couple together directly via the CuAAC reaction occurred between the N- or C-terminal amino acid residues of the center cores 110b, 210b. The solid dot 166 as depicted in Figure 3B represents the chemical bond formed between the N- or C-terminal amino acid residues.
[0213] Figure 3C is another embodiment of the present disclosure. The linker units 100C, 200C have the similar structures as the linker units 100A, 200A, except that the
WO 2017/036255
PCT/CN2016/090296 coupling arms 130b, 230b respectively have an azide group 162 and a DBCO group 172, instead of the azide group 152 and the alkyne group 154 as depicted in the linker units 100A, 200A of Figure 3A. Specifically, the center core 110a is linked with a coupling arm 130b (as the first coupling arm) having an azide group 162 at its free-terminus; and the center core 210a is linked with a coupling arm 230b (as the second coupling arm) having a DBCO group 172 at its free-terminus. The linker units 100C, 200C are then coupled via the SPAAC reaction occurred between the coupling arms 130b, 230b; and forming the chemical bond 182, depicted as a diamond.
[0214] In one embodiment, both the first and second center cores 110a, 210a depicted in Figure 3C are polypeptide cores. In another embodiment, both the first and second center cores 110a, 210a depicted in Figure 3C are compound cores. In still another embodiment, one of the first and second center cores 110a, 210a depicted in Figure 3C is a polypeptide core, while the other of the first and second center cores 110a, 210a depicted in Figure 3C is a compound core.
[0215] As would be appreciated, two linker units can be coupled to each other via the CuAAC reaction occurred between the center core and the coupling arm. Reference is now made to Figure 3D, in which the center core 110b comprises a N- or C-terminal amino acid residue that has an azide group 162 (e.g., the AHA residue), and the center core 210a is linked with a coupling arm 230b having a TCO group 172 at its free-terminus. Accordingly, the linker units 100B and 200C can be coupled via the SPAAC reaction occurred between the center core 110b and the coupling arm 230b; and forming the chemical bond 182.
[0216] According to one embodiment, the linker units 100B, 200C depicted in Figure 3D respectively comprise polypeptide cores. According to another embodiment, the center core 100B depicted in Figure 3D is a polypeptide core, while the center core 200C depicted in Figure 3D is a compound core.
[0217] Alternatively, the linker unit 200B that comprises a N- or C-terminal amino acid residue having an alkyne group 160b (e.g., the HPG residue), and the linker unit 100C comprising the coupling arm 130b with an azide group 160a at its free-terminus can be
WO 2017/036255
PCT/CN2016/090296 coupled together via the azide-alkyne cycloaddition occurred between the center core 210b and the coupling arm 130b.
[0218] Compared with other therapeutic construct, the present molecular construct is advantageous in at least the three following aspects:
(1) the linker unit comprising a specified number and/or type of targeting/effector element can be prepared independently, then proceed to be coupled together via the CuAAC reaction, the iEDDA reaction, or the SPAAC reaction;
(2) the number and kind of the targeting and/or effector elements may vary in accordance with the requirements of application (e.g., the disease being treating, and the binding avidity and/or affinity of the targeting and/or effector element). The combination of the targeting and effector elements may be adjusted according to specific needs and/or applications. Each of the present targeting and effector elements may vary with such factors like particular condition being treated, the physical condition of the patient, and/or the type of disease being treated. The clinical practitioner may combine the most suitable targeting element and the most suitable effector element so as to achieve the best therapeutic effect. According to embodiments of the present disclosure, the targeting element may be a growth factor, a peptide hormone, a cytokine, or an antibody fragment; and the effector element may be an immunomodulant, a chelator complexed with a radioactive nuclide, a cytotoxic drug, a cytokine, a soluble receptor, or an antibody; and (3) compared with other coupling reactions, the CuAAC reaction, the iEDDA reaction, or the SPAAC reaction is more efficient in terms of coupling any two linker units.
[0219] Reference is now made to Figure 4, in which six libraries are illustrated, and are prepared independently. In this embodiment, Libraries 1-6 respectively comprise a plurality of linker units 300A, 300B, 300C, 400A, 400B, and 400C that are linked with functional elements. Each linker units 300A, 300B, and 300C are similar in structures; in which each of the linker units 300A, 300B, and 300C comprises one center core 310, one coupling arm 330 linked thereto and has a tetrazine group 350 at its free terminus, and a specified number of the linking arm 320. For instance, Linker unit 300A comprises four linking arms 320, and accordingly, four targeting elements 340a can be respectively linked to the four linking arms 320. Similarly, two targeting elements 340b and five targeting elements 340c can be respectively linked to the linker units 300B and 300C. The targeting
WO 2017/036255
PCT/CN2016/090296 elements 340a, 340b, and 340c can be the same or different. As to the linker units 400A, 400B, and 400C, each of these linker units comprises one center core 410, one coupling arm 430 linked thereto and has a strained alkyne group 450 at its free terminus, and a specified number of the linking arm 420. As depicted, three effector elements 440a, five effector elements 440b, and eight effector elements 440c can be respectively linked to the linker units 400A, 400B, and 400C. The effector elements 440a, 440b, and 440c can be the same or different. The Libraries 1-6 may be prepared independently. One skilled artisan may select the first linker unit from Libraries 1, 2 and 3, and the second linker unit from Libraries 4, 5, and 6, then proceed to couple the first and second linker units via the iEDDA reaction occurred between the tetrazine group 350 and the strained alkyne group 450 so as to produce the molecular construct with the specified number of targeting and effector elements.
[0220] Based on the library concept, the present molecular construct can be produced with different configurations depending on the libraries selected. Figure 5A provides an example of the present molecular construct, in which each of the first and second center cores (310, 410) is linked with three linking arms (320, 420) and one coupling arm (330, 340). Three of the first targeting elements 340 are respectively linked to the linking arms 320; and three of the first effector elements 440 are respectively linked to the linking arms 420. The two linker units are coupled to each other via the iEDDA reaction occurred between two coupling arms 330, 430, and forming the chemical bond 356. By this configuration, equal numbers of multiple targeting and/or effector elements may be carried in one molecular construct.
[0221] Figure 5B provides another example of the present molecular construct, in which the first and second center cores respectively contain different numbers of amine groups (e.g., lysine residues), and accordingly, the molecular construct contains non-equal numbers of targeting and effector elements. In the depicted example, the first center core 310 is linked to one coupling arm 330, and two linking arms 320. The second center core 410 is linked to one coupling arm 430, and five linking arms 420. Accordingly, two targeting elements 340 are respectively linked to the linking arms 320; and five effector elements 440 are respectively linked to the linking arms 420. The ellipse 356 in Figure 5B represents the linkage between two coupling arms 330, 430.
WO 2017/036255
PCT/CN2016/090296 [0222] In optional embodiments, the present molecular construct may further comprise a relatively long PEG chain connected to either the first or second center core, so that the present molecular construct may be segregated further away from the reticuloendothelial system and attains a longer half-life after being administered to a subject. In the case where a protein is modified by a PEG chain so as to improve its pharmacokinetic properties and/or to decrease immunogenicity, PEG up to 20,000-50,000 Daltons in length, is preferred. Accordingly, in one preferred embodiment of the present invention, linking arms of relatively shorter lengths are used to connect the targeting and effector elements, while a PEG chain of 20,000 to 50,000 Daltons is connected to any of the linker units with the purpose of increasing in vivo half-life of the present molecular construct.
[0223] In some embodiments, multiple scFv fragments are used as the targeting and/or effector elements to construct the present molecular construct. The targeting element/effector element pharmaceuticals based on molecular constructs comprising scFv fragments should have longer in vivo half-lives than individual antibody fragments. For some clinical applications, much extended half-lives of the pharmaceuticals are desired, so as to eliminate the need of frequent administration of the drugs in these cases, PEG chains that are 20,000 to 50,000 Daltons by weight, may be used as the linking arms to link the scFv fragments that serve as targeting or effector elements. PEGs of these lengths have been used to modify a large number of therapeutic proteins to increase their half-lives.
[0224] According to some embodiments of the present disclosure, the linker unit may comprise two linking arms respectively linked to the different functional elements. Reference is now made to Figure 6, in which the molecular construct comprises two linker units 100A and 200D. The first and second functional elements 140, 240 (one serves as the targeting element, and the other serves as the effector element) are respectively linked to the first center core 110a and the second center core 210c via the linking arms 120, 220; and the two center cores 110a, 210c are coupled to each other via the iEDDA reaction occurred between the coupling arms 130a, 230a, in which the ellipse 156 represents the chemical bond forming therebetween. In addition to the functional element 240, the second center core 210c is further linked to a PEG chain 260. Specifically, the second center core 210c comprises an AHA residue, which can be reacted with and linked to the PEG chain 260 having a stained alkyne group via the SPAAC reaction, in which the
WO 2017/036255
PCT/CN2016/090296 diamond 182 represents the chemical bond forming from the SPAAC reaction. Depending on the intended and desired use, the third element can be a second targeting element, a second effector element, or an element capable of improving the pharmaceutical property of the molecular construct. According to one embodiment of the present disclosure, the PEG chain 260 has a molecular weight about 20,000 to 50,000 Daltons.
[0225] Based on the concept, a linker unit may comprise a plurality of linking arms, which can be linked to a plurality of functional elements. For example, a linker unit may comprise 5-12 linking arms, which can be linked to 5-12 functional elements. This is especially useful when the functional elements are small molecules, such as cytotoxic drugs or toll-like receptor agonists. The linker unit carrying multiple molecules of a cytotoxic drug is herein referred to as a drug bundle.
[0226] Further, the polypeptide cores can be employed to prepare the molecular construct comprising three linker units. Accordingly, another aspect of the present disclosure is directed to a molecular construct comprising three linker units. Among the three linker units, two of them may be connected to each other via the iEDDA reaction, while the third linker unit is connected to any of the two linker units by the SPAAC reaction or CuAAC reaction. The rationale for constructing a multi-linker unit (e.g., three linker units) is that two different sets of targeting elements or two different sets of effector elements can be incorporated therein.
[0227] Reference is now made to Figure 7, in which the molecular construct comprises three linker units (500, 600, 700A). The linker units 500, 600, 700A respectively comprise a center core (510, 610, 710), and an linking arm (520, 620, 720) with a functional element (540, 640, 740) linked thereto. The linker unit 600 is characterized in comprising a cysteine residue at one of its N- or C- terminus that is linked with a coupling arm 630; and an amino acid residue having an azide or alkyne group at the other of its N- or C- terminus. One of the coupling arms 530, 630 has a tetrazine group at its free terminus, and the other of the coupling arms 530, 630 has a strained alkyne group at its free terminus. Accordingly, the linker units 500, 600 can be coupled to each other via the iEDDA reaction occurred between the coupling arms 530, 630 as the linkage manner described in Figure 3A. As to the linkage of the linker unit 300, when the N- or C-terminal amino acid residue of the center
WO 2017/036255
PCT/CN2016/090296 core 610 has an azide group (e.g., the AHA residue), the center core 710 comprises an amino acid having an alkyne group (e.g., the HPG residue) at its N- or C- terminus; or, when the N- or C-terminal amino acid residue of the center core 610 has an alkyne group (e.g., the HPG residue), then the center core 710 comprises an amino acid having an azide group (e.g., the AHA residue) at its N- or C- terminus. Thus, as the linkage manner described in Figure 3B, the linker units 600, 700A can be directly coupled to each other via the CuAAC reaction occurred between the N- or C-terminal amino acid residues of the center cores 610, 710 without the presence of the coupling arms. The ellipse 560 and the solid dot 670 in Figure 7 respectively represent the chemical bonds resulted from the iEDDA reaction and the CuAAC reaction.
[0228] Alternatively, two of the three linker units may be connected to each other via the iEDDA reaction, while the third linker unit is connected to any of the two linker units by the SPAAC reaction. Reference is now made to Figure 7B, in which the linker units 500, 600 are coupled together via the iEDDA reaction as described in Figure 7A, whereas the linker unit 700B is linked to the linker unit 600 via the SPAAC reaction occurred between the center core 610 and the coupling arm 730. The diamond 672 in Figure 7B represents the chemical bond resulted from the SPAAC reaction.
[0229] As would be appreciated, each number of the functional elements 540, 640, 740 respectively linked to the linker units 100, 200, 300 are different depending on the intended use. With the library concept depicted in Figure 4, the linker units respectively carrying different numbers and/or types of functional elements can be prepared separately as different libraries, and one skilled artisan may select and combine the desired linker units from the libraries in accordance with the various applications.
[0230] Basically, the coupling arm of the present molecular construct described in above aspects and/or embodiments of the present disclosure that has an azide, alkyne, tetrazine, or strained alkyne group at the terminus is designed as a PEG chain having 2-12 repeats of EG units. The linking arm is designed as a PEG chain having 2-20 repeats of EG units.
[0231] Adopting a polypeptide as the center core provides versatility in the present molecular construct, in which multiple copies or types of targeting/effector elements may be present in one construct, accordingly, enhanced specificity of drug delivery and potency in
WO 2017/036255
PCT/CN2016/090296 the intended target sites are achieved. A large number of configurations can be adopted by employing the molecular construct comprising multiple linker units. A few examples are: a first linker unit carrying three scFvs targeting elements, and a second linker unit carrying 5 cytotoxic drugs; a first linker unit carrying three scFvs targeting elements, and a second linker unit carrying three scFvs effector elements; a first linker unit carrying two scFvs of the first set targeting elements, a second linker unit carrying two scFvs of the second set targeting elements, and a third linker unit carrying 5 cytotoxic drugs; a first linker unit carrying 2 bi-scFv targeting elements, and a second linker unit carrying two scFvs effector elements; or a first linker unit carrying three scFvs targeting elements, a second linker unit carrying two scFvs effector elements plus a linking arm attached with a long PEG of 20,000-50,000 Daltons for the purpose of increasing pharmacokinetic properties.
[0232] In some embodiments of this invention, a bi-functional PEG acting as a linking arm is used to link the antigen-binding fragments of antibodies, which serve as targeting or effector elements, to the amine groups located in the polypeptide core. Each PEG may have NHS group at one end and maleimide group at the other end. The NHS group may couple with amine group in the polypeptide core, while the maleimide group may couple with sulfhydryl group of a cysteine residue of an scFv, bi-scFv, or Fab fragment of an antibody. The scFv and bi-scFv are engineered to have a polypeptide linker with terminal cysteine residue at the C-terminal. Fab may be derived from a whole IgG by pepsin cleavage, and the free sulfhydryl groups are derived from the inter-chain disulfide bond by a mild reduction reaction.
[0233] Schemes 8-12 provide several working example respectively depicting the coupling and preparation of specified linker units.
[0234] Scheme 8 is a schematic diagram depicting the preparation of the present molecular construct in accordance with one embodiment of the present disclosure, in which NHS represents NHS ester, Mai represents maleimide group, Aah represents L-azidohomoalanine (AHA) residue, AAH represents homopropargylglycine (HPG) residue, Ac represents acetyl group, and scFv represent single-chain variable fragment.
[0235] In step 1, the first center core comprising the amino acid sequence of (GSK)3 and a L-azidohomoalanine (AHA) residue at the C-terminus thereof; and the second center core
WO 2017/036255
PCT/CN2016/090296
Figure AU2016316202B2_D0014
comprising the amino acid sequence of (GSK)5 and a homopropargylglycine (HPG) residue at the C-terminus thereof, are respectively prepared. For the purpose of stabilizing the polypeptide, the N-terminuses of the first and second center cores are respectively modified with an acetyl group. In step 2, the linking arms are respectively linked to the lysine residues in the first and second center cores via forming an amide linkage there between;
the linked arm linked to the center core has a maleimide group at the free-terminus. In step 3, the first targeting element (such as an scFv specific for fibrin) having a thiol group (e.g., a cysteine residue) is linked to the linking arm linked with the first center core via the thiol-maleimide reaction; similarly, the effector element (i.e., the drug, such as a Factor Xa 10 inhibitor or thrombin inhibitor) having a thiol group is linked to the linking arm linked with the second center core via the thiol-maleimide reaction. In step 4, the two linker units are coupled via a CuAAC reaction occurred between the AHA and HPG residues.
«Scheme 8 Coupling of linker units via C-terminal amino acid residues»
N-terminal N-terrrtinal
AMGSK)3-(GGGGS)rAAH
I
Ac~(GSK)3-(GGGGS)2~Aah
Γ ’ Mai * scFv a fibrin
I ^-terminal
Ac-(GSK)3-(GGGGS)2-A*« scFv ά fibrin i azide-alkyne cycloaddition ί reaction
Figure AU2016316202B2_D0015
WO 2017/036255
PCT/CN2016/090296 [0236] Optionally, the targeting/effector element can be linked to the center core in an alternative method. Scheme 9 is a scheme illustrating the coupling of the effector element with the polypeptide core, in which the linking arm is first linked to the center core, and then the effector element (i.e., the drug) is linked to the linking arm via the thiol-maleimide reaction.
«Scheme 9 Method of coupling of effector element with polypeptide core through linking to linking arms»
Ac-Aah-(SGGGG)2-(GSK)5
I + NHS—PEG—Ma!
i
Ac-Aah-(SGGGG)2-(GSK)5
Mai i + drug ¥
Ac-Aah-(SGGGG)2-(GSK)5 drug [0237] In the alternative method of scheme 10, the effector element (i.e., the drug) is 10 coupled to the linking arm so as to produce a linking arm-effector conjugate (i.e., PEG-drug);
next, the linking arm-effector conjugate is linked to the center core via forming an amide linkage between the lysine residues and the NHS esters.
«Scheme 10 Alternative method of coupling of effector element with polypeptide core by first conjugating with PEG chain and then linking to amino groups of lysine 15 residues»
Ac-Aah-(SGGGG)2-(GSK)5 + NHS—PEG—drug ¥
Ac-Aah-(SGGGG)2-(GSK)5 drug
WO 2017/036255
PCT/CN2016/090296 [0238] Alternatively, the linking arms for the joint-linker configuration may also be used to link bispecific scFv, which act as targeting elements or effector elements. These configurations will increase the specificity of targeting and/or the potency of the effector mechanisms.
[0239] Scheme 11 provides an example of preparing the present molecular construct, which comprises two linker units; both linker units comprises the amino acid sequence of (K-Xaa4)3 and a cysteine (C) residue at the C-terminus thereof.
«Scheme 11 Preparation of molecular construct via iEDDA reaction occurred between coupling arms»
N-terminal
AofK-Xaa^a-C
Ma ~PEG4~tetraz ne
Mai-PEGs-TCO
Ac-(K * Xaa^-OPEG^tetrazine
Ac-(K‘ Xaa4)3-C-PEG3-TCO + NHS——Mai v
Ac-(^« Xaa4)3»C’PEG4»tetrazine 5
Mai + scFv a fibrin
Ac-(K · Xaa4)3-C-PEG4~tetrazine j scFv a fibrin\
Ac-(K· Xaa4)3-C-PEG3»TCO
ΜβΙ ] + tPA analogue
I
Ac-(K · Xaa4)3-C-PEG3-TCO [0240] In step 1, two coupling arms are respectively linked to the C residues of the linker units, in which one of the coupling arms has a maleimide (Mai) group at one terminus and a tetrazine group at the other terminus, while the other coupling arm has a Mai group at one terminus and a TCO group at the other terminus. In step 2, the linking arms are respectively linked to the lysine (K) residues via forming the amide bond between the linking
WO 2017/036255
PCT/CN2016/090296 arm and the K residue. Then, in step 3, three anti-fibrin scFvs (scFv a fibrin) and three tPA analogues are respectively linked to the linking arms of the linker units via the thiol-maleimide reaction. Finally, in step 4, the two linker unit are coupled to each other via the iEDDA reaction occurred between the tetrazine and TCO group.
[0241] When the targeting and effector elements are all scFv, and linking arms of 600 Daltons (12 EG units) are used, a molecular construct with a total of six scFvs has a molecular weight of about 170,000 Daltons. A molecular construct with seven scFvs has a molecular weight of about 200,000 Daltons, and a molecular construct with eight scFvs has a molecular weight of about 230,000 Daltons. Most of the molecular constructs of this invention have molecular weights smaller than 200,000 Daltons, and a few molecular constructs have molecular weights in 200,000-250,000 Daltons.
[0242] When four different sets of scFv are to be carried in one molecular construct, it is preferable to have one linker unit carrying a joined single-chain, bi-specific scFv (bi-scFv), such as scFv1-scFv2, and the other two linker units each carrying one scFv (i.e., scFv3 and scFv4 respectively). There are two ways to construct bi-specific scFv1-scFv2. In the “tandem” configuration, Vl1-Vh1-Vl2-Vh2 or Vh1-Vl1-Vh2-Vl2 is arranged; in the “diabody” configuration, Vl2-Vi_1-Vh1-Vh2 or Vh2-Vh1-Vl1-Vi_2 is arranged. Proper linkers with GGGGS (SEQ ID NO: 6) repeats or other sequences are placed between the immunoglobulin domains.
[0243] In our experience, a peptide or a PEG linker, which contain maleimide and azide groups may become polymerized upon long-term storage, due to the automatic coupling reaction between the maleimide and azide groups. Therefore, it is preferable that each linker unit is prepared freshly and independently, and processed to connecting the targeting or effector elements onto the linker units, and the coupling of the linker units through click reaction without delay. An alternative preferred embodiment is that the targeting elements and effector elements are both conjugated to linker units with alkyne groups, and the alkyne group in one of the linker units is then converted to azide with a short homo-bifunctional linker with azide at both ends. The linker units, one with alkyne and the other with azide, are then coupled via a click reaction.
WO 2017/036255
PCT/CN2016/090296 [0244] The preferred linking arms for this invention are PEG. The length of the linking arms is important for several considerations. It should be long enough to allow flexibility of the linked scFv or other types of functional elements to reach targeted antigenic sites on targeted cell surface without steric constraints; yet not long enough to cause intra-molecular and inter-molecular tangling of the linking arms and their linked scFv fragments or functional elements, or to unnecessarily increase the size of the whole molecular construct for hindering tissue penetration. Linking arms that are too long may also fail to pull antigen molecules to form compacted clusters, if such clusters are required to initiate signal-transducing process for apoptosis or other cellular effects. The optimal length of linking arms for different types of combinations of targeted antigens and their binding agents may be determined by any skilled artisan in the related field without undue experimentation. A linking arm of NHS-(PEG)i2-Maleimide (approximately 500 Daltons) is preferred in a number of molecular construct of this invention. A fully stretched (PEG)i2 has a length of 40-50 A.
[0245] Applicable linking arms and coupling arms are not limited by PEG chains. Peptides comprising glycine, serine and other amino acid hydrophilic residues, and polysaccharides, and other biocompatible linear polymers, which are modified to contain NHS and maleimide groups, can be used.
[0246] For certain therapeutic applications, it is desirable that the effector elements in the molecular constructs of this disclosure be released from the linking arms, so that they can get into cells in the targeted site, including cells bound by the targeting elements or surrounding cells, to cause pharmacological effects. In those cases, a cleavable bond is engineered in the linking arm. Cleavable bonds, which are susceptible for cleavage by hydrolysis, acid exposure, reduction, and enzymes, have been developed. For example, peptide segments susceptible to matrix metalloproteinases, which are present in inflammatory tissues, have been used in constructing therapeutic constructs. One embodiment of the present invention is to use PEG linkers with S-S bond adjacent to the maleimide group NHS-PEG2_i2-S-S-maleimide, wherein S-S is a disulfide bond, which can be slowly reduced.
WO 2017/036255
PCT/CN2016/090296 [0247] According to some embodiments of the present disclosure, the targeting element described in above-mentioned embodiments is selected from the group consisting of a growth factor, a peptide hormone, a cytokine, and an antibody fragment; and the effector element is an immunomodulant, a chelator complexed with a radioactive nuclide, a cytotoxic drug, a cytokine, a soluble receptor, or an antibody.
[0248] In the embodiments, the antibody is in the form of an antigen-binding fragment (Fab), a variable fragment (Fv), a single-chain variable fragment (scFv), a single domain antibody (sdAb), or a bi-specific single-chain variable fragment (bi-scFv). According to one embodiment, the bi-scFv is a bi-specific tandem scFv or a bi-specific diabody scFv.
[0249] In order to retain diffusing ability of the molecular constructs, a molecular size smaller than 250,000 Daltons is preferred. Thus, scFv fragments are preferred for most of the embodiments. At the DNA level, genes are constructed so that the VL and VH are linked as a single polypeptide in either order (VL-VH or VH-VL) by a peptide linker of 10-25 amino acid residues with glycine and serine being the major residues. At the C-terminal, a short stretch with glycine and serine and a terminal residue cysteine is engineered. Recombinant scFv and bi-scFv can be produced in bacteria, such as E. coli and Pseudomonas putida, in yeast, such as Pichia pastoris, or in mammalian cells, such as CHO and HEK293 cell lines.
[0250] The inventors’ laboratory have produced a large number of IgG antibodies, Fab, scFv and various antibody fragments, Fc-based proteins, and other recombinant antibodies in HEK293 and CHO cell lines for experimentation in in vitro systems and in animal models. Our laboratory has also developed cell lines for producing antibodies for human clinical trials. The HEK293 transient expression system can be conveniently employed to produce up to 1 g of IgG or antibody fragments using a few flasks of 1-2 liters in the research laboratory. The scFv fragments to be used in the molecular constructs of this invention generally do not have a carbohydrate modification, and carbohydrate modification is not required for the binding activity of the scFv to their antigenic targets. Furthermore, only one disulfide bond and one terminal cysteine are present in the scFv fragment. Therefore, small-scale bacterial expression systems have been developed as a manufacturing alternative for producing scFv. With E. coli, expression systems for recovering scFv in
WO 2017/036255
PCT/CN2016/090296 intracellular inclusion bodies, in periplasm, and in secreted form have been employed. The scFv can be purified in most cases with an affinity column with Protein L, which interacts with Vh of most κ light chain, or in other cases with ion-exchange columns.
[0251] The examples of this invention based on the joint-linker platform employ mainly scFv and Fab as the targeting and/or effector elements. However, specific binding molecules may also be screened from large libraries of binding molecules based on sdAb or other antibody fragments. Libraries of binding molecules, which are not based on immunoglobulin domains but resemble antibodies in having specific binding affinities to selected target molecules, include (1) aptamers, which are oligonucleotides or short peptides selected for binding to target molecules, (2) fynomers, which are small binding proteins derived from the human Fyn SH3 domain, (3) affimers, which are binding proteins derived from the cysteine protein inhibitor family of cystatins, and (4) DARPins (designed ankyrin repeat proteins), which are genetically engineered proteins with structures derived from the natural ankyrin proteins and consist of 3, 4, or 5 repeat motifs of these proteins. These antibody-mimetics have molecular weights of about 10K to 20K Daltons.
[0252] //-(77) Functional Elements Suitable for Use with Joint-linker Molecular
Construct [0253] As discussed above, the present joint-linker comprises at least two linker units, in which the first linker unit carries one or more targeting elements, and the second linker unit carries one or more effector elements or pharmacokinetic property-enhancing elements, and vice versa. Specific examples of the functional elements incorporated in the present joint-linker molecular construct for treating a particular disease are discussed below.
[0254] In constructing joint-linker molecular constructs for treating diseases/conditions associated with blood clots, one may use an scFv specific for fibrin as the targeting element. In the case where the prevention of blood clot formation is the main purpose, the present joint-linker molecular constructs may use Factor Xa inhibitors or thrombin inhibitors as the effector element. Illustrative examples of Factor Xa inhibitors include apixaban, edoxaban, and rivaroxaban. Non-limiting examples of thrombin inhibitors include argatroban and melagatran. For joint-linker molecular constructs aiming to treat thrombosis, tissue
WO 2017/036255
PCT/CN2016/090296 plasminogen activators, such as alteplase, reteplase, tenecteplase, and lanoteplase, can be used as the effector element.
[0255] ll-(iii) Use of Joint-linker Molecular Construct [0256] The present disclosure also pertains to methods for preventing the formation of blood clot and treating thrombosis using the suitable joint-linker molecular construct. Generally, the method comprises the step of administering to a subject in need of such treatment an effective amount of the joint-linker molecular construct according to embodiments of the present disclosure.
[0257] PART III Fc-based Molecular Constructs for Preventing the Formation of Blood Clot and Treating Thrombosis and Uses thereof [0258] In the broad sense of the Fc-based configuration, immunoglobulin antibody can serve as the base of a targeting or effector element, and its corresponding effector or targeting element can be incorporated at the C-terminal of its two heavy γ chains in the form of scFv domains. For a typical “Fc-based” configuration, two-chain IgG.Fc is used as the base of the molecular platform. Each of the polypeptide chain is fused with one or two targeting and one or two effector elements, for a total of two to three elements on each chain. The T-E molecule with an Fc-based configuration will have a total of four to six elements (e.g., scFv, growth factor, or cytokines). Optionally, the Fc portion of the molecular constructs also carries Fc-mediated effector functions, ADCC, and/or complement-mediated activation. While in certain other applications, such Fc-mediated effector functions are avoided.
[0259] By selecting the T-E elements of the present Fc-based molecular construct, the molecular construct can be used to prevent and/or treat conditions associated with coagulation, including the formation of the blood clot and thrombosis. The present disclosure is also advantageous in that, in some embodiments, it utilizes the linker unit proposed in the present disclosure, which provides a facile means for controlling the amount of the cytotoxic drug payload of the present Fc-based molecular constructs. Depending on the targeting and/or effector elements selected, the present Fc-based
WO 2017/036255
PCT/CN2016/090296 molecular construct may take different configurations, which are discussed below, respectively.
[0260] In a first series of Fc-based molecular constructs, the targeting element is an antibody or a fragment thereof, whereas the effector element is a peptide.
[0261] Referring to Figure 8A, which is a schematic diagram illustrating an Fc-based molecular construct 1200A comprises a pair of targeting elements T1 (as scFvs) linked to the N-termini of the pair of CH2-CH3 segments 1210, and a pair of effector elements E1 (in the form of therapeutic peptides) linked to the C-termini of the pair of CH2-CH3 segments 1210. Alternatively, in the Fc-based molecular construct 1200B of Figure 8B, the pair of targeting elements T1 (as scFvs) is linked to the C-termini of the pair of CH2-CH3 segments 1210, whereas the pair of effector elements E1 (in the form of therapeutic peptides) is linked to the C-termini of the pair of CH2-CH3 segments 1210.
[0262] In some embodiments, the CH2-CH3 chains are adopted from human immunoglobulins γ1 or γ4. In general, γ1 is chosen, when Fc-mediated functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-mediated activity (inflammatory activation or target cell lysis), are desired. In the case where Fc-mediated functions are avoided, γ4 is chosen for constructing the present Fc-based molecular constructs.
[0263] In some embodiments, the pair of the targeting elements takes a Fab configuration (i.e., consisting of the Vh-CH1 domain and the Vl-Ck domain); this Fab fragment is linked to the N-termini of the CH2-CH3 chains, so that the Fc-based molecular construct adopts an IgG configuration. In these cases, the pair of effector elements may be linked to the C-termini of the pair of CH2-CH3 segments.
[0264] For example, in the Fc-based molecular construct 1200C of Figure 8C, each of the two targeting elements T1 comprises the Vh-CH1 domain 820 and the Vl.Ck domain 825, thereby forming a Fab configuration 830 that is linked to the N-termini of the CH2-CH3 chains 810, so that the Fc-based molecular construct 1200C adopts the IgG configuration. In this case, the pair of effector elements E1 (a therapeutic peptide) is linked to the C-termini of the pair of CH2-CH3 chains 810.
WO 2017/036255
PCT/CN2016/090296 [0265] In a second series of Fc-based molecular constructs, the targeting element can be an antibody or a fragment thereof, and the elector element can be a drug bundle.
[0266] In these cases, the Fc-based molecular constructs for treating diseased cells may have the configuration of molecular construct 1000A of Figure 9A or molecular construct 1000B of Figure 9B. As illustrated in Figure 9A, the effector elements E1 (for example, drug bundles) are linked to the C-termini of the pair of CH2-CH3 segments 1010, whereas the targeting elements T1 (in this case, an scFv) are linked to the N-termini of the pair of CH2-CH3 segments 1010. According to alternative embodiments, the molecular construct 1000B (see, Figure 9B) has a pair of targeting elements T1 that takes the form of a Fab 1030. Specifically, the Fab 1030 configuration comprises the Vh-CH1 domain 1020 and the Vl-Ck domain 1025, and is linked to the N-termini of the pair of CH2-CH3 segments 1010, so that the Fc-based molecular construct 1000A adopts the IgG configuration. In this case, the pair of effector elements E1 is linked to the C-termini of the pair of CH2-CH3 chains 1010.
[0267] In some embodiments, the CH2-CH3 chains are adopted from human immunoglobulins y1 or y4. In general, y1 is chosen, when Fc-mediated functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-mediated activity (inflammatory activation or target cell lysis), are desired. In the case where Fc-mediated functions are avoided, y4 is chosen for constructing the present Fc-based molecular constructs.
[0268] As could be appreciated, the drug bundle (i.e., effector element E1) may be provided as the linker unit discussed in the present disclosure (see, for example Figure 1A to Figure 1C). According to the principles and spirits of the present disclosure, a targeting construct (comprising the pair of CH2-CH3 segments 1010 and the targeting elements T1) and the drug bundles (for use as effector elements E1) can be prepared separately and then conjugated with each other.
[0269] According to embodiments of the present disclosure, the drug bundle comprises a center core, a plurality of linking arms, and optionally, a coupling arm. The center core may be a compound having a plurality of amine groups or a polypeptide comprising a plurality of lysine (K) residues, according to various embodiments of the present disclosure.
WO 2017/036255
PCT/CN2016/090296
Each of the linking arms has one terminus that is linked to the center core by reacting with the amine groups of the compound core or the amine side chain of the K residues of the polypeptide core. The linking arm also carries a maleimide group at the free terminus thereof, wherein each of the drug molecules is linked to the center core via connecting through the linking arm by reacting with the maleimide group. According to optional embodiments of the present disclosure, each of the effector elements E1 is a drug bundle with 3-5 cytotoxic molecules.
[0270] In the case where the center core is the polypeptide core, then the amino acid residue at the N- or C-terminus of the center core is a cysteine residue or has an azide group or an alkyne group. According to certain embodiments, for polypeptide cores with a terminal amino acid residue having the azide group, the drug bundle is linked to the peptide extension via the SPAAC reaction or CuAAC reaction occurred between said terminal residue and the C-terminus of the peptide extension. Alternatively, when the polypeptide cores has a terminal amino acid residue with the alkyne group, the drug bundle is linked to the peptide extension via the CuAAC reaction occurred between said terminal residue and the C-terminus of the peptide extension. Still alternatively, for polypeptide cores with a terminal residue that is cysteine or for compound cores, the drug bundle further comprises said coupling arm. Specifically, the coupling arm has one terminus linked to the center core by reacting with the cysteine residue of the polypeptide core or one amine group of the compound core. The coupling arm also carries an alkyne group, azide group, tetrazine group, or strained alkyne group at the free terminus thereof, so that the drug bundle is linked to the C-terminus of the peptide extension via the iEDDA reaction (for coupling arms with the tetrazine or cyclooctene group), SPAAC (for coupling arms with the azide or cyclooctyne group) reaction or CuAAC reaction (for coupling arms with the alkyne or azide group) occurred therebetween.
[0271] According to certain embodiments, the present Fc-based molecular construct for treating diseased cells further comprises a pair of peptide extensions 1050 (see, Figures 9A and 9B) respectively having the sequence of (G2.4S)2.8C. As illustrated, the pair of peptide extensions 1050 is linked to the C-termini of the pair of CH2-CH3 segments 1010. The cysteine residue at the C-terminus of the peptide extension is linked with a coupling arm 1055 via thiol-maleimide reaction occurred therebetween. Also, before being conjugated
WO 2017/036255
PCT/CN2016/090296 with the effector element E1 (in this case, a drug bundle), the free terminus of the conjugating arm (that is, the terminus that is not linked to the cysteine residue) is modified with an alkyne, azide, strained alkyne, or tetrazine group, so that the drug bundle is linked thereto via iEDDA reaction (see, Figure 9A), SPAAC (see, Figure 9B), or CUAAC (not shown) reaction occurred therebetween.
[0272] For example, in Figure 9A, the coupling arm 1040 of the effector element E1 (in this case, a drug bundle) is linked to the CH2-CH3 segment 1010 via iEDDA reaction. The ellipse 1045 as depicted in Figure 9A represents the chemical bond resulted from the iEDDA reaction occurred between the peptide extension 1050 and the effector element E1. As could be appreciated, an iEDDA reaction is occurred between a tetrazine group and a cyclooctene group, such as a transcyclooctene (TCO) group.
[0273] Alternatively, in Figure 9B, the effector element E1 is linked to the CH2-CH3 segment 1010 via SPAAC reaction. The diamond 1045 as depicted in Figure 9B represents the chemical bond resulted from the SPAAC reaction occurred between the peptide extension 1050 and the effector element E1. Specifically, an SPAAC reaction is occurred between an azide group and a strained alkyne group (e.g., a cyclooctyne group, including, dibenzocyclooctyne (DBCO), difluorinated cyclooctyne (DIFO), bicyclononyne (BCN), and dibenzocyclooctyne (DICO) group).
[0274] In a third series of Fc-based molecular constructs, one of the targeting and effector elements can be a peptide.
[0275] As could be appreciated, the discussions above regarding the Fc region and drug bundle of the Fc-based molecular constructs are also applicable here, and hence, detailed description regarding the same is omitted herein for the sake of brevity.
[0276] lll-(ii) Functional Elements Suitable for Use with Fc-based Molecular Construct [0277] Now that the basic structural arrangements of the Fc-based molecular constructs have been discussed above, certain combinations of particular effector element(s) and targeting element(s) are provided below for the illustration purpose.
WO 2017/036255
PCT/CN2016/090296 [0278] In constructing Fc-based molecular constructs for preventing and/or treating diseases/conditions associated with blood clots, one may use an antibody (or a fragment thereof) specific for fibrin as the targeting element.
[0279] In the case where the prevention of blood clot formation is the main purpose, the present Fc-based molecular constructs may use a drug bundle comprising multiple molecules of a Factor Xa inhibitor or thrombin inhibitor as the effector element. Illustrative examples of Factor Xa inhibitors include apixaban, edoxaban, and rivaroxaban. Non-limiting examples of thrombin inhibitors include argatroban and melagatran. The Fc-based molecular constructs for preventing blood clot formation may take the configuration described in connection with Figure 9A or 9B [0280] On the other hand, for Fc-based molecular constructs aiming to treat thrombosis, the effector element can be a tissue plasminogen activator (such as alteplase, reteplase, tenecteplase and lanoteplase), which is a single-chain polypeptide. The Fc-based molecular constructs for treating thrombosis may take the configuration described in connection with Figure 8Ato 8C.
[0281] The essence of this invention is the rationalization and conception of the specific combination or pairing of the targeting and effector elements. The adoption of Fc-fusion configuration in the molecular constructs is a preferred embodiment. It is conceivable for those skilled in the arts to link the pairs of targeting and effector elements of this invention employing other molecular platforms, such as peptides, proteins (e.g., albumin), polysaccharides, polyethylene glycol, and other types of polymers, which serve as a structural base for attaching multiple molecular elements.
[0282] lll-(iii) Use of Fc-based Molecular Construct [0283] The present disclosure also pertains to method for treating various diseases using the suitable Fc-based molecular construct. Generally, the method comprises the step of administering to a subject in need of such treatment an effective amount of the Fc-based molecular construct according to embodiments of the present disclosure.
[0284] EXPERIMENTAL EXAMPLES
WO 2017/036255
PCT/CN2016/090296 [0285] Example 1: Synthesis of peptide 1 (SEQ ID NO: 18) as peptide core, and conjugation of SH group of cysteine residue with maleimide-PEG4-tetrazine as conjugating arm [0286] The synthesized peptide 1 (Chinapeptide Inc., Shanghai, China) was dissolved in 100 mM sodium phosphate buffer (pH 7.0) containing 50 mM NaCI and 5 mM EDTA at 2 mM final concentration. The dissolved peptide was reduced by 1 mM TCEP at 25°C for 2 hours. For conjugating the SH group of cysteine residue with maleimide-PEG4-tetrazine (Conju-probe Inc.) to create a functional linking group tetrazine, the peptide and maleimide-PEG4-tetrazine were mixed at a 1/5 ratio and incubated at pH 7.0 and 4°C for 24 hours. Tetrazine-conjugated peptides were purified by reverse phase HPLC on a Supelco C18 column (250 mm X 10 mm; 5 pm), using a mobile phase of acetonitrile and 0.1% trifluoroacetic acid, a linear gradient of 0% to 100% acetonitrile over 30 minutes, at a flow rate of 1.0 mL/min and a column temperature of 25°C.
[0287] The present tetrazine-peptide 1, as illustrated below, had a m.w. of 2,185.2 Daltons.
Ac
Tetrazine-PEG4-CGGSGGSGGSKGSGSKGSK [0288] Example 2: Synthesis of peptide 2 (SEQ ID NO: 26) as peptide core, and conjugation of the SH group of cysteine residue with maleimide-PEG3-transcyclooctene (TOO) as a coupling arm [0289] The synthesized peptide 2 (Chinapeptide Inc., Shanghai, China) was processed similarly. Briefly, the peptide was dissolved in 100 mM sodium phosphate buffer (pH 7.0) containing 50 mM NaCI and 5 mM EDTA at a final concentration of 2 mM. The dissolved peptide was reduced by 1 mM tr/s(2-carboxyethyl)phosphine (TCEP) at 25°C for 2 hours. For conjugating the SH group of the cysteine residue with maleimide-PEG3-TCO (Conju-probe Inc.) to create a functional linking group TCO, the peptide and maleimide-PEG3-TCO were mixed at a 1/7.5 ratio and incubated at pH 7.0 and 25°C for 18 hours. TCO-conjugated peptides were purified by reverse phase HPLC on a Supelco C18 column (250 mm X 10 mm; 5 pm), using a mobile phase of acetonitrile and 0.1% trifluoroacetic acid, a linear gradient of 0% to 100% acetonitrile over 30 minutes, at a flow
WO 2017/036255
PCT/CN2016/090296 rate of 1.0 mL/min and a column temperature of 25°C.
[0290] The identification of the synthesized TCO-peptide (illustrated below) was carried out by MALDI-TOF mass spectrometry. Mass spectrometry analyses were performed by the Mass Core Facility at the Institute of Molecular Biology (IMB), Academia Sinica, Taipei, Taiwan. Measurements were performed on a Bruker Autoflex III MALDI-TOF/TOF mass spectrometer (Bruker Daltonics, Bremen, Germany).
[0291] The thus-synthesized TCO-peptide 2, as illustrated below, had a m.w. of 2, 020.09 Daltons.
Ac
TCO-PEG3-CGSKGSKGSKGSKGSK [0292] Example 3: Synthesis of linker unit by conjugating NHS-PEGi2-maleimide to NH2 groups of tetrazine-peptides 1 [0293] Three linking arms of PEGi2-maleimide were attached to the peptide core tetrazine-peptide 1. The crosslinker, NHS-PEGi2-maleimide (succinimidyl-[(N-maleimidopropionamido)-dodecaethyleneglycol] ester, was purchased from Conju-probe Inc. The conjugation procedure was performed per the manufacturer’s instruction; the peptide with lysine residues was dissolved in the conjugation buffer, phosphate buffered saline (PBS, pH 7.5) at 100 mM. NHS-PEGi2-maleimide crosslinker was added to the dissolved peptide at 1 mM final concentration (10-fold molar excess over 0.1 mM peptide solution). The reaction mixtures were incubated for 18 hours at room temperature. PEGi2-maleimide-conjugated tetrazine-peptide 1 was purified by reverse phase HPLC on a Supelco C18 column (250 mm X 4.6 mm; 5 pm), using a mobile phase of acetonitrile and 0.1% trifluoroacetic acid, a linear gradient of 0% to 100% acetonitrile over 30 minutes, at a flow rate of 1.0 ml/min and a column temperature of 25°C.
[0294] As illustrated below, the present PEGi2-maleimide-conjugated tetrazine-peptide 1 carried one coupling arm with a tetrazine group and three PEG linking arms with maleimide groups; it had a m.w. of 4,461 Daltons.
WO 2017/036255
PCT/CN2016/090296
Mai Mai
Tetrazine-PEG4-CGGSGGSGGSKGSGSI^GSK
CM
CD
LU
0.
{
Mai [0295] Example 4: Synthesis of linker unit by conjugating NHS-PEG6-Mal to NH2 groups of TCO-peptide 2 [0296] The procedure for conjugating NHS-PEG6-Mal to NH2 groups of TCO-peptide 2 was performed similarly as described in the previous Example. Briefly, NHS-PEG6-maleimide crosslinker was added to the dissolved peptide at 40 mM final concentration (20-fold molar excess over 2 mM peptide solution). The reaction mixtures were incubated for 3 hours at room temperature.
[0297] The present PEG6-maleimide-conjugated peptide 2, as illustrated below, had a
m.w. of 4,478 Daltons; it was a peptide core-based linker unit carrying one TCO group and five PEG linking arms with maleimide groups (Figure 10).
[0298]
Figure AU2016316202B2_D0016
CD 0 LU Ο- ι CD 0 LU Ο- ι
) Mai > Mai
Example 5: Conjugation of apixaban carboxylic acid molecule with
NH2-PEG3-S-S-PEG3-NH2 crosslinker [0299] Apixaban carboxylic acid was purchased from KM3 Scientific Inc. (New Taipei City,
Taiwan). The activated carboxyl group of apixaban carboxylic acid molecule was reacted with a homo-bifunctional cleavable crosslinker, NH2-PEG3-S-S-PEG3-NH2 as shown in scheme 12.
WO 2017/036255
PCT/CN2016/090296 [0300] Apixaban carboxylic acid was dissolved in 100% DMSO at a final concentration of mM, and NH2-PEG3-S-S-PEG3-NH2, a homo-bifunctional cleavable crosslinker, was dissolved in PBS at a 10 mM final concentration. To activate the carboxyl group of apixaban carboxylic acid, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 5 (EDC) (KM3 Scientific Inc.) was added to the apixaban carboxylic acid solution at a molar ratio of 1:2 ([apixaban]:[EDC]) and then incubated for 15 minutes.
[0301] The activated apixaban carboxylic acid solution was added to the NH2-PEG3-S-S-PEG3-NH2 crosslinker at a 2 mM final concentration (5-fold molar excess over 0.4 mM NH2-PEG3-S-S-PEG3-NH2 crosslinker solution). The reaction mixture was incubated for 3 hours at room temperature.
«Scheme 12 Conjugation of two apixaban carboxylic acid molecules to an
NH2-PEG3-S-S-PEG3-NH2 crosslinker»
Figure AU2016316202B2_D0017
[0302] Apixaban-PEG3-S-S-PEG3-apixaban was purified by reverse phase HPLC on a 15 Supelco C18 column (250 mm X 4.6 mm; 5 pm), using a mobile phase of acetonitrile and
0.1% trifluoroacetic acid, a linear gradient of 0% to 100% acetonitrile over 30 minutes, at a flow rate of 1.0 ml/min and a column temperature of 25°C.
[0303] The mass spectroscopic analysis of the thus-synthesized
WO 2017/036255
PCT/CN2016/090296 apixaban-PEG3-S-S-PEG3-apixaban (see, Figure 11) indicated that the molecular construct had m.w. of 1,301.64 and 1,323.68 Daltons, corresponding to [M+H]+ and [M+Na]+, respectively.
[0304] Example 6: Conjugation of two argatroban molecules to an 5 NH2-PEG3-S-S-PEG3-NH2 crosslinker [0305] Argatroban was purchased from KM3 Scientific Inc. (New Taipei City, Taiwan). The procedure for conjugating NH2-PEG3-S-S-PEG3-NH2 to COOH groups of argatroban molecule was performed similarly as described in the previous Example. Briefly, argatroban was dissolved in 100% DMSO at a final concentration of 20 mM. EDC solution 10 was added to the argatroban solution to activate COOH group of argatroban and then incubated for 15 minutes. The activated argatroban solution was added to NH2-PEG3-S-S-PEG3-NH2 crosslinker solution at a 2 mM final concentration (5-fold molar excess over 0.4 mM NH2-PEG3-S-S-PEG3-NH2 crosslinker solution) (see, scheme 13).
«Scheme 13 Conjugation of argatroban molecule with an NH2-PEG3-S-S-PEG3-NH2 15 crosslinker»
Figure AU2016316202B2_D0018
NH2-PEG3-S-S-PEG3-NH2
L
Figure AU2016316202B2_D0019
[0306] The MALDI-TOF result provided in Figure 12 shows that the thus-synthesized argatroban-PEG3-S-S-PEG3-argatroban had a m.w. of 1,378.61 Daltons.
WO 2017/036255
PCT/CN2016/090296 [0307] Example 7: Conjugation of apixaban-PEG3-SH and argatroban-PEG3-SH to maleimide-PEG6-conjugated TCO-peptide 2 [0308] Prior to conjugation with the TCO-peptide 2 that had five maleimide-PEG6 linking arms, apixaban-PEG3-S-S-PEG3-apixaban and argatroban-PEG3-S-S-PEG3-argatroban (prepared in the preceding Examples) were incubated with 4 mM TCEP at a molar ratio of 3:1 ([TCEP]:[drug-linker]) at room temperature for 90 minutes with gentle shaking to generate the apixaban-PEG3-SH and argatroban-PEG3-SH molecule with a free sulfhydryl group.
[0309] The thus-synthesized drug bundle, as illustrated below, was composed of a linker unit with a free TCO functional group and a set of five apixaban molecules as effector elements. The present molecular construct had a m.w. of 7,713 Daltons, corresponding to [M+H]+.
apixaban
CO
LU CL . . . (
TCO-PEG3-CGSKGSKGSKGSKGSK ( ,
CO
LU Qapixaban apixaban <0
LU Ac °I ( apixaban (
CO 0 LU D_ (
CO 0 LU Q.
( apixaban [0310] Another thus-synthesized drug bundle, as illustrated below, was composed of a 15 linker unit with a free TCO functional group and a set of five argatroban molecules as effector elements. The present molecular construct had a m.w. of 8,112.8 Daltons, corresponding to [M+H]+.
argatroban <0
LU CL ( argatroban <0
LU Ac αΙ ( argatroban co
LU CL . . . (
TCO-PEG3-CGSKGSKGSKGSKGSK
LU Q( argatroban
LU D_ argatroban
WO 2017/036255
PCT/CN2016/090296 [0311] Example 8: Production of mouse scFv of mAb specific for human fibrin by Expi293F overexpression system [0312] The V|_ and Vh of the scFv specific for human fibrin were from mouse monoclonal antibody 102-10 (Japanese Patent Application Publication No.2012-72). The scFv derived from this antibody was designed to contain a flexible linker of GGGGSGGGGS and a terminal cysteine residue at the C-terminus. The cysteine residue provides a sulfhydryl group for conjugation with maleimide group present at the free ends of liking arms in various linker units. To produce the scFv of mAb specific for human fibrin, we used the Vh and Vl DNA sequences of mAb 102-10 with further codon optimization. DNA sequences encoding Vl-GSTSGSGKPGSGEGSTKG-Vh-(GGGGS)2-C were synthesized. The amino acid sequence of the scFv of mAb 102-10 prepared for the experiments in the present invention is set forth in SEQ ID NO: 27.
[0313] For preparing scFv proteins using a mammalian expression system, we used the overexpression system based on Expi293F™ cell line for experimentation. The system employed ExpiFectamine™ 293 transfection kit (Life Technologies, Carlsbad, USA) consisting of the Expi293F™ cell line, the cationic lipid-based ExpiFectamine™ 293 Reagent and ExpiFectamine™ 293 transfection Enhancers 1 and 2, and the medium (Gibco, New York, USA).
[0314] The scFv-encoding sequence was placed in pG1K expression cassette. Expi293F cells were seeded at a density of 2.0 χ 106 viable cells/ml in Expi293F expression medium and maintained for 18 to 24 hours prior to transfection to ensure that the cells were actively dividing at the time of transfection. On the day of transfection, 7.5x108 cells in 255ml medium in a 2-liter Erlenmeyer shaker flask were transfected by ExpiFectamine™ 293 transfection reagent. The transfected cells were incubated at 37°C for 16 to 18 hours post-transfection in an orbital shaker (125 rpm) and the cells were added ExpiFectamine™ 293 transfection enhancer 1 and enhancer 2 to the shaker flask, and incubated for another 5 to 6 days. Culture supernatants were harvested and scFv proteins in the media were purified using Protein L affinity chromatography. Figures 13A and 13B respectively show the results of SDS-PAGE and Mass spectrometric analysis of purified scFv of mAb specific for human fibrin. The scFv of mAb specific for human fibrin in SDS-PAGE migrated in two
WO 2017/036255
PCT/CN2016/090296 major bands of 26 and 30 kDa. The same protein solution was further analyzed by
MALDI-TOF and showed that the 102-10 scFv specific for human fibrin had only the molecular weight of 26,838 Daltons, which is consistent with the calculated molecular weight.
[0315] Example 9: ELISA analysis of purified mouse scFvs specific for human fibrin [0316] To prepare fibrinogen-coated plates, each plate was prepared according to procedures described in US patent application publication 2016/0011217A1. Briefly, 100 pl of human fibrinogen (Sigma) in PBS was added to 96-well flat-bottom plates (Nunc) at 1 pg/well, and the plate was sealed and allowed to stand at 4°C overnight.
[0317] The fibrin plate was prepared as follows. The fibrinogen solution was removed and then 100 pL of TBS containing 0.05 U/ml thrombin (Sigma), 2 mM CaCI2 and 7 mM L-cysteine (Sigma) was added to the wells. The thrombin-treated plate was incubated at 37°C for 1 hour to allow fibrin formation. The thrombin solution was then removed and blocked with 10% skim milk at room temperature for 1 hour.
[0318] Then, 100 pl of the 102-10 scFv solution was added to the fibrinogen plate and the fibrin plate, which were then shaken at room temperature for 1 hour. After that, each plate was washed with TBS-T, and 50 pl of TMB (Thermo Fisher Scientific Inc., Waltham, USA) was added, and colorimetry was conducted. The reaction was stopped by adding 50 pl of 1N HCI. Then the absorbance (O.D.) was obtained by measuring the absorbance at 450 nm with a plate reader.
[0319] Figure 13C shows the ELISA result, indicating that the purified 102-10 scFv bound specifically to human fibrin, but not to fibrinogen.
[0320] Example 10: Construction and selection of phage-displayed human scFvs specific for human fibrin [0321] The phage clones carrying the human scFv specific for human fibrin were obtained through a contractual arrangement with Dr. An-Suei Yang’s laboratory at the Genomics Research Center, Academia Sinica, Taipei, Taiwan. The framework sequence of the GH2 scFv library was derived from a human IgG antibody fragment, G6 anti-VEGF Fab (Protein
WO 2017/036255
PCT/CN2016/090296
Bank Code 2FJG) and cloned into restriction sites Sfil and Notl of phagemid vector pCANTAB5E (GE Healthcare), carrying an ampicillin resistance, a lacZ promotor, a pelB leader sequence for secretion of scFv fragments into culture supernatants, and an E-tag applicable for detection. The VH and VL domains of the scFv template were diversified separately based on the oligonucleotide-directed mutagenesis procedure; the three CDRs in each of the variable domains were diversified simultaneously. The scFv library of over 109 clones was used for selections on human fibrin.
[0322] The thrombin-treated fibrin plates (1 pg/100 pl per well) were prepared as described in the preceding Examples. The fibrin plates were used for panning anti-fibrin antibodies. In brief, the fibrin-coated wells were treated with blocking buffer (5% skim milk in PBST (phosphate buffered saline with 0.1% tween-20)) for 1 hour at room temperature. Recombinant phages in the blocking buffer diluted to 8x1011 CFU/ml was added to the fibrin-coated wells for 1 hour with gentle shaking; CFU stands for colony-forming unit. The wells were then washed vigorously 10 times with PBST, followed by 6 times with PBS to remove nonspecific binding phages. The bound phages were eluted using 0.1 M HCI/glycine buffer at pH 2.2, and eluted fraction was neutralized immediately by 2 M Tris-base buffer at pH 9.0. E. coli strain ER2738 (OD600 = -0.6) was used for phage infection at 37 °C for 30 minutes; non-infected E. coli was eliminated by treating with ampicillin for 30 minutes. After ampicillin treatment, helper phage M13KO7 carrying kanamycin resistance was added for another 1 hour incubation. The selected phages rescued by helper phage in the E. coli culture were amplified with vigorously shaking overnight at 37 °C in the presence of kanamycin. The amplified phages were precipitated in PEG/NaCI, and then resuspended in PBS for the next selection-amplification cycle. A total of three consecutive panning rounds were performed on human fibrin by repeating this selection-amplification procedure.
[0323] Phage-infected ER2738 colonies were enumerated by serial dilution series were counted and phage titers were calculated, yielding the output titer/ml (CFU/ml) per panning round. A 1000-fold increase in phage output title from 2.5E+06 CFU/well to 4.3E+09 CFU/well was obtained after three rounds of panning. The phage output/input titer ratios from each round are shown in Figure 14A. For each panning round, the phage output/input titer ratios are given on the y-axis. There was clear enrichment of the positive
WO 2017/036255
PCT/CN2016/090296 clones over the three rounds of panning. The third panning round resulted in a 500-fold on the ratios of phage output/input titer over the first round, as the binding clones became the dominant population in the library.
[0324] In a typical selection procedure, after three rounds of antigen-panning on human fibrin-coated wells in ELISA plates, approximately 80% of the bound phage particles bound to fibrin specifically in ELISA with coated fibrin.
[0325] Example 11: Single colony ELISA analysis of human phage-displayed scFvs specific for human fibrin [0326] E. coli strain ER2738 infected with single-clonal phages each harboring a selected scFv gene in its phagemid was grown in the mid-log phase in 2YT broth (16 g/L tryptone, 10 g/l yeast extract, 5 g/l NaCI, pH 7.0) with 100 pg/ml ampicillin in deep well at 37 °C with shaking. After broth reaching an OD600 of 1.0, IPTG was added to final concentration of 1 pg/ml. The plates were incubated at 37 °C overnight with rigorously shaking. After overnight incubation at 37°C with vigorous shaking, the plates were centrifuged at 4,000 g for 15 minutes at 4°C.
[0327] For soluble scFv binding test, ELISA was carried out. In brief, 96-well Maxisorp 96-well plate (Nunc) was coated with fibrin (1 pg/100 pl PBS per well) ora negative control antigen human fibrinogen for 18 hours with shaking at 4°C. After treated with 300 pl of blocking buffer for 1 hour, 100 pl of secreted scFv in the supernatant was mixed with 100 pl of blocking buffer and then added to the coated plate for another 1 hour. Goat anti-E-tag antibody (conjugated with HRP, 1:4000, Cat. No. AB19400, Abeam) was added to the plate for 1 hour. TMB substrate (50 pl per well) was added to the wells and the absorbance at 450 nm was measured after reactions were stopped by adding 1N HCI (50 pl per well).
[0328] A total of 960 phage clones after the 3rd round of panning were subjected to the present analysis. Among them, six scFv clones that bound to fibrin with a differential of OD450 greater than 10 over fibrinogen were further characterized by DNA sequencing of their encoding scFv genes. Four different DNA sequences were identified. Figure 14B shows the ELISA result of an scFv clone D10. The amino acid sequence of an scFV clone
WO 2017/036255
PCT/CN2016/090296
D10, which binds to human fibrin with an OD450 of 1.09, is shown in as SEQ ID NO: 29.
[0329] Example 12: Production of recombinant reteplase by Expi293F overexpression system [0330] The amino acid sequence of reteplase was from DrugBank. The recombinant protein was designed to contain a flexible linker of GGGGSGGGGS and a terminal cysteine residue at the C-terminus. The cysteine residue provides a sulfhydryl group for conjugation with maleimide group present at the free ends of linking arms in various linker units. The amino acid sequences of reteplase prepared for the experiments of the invention are set forth in SEQ ID NO: 28.
[0331] In this Example, the gene-encoding sequence was placed in pcDNA3 expression cassette. For preparing reteplase protein using a mammalian expression system, we used the overexpression system based on Expi293F™ cell line for experimentation as described in the above Examples.
[0332] Figures 15A and 15B respectively show results of SDS-PAGE and mass spectrometric analyses of purified reteplase. The recombinant reteplase in SDS-PAGE migrated in two major bands of 43 and 48 kDa. The same protein solution was further analyzed by MALDI-TOF and showed that the recombinant reteplase had only a molecular weight of 43,415 Daltons, which is consistent with the calculated molecular weight.
[0333] Example 13: Preparation of TCO-conjugated reteplase [0334] For the conjugation of SH group of reteplase with Mal-PEG3-TCO (Conju-probe, Inc.), the cysteine residue at the C-terminal end of the purified reteplase was reduced by incubating with 5 mM dithiothreitol (DTT) at room temperature for 4 hours with gentle shaking. The buffer of reduced proteins was exchanged to sodium phosphate buffer (100 mM sodium phosphate, pH7.0, 50 mM NaCI, and 5 mM EDTA) by using NAP-10 Sephadex G-25 column. After the reduction reaction and buffer exchange, conjugation was conducted overnight at room temperature in a reaction molar ratio of 10:1 ([Mal-PEG3-TCO:[protein]]. The excess crosslinker was removed by a desalting column and the TCO-conjugated protein product was analyzed.
WO 2017/036255
PCT/CN2016/090296 [0335] The results of mass spectroscopy MALDI-TOF analysis indicated that the sample of TCO-conjugated reteplase protein had a m.w. of 45,055 Daltons. The purity of
TCO-conjugated reteplase protein was identified through Coomassie blue staining of 10%
SDS-PAGE. Figure 16 shows mass spectrometric analysis of TCO-conjugated reteplase.
[0336] Example 14: Conjugation of three scFvs specific for human fibrin to the three maleimide-PEGi2 linking arms based on tetrazine-peptide 1 [0337] The DNA sequence encoding SEQ ID NO: 27 was synthesized and expressed as in the above Examples. Prior to conjugation with the tetrazine-peptide 1 that had three PEGi2-maleimide linking arms, the cysteine residue at the C-terminal end of the purified 102-10 scFv of mAb specific for human fibrin was reduced by incubating with 5 mM DTT at a molar ratio of 2:1 ([DTT]:[scFv]) at room temperature for 4 hours with gentle shaking. Subsequently, the buffer of the reduced 102-10 scFv was exchanged to maleimide-SH coupling reaction buffer (100 mM sodium phosphate, pH 7.0, 50 mM NaCl and 5 mM EDTA) by using an NAP-10 Sephadex G-25 column (GE Healthcare). After the reduction and buffer exchange, the conjugation to the tetrazine-peptide 1 having three PEGi2-maleimide linking arms was conducted overnight at 4°C at a molar ratio of 1:4 ([linker]:[Protein]).
[0338] The reaction mixture was applied to a size exclusion chromatography column S75. The PEGi2-maleimide-conjugated tetrazine-peptide 1 conjugated with three 102-10 scFvs specific for human fibrin was separated from the free scFv, free PEGi2-maleimide-conjugated tetrazine-peptide 1 and the PEGi2-maleimide-conjugated tetrazine-peptide 1 conjugated with one and two 102-10 scFvs specific for human fibrin by size exclusion chromatography column S75. The product (i.e., the PEGi2-maleimide-conjugated tetrazine-peptide 1 having a free tetrazine functional group and being conjugated with a set of three 102-10 scFvs specific for human fibrin) was purified and shown in the 10% SDS-PAGE analysis shown in Figure 17.
[0339] Example 15: Analysis of a targeting linker unit containing three scFvs specific for human fibrin linked to the three maleimide-PEGi2 linking arms based on tetrazine-peptide 1 by MALDI-TOF [0340] The sample of the targeting linker unit of threel 02-10 scFvs specific human fibrin
WO 2017/036255
PCT/CN2016/090296 linked to the three maleimide-PEGi2 linking arms based on tetrazine-peptide 1 was analyzed by MALDI-TOF. The median of the experimental molecular weight was consistent with the median of theoretical molecular weight of three 102-10 scFvs specific for human fibrin conjugated to tetrazine-peptide 1 with three maleimide-PEGi2 linking arms. According to the mass spectrometric profile in Figure 18, the synthesized targeting linker unit had the median molecular weight of 84,974 Daltons.
[0341] Illustrated below is the synthesized targeting linker unit that was composed of a linker unit with a free tetrazine functional group and a set of three 102-10 scFvs specific for human fibrin as targeting elements.
Figure AU2016316202B2_D0020
[0342] Example 16: Preparation of molecular construct with three scFvs specific for human fibrin as targeting elements and one reteplase molecule as an effector element [0343] In this example, the targeting linker unit of the preceding examples and a TCO-conjugated reteplase protein was coupled via a tetrazine-TCO iEDDA reaction. Specifically, the targeting linker unit had three 102-10 scFvs specific for human fibrin and one free tetrazine group.
[0344] The procedure for tetrazine-TCO ligation was performed per the manufacturer’s instructions (Jena Bioscience GmbH, Jena, Germany). Briefly, 100 pl of the targeting linker unit (0.3 mg/ml) was added to the solution containing the effector element at a molar ratio of 1:1.2 ([tetrazine]:[TCO]). The reaction mixture was incubated for 1 hour at room temperature.
[0345] Illustrated below is the present joint-linker molecular construct with three 102-10 scFvs specific for human fibrin as targeting elements and with a reteplase molecule as effector elements. In 8% SDS-PAGE analysis of the reaction mixture, a band of about 180
WO 2017/036255
PCT/CN2016/090296 kDa in size was observed.
scFv a
Figure AU2016316202B2_D0021
[0346] Example 17: Preparation of molecular construct with three scFvs specific for human fibrin as targeting elements and five apixaban or argatroban molecules as an 5 effector elements [0347] In this example, a joint-linker molecular construct with three 102-10 scFvs specific for human fibrin and a drug bundle of five apixaban molecules was constructed. The molecular construct was made by a TCO-tetrazine iEDDA reaction as described in the preceding Examples. Briefly, 100 pl of the targeting linker unit (0.3 mg/ml) was added to 10 the solution containing the effector element at a molar ratio of 1:1.2 ([tetrazine]:[TCO]).
The reaction mixture was incubated for 1 hour at room temperature.
[0348] The resultant joint-linker molecular construct, as illustrated below, had three 102-10 scFvs specific for human fibrin as targeting elements and with a drug bundle of five apixaban molecules as effector elements. In 10% SDS-PAGE analysis of the reaction 15 mixture, a band of about 160 kDa in size was observed.
Figure AU2016316202B2_D0022
[0349] Illustrated below is the present joint-linker molecular construct with three 102-10 scFvs specific for human fibrin as targeting elements and with a drug bundle of five
WO 2017/036255
PCT/CN2016/090296 argatroban molecules as effector elements. In 10% SDS-PAGE analysis of the reaction mixture, a band of about 165 kDa in size was observed.
Figure AU2016316202B2_D0023
[0350] Example 18: Inhibition assay of apixaban-PEG3-SH molecule [0351] Factor Xa catalyzes the conversion of inactive prothrombin to active thrombin. Apixaban has been used as a Factor Xa inhibitor, indirectly to decrease clot formation induced by thrombin. The synthesis of the modified apixaban molecule (apixaban-PEG3-SH) has been shown in the preceding examples. To examine the inhibitory activities of the modified apixaban molecule (apixaban-PEG3-SH), Factor Xa inhibition assay (BioVision, Milpitas, USA) was performed. The Factor Xa inhibition assay utilizes the ability of Factor Xa to cleave a synthetic substrate thereby releasing a fluorophore, which can be detected by a fluorescence reader. In the presence of a Factor Xa inhibitor, the extent of cleavage reaction catalyzed by Factor Xa is reduced or completely abolished.
[0352] In this example, 50 pl of Factor Xa enzyme solution (provided by manufacturer) was added to the 96-well flat-bottom plate (Nunc). 10 pl of 1 μΜ apixaban-PEG3-SH and apixaban carboxylic acid were added to the plate contained Factor Xa enzyme solution and incubated for 15 minutes at room temperature. Then, 40 pl of Factor Xa substrate solution (provided by manufacturer) was added to the plate and incubated at 37°C for 30 minutes. The fluorescence intensity of fluorophores (relative fluorescence units, RFU) was obtained by measuring the emission at 450 nm under the excitation at 350 nm with fluorescence plate reader.
[0353] Figure 19 shows the assay results of the inhibitory activity of apixaban-PEG3-SH. In the presence of synthetic substrate, Factor Xa activity was measured in the absence of
WO 2017/036255
PCT/CN2016/090296
Factor Xa inhibitor (substrate only). The result indicates that the apixaban molecule conjugated with a connecting arm had a similar biological activity to inhibit action of factor
Xa as the unmodified apixaban carboxylic acid. A Factor Xa inhibitor (GGACK
Dihydrochloride, provided by manufacturer) is used as the control inhibitor.
[0354] Example 19: Assay of biological activity of recombinant reteplase [0355] Reteplase is a recombinant human tissue plasminogen activator that catalyzes the conversion of plasminogen to plasmin; this process is involved in breakdown of blood clots. To investigate the biological activity of the recombinant reteplase, a chromogenic assay in 96-well flat-bottom plate was performed.
[0356] Briefly, 1 pl of 1 μΜ recombinant reteplase, 25 pl of 10 μΜ human plasminogen (Cat. No.7549-1, Biovision) and 62.5 pl of 100 mM Tris buffer at pH 8.5 were added and incubated in the well of the plate at 37°C for 30 minutes. Next, 1 pl of 50 mM chromogenic substrate D-Val-Leu-Lys-p-Nitroanilide dihydrochloride (Cat. No.V7127, Sigma), a synthetic plasmin substrate, was added to the well and incubated at 25°C for 30 minutes. 31.5 pl of 10 % citric acid was then added to each well to stop the reaction. The recombinant reteplase catalyzes plasminogen to form plasmin, which in turn cleaves the chromogenic substrate to release yellow colored p-Nitroanilide, which was measured at 405 nm by a plate reader.
[0357] The result shows that recombinant reteplase exhibited a protease activity with an OD405 of 1.8, whereas the positive control protein, the commercially available tPA protein (Cat. No.T0831, Sigma) had an OD405 of 1.5.
[0358] Example 20: Construction of a gene segment encoding 2-chain lgG4.Fc fusion protein containing reteplase [0359] The reteplase-CH2-CH3 (human y4) recombinant chain was configured by fusing reteplase to the N-terminal of CH2 domain of lgG4.Fc through a flexible hinge region. The sequence of the recombinant chain in the lgG4.Fc fusion protein molecular construct is shown as SEQ ID NO: 30.
[0360] Illustrated below is the configuration of the prepared 2-chain (reteplase)-hlgG4.Fc
WO 2017/036255
PCT/CN2016/090296 molecular construct.
Figure AU2016316202B2_D0024
[0361] Example 21: Expression and purification of recombinant 2-chain lgG4.Fc fusion protein containing reteplase [0362] In this Example, the gene-encoding sequence was placed in pcDNA3 expression cassette. Expi293F cells were seeded at a density of 2.0 χ 106 viable cells/ml in Expi293F expression medium and maintained for 18 to 24 hours prior to transfection to ensure that the cells were actively dividing at the time of transfection. At the time of transfection, 7.5x108 cells in 255-ml medium in a 2-liter Erlenmeyer shaker flask were transfected by ExpiFectamine™ 293 transfection reagent. The transfected cells were incubated at 37°C for 16 to 18 hours post-transfection in an orbital shaker (125 rpm) and the cells were added ExpiFectamine™ 293 transfection enhancer 1 and enhancer 2 to the shaker flask, and incubated for 7 days. Culture supernatants were harvested and recombinant 2-chain (reteplase)-hlgG4.Fc fusion protein in the media was purified using Protein A chromatography. Following buffer exchange to PBS, the concentration of (reteplase)-hlgG4.Fc protein was determined and analyzed by 8% SDS-PAGE shown in Figure 20. The Fc-fusion molecular construct was revealed as the major band at about 74 kDa, consistent with the expected size.
[0363] Example 22: Construction of a gene segment encoding 2-chain lgG4.Fc fusion protein containing reteplase and scFv specific for human fibrin [0364] The reteplase-CH2-CH3-scFv (human γ4) recombinant chain was configured by fusing reteplase to the N-terminal of CH2 domain of lgG4.Fc through a flexible hinge region,
WO 2017/036255
PCT/CN2016/090296 and the 102-10 scFv specific for human fibrin was fused to the C-terminal of CH3 domain through a flexible linker, (GGGGS)3.
[0365] The scFvs had an orientation of VL-linker-Vn. The Vl and Vh in the scFv were connected by a hydrophilic linker, GSTSGSGKPGSGEGSTKG. The sequence of the recombinant chain in the lgG4.Fc fusion protein molecular construct is shown as SEQ ID NO: 31. The expression of the constructed gene in Expi293F cells and the purification of the expressed fusion protein were performed as in preceding Examples. Characterization of the new construct was performed with SDS-PAGE. The 8% SDA-PAGE results in Figure 21 shows that the recombinant chain of the new construct has a size of about 100 kDa, consistent with the expected size.
[0366] Illustrated below is the configuration of the prepared 2-chain (reteplase)-hlgG4.Fc-(scFv a fibrin) molecular construct.
Reteplase
Figure AU2016316202B2_D0025
23: Construction of a gene segment encoding fusion protein [0367] Example containing reteplase and scFv specific for human fibrin [0368] The (reteplase)-scFv recombinant chain was configured by fusing reteplase to the N-terminal of the 102-10 scFv specific for human fibrin through a flexible linker, (GGGGSY [0369] The scFv had an orientation of VL-linker-VH. The VL and VH in the scFv were connected by a hydrophilic linker, GSTSGSGKPGSGEGSTKG. The sequence of the recombinant fusion protein molecular construct is shown as SEQ ID NO: 32.
WO 2017/036255
PCT/CN2016/090296
Characterization of the new construct was performed with SDS-PAGE. The 8% SDA-PAGE results in Figure 22 shows that the recombinant chain of the new construct has a size of about 72 kDa, consistent with the expected size.
[0370] Illustrated below is the configuration of the prepared (reteplase)-(scFv a fibrin) molecular construct.
Reteplase
Figure AU2016316202B2_D0026
[0371] Example 24: Construction of a gene segment encoding 2-chain lgG4.Fc fusion protein containing tenecteplase (TNK-tPA) [0372] The (TNK-tPA)-CH2-CH3 (human γ4) recombinant chain was configured by fusing
TNK-tPA to the N-terminal of CH2 domain of lgG4.Fc through a flexible hinge region. The sequence of the recombinant chain in the lgG4.Fc fusion protein molecular construct is shown as SEQ ID NO: 33. The 8% SDA-PAGE assay results in Figure 23 shows that the recombinant chain of the new construct has a size of about 98 kDa, consistent with the expected size.
[0373] Illustrated below is the configuration of the prepared 2-chain (TNK-tPA)-hlgG4.Fc molecular construct.
.^TNK-tPA
I /+- I I
—E,
CH2 igG4.Fc
CH3 [0374] Example 25: Construction of a gene segment encoding 2-chain lgG4.Fc fusion protein containing TNK-tPA and human scFv specific for human fibrin
WO 2017/036255
PCT/CN2016/090296 [0375] The (TNK-tPA)-CH2-CH3-scFv (human γ4) recombinant chain was configured by fusing TNK-tPA to the N-terminal of CH2 domain of lgG4.Fc through a flexible hinge region, and the human scFv D10 specific for human fibrin was fused to the C-terminal of CH3 domain through a flexible linker, (GGGGS)3.
[0376] The scFvs had an orientation of VL-linker-VH. The VL and VH in the scFv were connected by a hydrophilic linker, GSTSGSGKPGSGEGSTKG. The sequence of the recombinant chain in the lgG4.Fc fusion protein molecular construct is shown as SEQ ID NO: 34.
[0377] To detect the recombinant 2-chain (TNK-tPA)-hlgG4.Fc-(scFv a fibrin) expressed at low level, In-gel digestion of protein isolated by gel electrophoresis and tandem mass spectrometric analysis of trypsin-digested 2-chain (TNK-tPA)-hlgG4.Fc-(scFv a fibrin) were performed for the identification of the molecular constructs. All mass spectrometry experiments were done using a Bruker Autoflex III MALI TOF/TOF mass spectrometer (Bremen, Germany) equipped with a 200 Hz Smart Bean Laser in positive ion mode with delayed extraction in the reflection mode. Data acquisition was done manually with Flex Control 3.4, and data processing was performed with Flex-Analysis 3.4 (both Bruker Dalton).
[0378] To identify the peptide by molecular mass searching of protein fragment in protein database with the Mascot search engine, the m/z values of two protein fragments in MS/MS spectrum, corresponding to 1,617.8223 and 1,053.5074 Daltons, were matched to the amino acid sequences of two TNK-tPA fragments, VYTAQNPSAQALGLGK and QYSQPQFR. The m/z value of a protein fragment in MS/MS spectrum, corresponding to 830.4496 Daltons, was matched to the amino acid sequence of a peptide fragment in the human lgG4.Fc region, GLPSSIEK. The m/z values of two protein fragments in MS/MS spectrum, corresponding to 737.3866 and 620.3044 Daltons, were matched to the amino acid sequences of two peptide fragments in the D10 scFv region, NTAYLR and MNSLR.
[0379] Illustrated below is the configuration of the prepared 2-chain (TNK-tPA)hlgG4.Fc-(scFv a fibrin) molecular construct.
WO 2017/036255
PCT/CN2016/090296
Figure AU2016316202B2_D0027
[0380] Example 26: Construction of a gene segment encoding fusion protein containing TNK-tPAand scFv specific for human fibrin [0381] The (TNK-tPA)-(scFv a fibrin) recombinant chain was configured by fusing
TNK-tPA to the N-terminal of the human scFv D10 specific for human fibrin through a flexible linker, (GGGGS)3.
[0382] The scFvs had an orientation of VL-linker-VH. The VL and VH in the scFv were connected by a hydrophilic linker, GSTSGSGKPGSGEGSTKG. The sequence of the recombinant fusion protein molecular construct is shown as SEQ ID NO: 35. To detect the 10 recombinant (TNK-tPA)-(scFv a fibrin) expressed at low level, In-gel digestion of protein isolated by gel electrophoresis and tandem mass spectrometric analysis of trypsin-digested (TNK-tPA)-(scFv a fibrin) were performed and confirmed for the identification of the present molecular constructs (see, the above Example).
[0383] Illustrated below is the configuration of the prepared (TNK-tPA)-(scFv a fibrin) molecular construct.
Figure AU2016316202B2_D0028
[0384] Example 27: Assay of biological activity of fusion protein containing reteplase and scFv specific for human fibrin
WO 2017/036255
PCT/CN2016/090296 [0385] Reteplase is a recombinant human tissue plasminogen activator involved in breakdown of blood clots. To investigate the biological activity of the recombinant reteplase-containing proteins fused with scFv 102-10 specific for human fibrin, a chromogenic assay in fibrin-coated plate was performed (scheme 14).
«Scheme 14 Chromogenic assay of recombinant reteplase-containing proteins fused with scFv specific for human fibrin» chromogenic substrate p-Nitroanilide
Effector ·<.......z:
\ Anti-fibrin scFv ,/
Targeting [0386] Briefly, to prepare fibrinogen plate, 100 pl of human fibrinogen (Sigma) in PBS was added 96-well flat-bottom plates (Nunc) at 10 pg/well; the plate was then sealed and allowed to stand at 4°C overnight. The fibrin plate was prepared as follows. The fibrinogen solution was removed, and then 100 pL of TBS containing 0.05 U/ml thrombin (Sigma), 2 mM CaCI2 and 7 mM L-cysteine (Sigma) was added to the wells. The thrombin-treated plate was incubated at 37°C for 1 hour to allow fibrin formation. The thrombin solution was removed and blocked with 10% skim milk at room temperature for 1 hour.
[0387] Then, 100 pl of sample solution was added to the fibrinogen plate and the fibrin plate, which were then shaken at room temperature for 1 hour. After that, each plate was washed twice with PBST, followed by one PBS washing to remove nonspecific binding proteins. 25 pl of 10 μΜ human plasminogen (Cat. No.7549-1, Biovision) was added and incubated in each well of the fibrinogen and fibrin plates at 37°C for 30 minutes. 62.5 pl of 100 mM Tris buffer at pH 8.5 and 1 pl of 50 mM chromogenic substrate D-Val-Leu-Lys-p-Nitroanilide dihydrochloride (Cat. No.V7127, Sigma), a synthetic plasmin
WO 2017/036255
PCT/CN2016/090296 substrate, were then added to the well and incubated at 25°C for 30 minutes. 31.5 μΙ of 10 % citric acid was added to each well to stop the reaction. The reteplase-containing proteins catalyze plasminogen to form plasmin, which in turn cleaves the chromogenic substrate to release yellow colored p-Nitroanilide; it was measured at 405 nm by a plate reader.
[0388] Figure 24 shows that recombinant 2-chain (reteplase)-hlgG4.Fc, 2-chain (reteplase)-hlgG4.Fc-(scFv a fibrin) and (reteplase)-(scFv a fibrin) showed protease activity as positive control proteins, recombinant reteplase and commercially available tPA protein (Cat. No.T0831, Sigma). The hlgG4.Fc and anti-fibrin 102-10 scFv were used as negative controls. The binding assay shows that both TPA and reteplase bind to fibrin. Moreover, the fusion protein of reteplase and scFv specific for fibrin, in particular the one with the G4S linker, exhibited better binding activity.
[0389] It will be understood that the above description of embodiments is given by way of example only and that various modifications may be made by those with ordinary skill in the art. The above specification, examples, and data provide a complete description of the structure and use of exemplary embodiments of the invention. Although various embodiments of the invention have been described above with a certain degree of particularity, or with reference to one or more individual embodiments, those with ordinary skill in the art could make numerous alterations to the disclosed embodiments without departing from the spirit or scope of this invention.
2016316202 26 Feb 2018

Claims (21)

  1. WHAT IS CLAIMED IS:
    1. A linker unit comprising a first center core, a plurality of first linking arms, a plurality of first elements, and optionally a first coupling arm, wherein the first center core comprises, (1) a first polypeptide comprising a plurality of lysine (K)
    5 residues, wherein each K residue and its next K residue are separated by a filler sequence comprising glycine (G) and serine (S) residues, and the number of K residues ranges from 2 to 15; or (2) a second polypeptide comprising the sequence of (Xaa-K)n, where Xaa is a PEGylated amino acid having 2 to 12 repeats of ethylene glycol (EG) unit, and n is an integral from 2 to 15;
    10 the plurality of first linking arms are respectively linked to the K residues of the first center core;
    the plurality of first elements are respectively linked to the plurality of first linking arms via forming an amide bound therebetween, or via thiol-maleimide reaction, copper catalyzed azide-alkyne cycloaddition (CuAAC) reaction, strained-promoted azide-alkyne .5 click chemistry (SPAAC) reaction, or inverse electron demand Diels-Alder (iEDDA) reaction, wherein each of the first elements is a tissue plasminogen activator, an inhibitor of Factor Xa or thrombin, or an single-chain variable fragment (scFv) specific for fibrin; and the amino acid residue at the N- or C-terminus of the first center core has the azide or the alkyne group; or the amino acid residue at the N- or C-terminus of the first center core is *0 a cysteine residue, and the thiol group of the cysteine residue is linked with the first coupling arm having the azide, the alkyne, the tetrazine, the cyclooctene, or the cyclooctyne group at the free terminus of the first coupling arm, wherein, when the plurality of first elements are respectively linked to the plurality of first linking arms via CuAAC or SPAAC reaction, then the amino acid residue at the N- or 25 C-terminus of the first center core is a cysteine residue, and the free terminus of the first coupling arm is the tetrazine or the cyclooctene group; or when the plurality of first elements are respectively linked to the plurality of first linking arms via iEDDA reaction, then the amino acid residue at the N- or C-terminus of the first center core has the azide or the alkyne group, or the amino acid residue at the N- or 30 C-terminus of the first center core is a cysteine residue, and the free terminus of the first coupling arm is the azide, the alkyne, or the cyclooctyne group.
    2016316202 26 Feb 2018
  2. 2. The linker unit of claim 1, wherein each of the first linking arms is a PEG chain having 2-20 repeats of EG units; and the first coupling arm is a PEG chain having 2-12 repeats of EG units.
  3. 3. The linker unit of claim 1, wherein
    5 the amino acid residue having the azide group is L-azidohomoalanine (AHA), 4-azido-L-phenylalanine, 4-azido-D-phenylalanine, 3-azido-L-alanine, 3-azido-D-alanine, 4-azido-L-homoalanine, 4-azido-D-homoalanine, 5-azido-L-ornithine, 5-azido-d-ornithine,
    6-azido-L-lysine, or 6-azido-D-lysine;
    the amino acid residue having the alkyne group is L-homopropargylglycine (L-HPG), IO D-homopropargylglycine (D-HPG), or beta-homopropargylglycine (β-HPG);
    the cyclooctene group is trans-cyclooctene (TCO); and the cyclooctyne group is dibenzocyclooctyne (DBCO), difluorinated cyclooctyne(DIFO), or bicyclononyne (BCN); and the tetrazine group is 1,2,3,4-tetrazine, 1,2,3,5-tetrazine or 1,2,4,5-tetrazine, or derivatives thereof.
    15 4. The linker unit of claim 1, further comprising a second element that is linked to the first center core via any of the following reactions,
    CuAAC reaction occurred between the azide or alkyne group and the second element; SPAAC reaction occurred between the azide or cyclooctyne group and the second element; and >0 iEDDA reaction occurred between the cyclooctene group or tetrazine group and the second element.
    5. The linker unit of claim 4, wherein one of the first and second elements is an scFv specific for fibrin, and the other of the first and second elements is a tissue plasminogen activator or an
    25 inhibitor of Factor Xa or thrombin.
    6. The linker unit of claim 5, wherein the tissue plasminogen activator is alteplase, reteplase, tenecteplase, or lanoteplase; the inhibitor of Factor Xa is apixaban, edoxaban, or rivaroxaban; and the inhibitor of thrombin is argatroban or melagatran.
    too
    2016316202 26 Feb 2018
    7. A method for preventing the formation of blood clot in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the linker unit of claim 5, wherein one of the first and second elements is the scFv specific for fibrin, and the other of the first and second elements is the inhibitor of Factor Xa or thrombin.
    5 8. A method for treating thrombosis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the linker unit of claim 5, wherein one of the first and second elements is the scFv specific for fibrin, and the other of the first and second elements is the tissue plasminogen activator.
    9. A molecular construct comprising a first linker unit and a second linker unit, wherein,
    10 the first linker unit is the linker unit of claim 1;
    the second linker unit comprises, a second center core comprising a plurality of amine groups, a plurality of second linking arms respectively linked to the plurality of amine groups of the second center core,
    15 a plurality of second elements respectively linked to the plurality of second linking arms, and optionally, a second coupling arm linked to the second center core;
    one of the first and second elements is the scFv specific for fibrin, and the other of the first and second elements is the tissue plasminogen activator or the inhibitor of Factor Xa or 20 thrombin; and the first and second linker units are coupled to each other via CuAAC reaction, SPAAC reaction or iEDDA reaction occurred between any of the followings: the first and second center cores, the first coupling arm and the second center core, the first and second coupling arms, or the first center core and the second coupling arm.
    25 10. The molecular construct of claim 9, wherein, each of the plurality of second linking arms is a PEG chain having 2-20 repeats of ethylene glycol (EG) units; and the second coupling arm is a PEG chain having 2-12 repeats of EG units.
    101
    2016316202 26 Feb 2018
    11. The molecular construct of claim 9, wherein the second center core is a compound core, wherein the second coupling arm linked to said compound core is linked thereto via forming an amide bond with one of the plurality of amine groups of the compound core and has an azide, an alkyne, a cyclooctene, a cyclooctyne or a tetrazine group at the free-terminus
    5 thereof.
    12. The molecular construct of claim 11, wherein the compound is selected from the group consisting of, benzene-1,3,5-triamine, 2-(aminomethyl)-2-methylpropane-1,3-diamine, tris(2-aminoethyl)amine, benzene-1,2,4, 5-tetraamine, 3,3’,5,5’-tetraamine-1,r-biphenyl, tetrakis(2-aminoethyl)methane, tetrakis- (ethylamine)hydrazine,
    10 N,N,N’,N’,-tetrakis(aminoethyl)ethylenediamine, benzene-1,2,3,4, 5,6-hexaamine,
    1-N,1-N,3-N,3-N,5-N,5-N-hexakis(methylamine)-benzene-1,3,5-triamine, 1-N,1-N,2-N,2-N,4-N,4-N,5-N,5-N,-octakis(methylamine)-benzene-1,2,4,5-triamine, and N,N-bis[(1 -amino-3,3-diaminoethyl)pentyl] methanediamine.
    13. The molecular construct of claim 9, wherein
    15 the tissue plasminogen activator is alteplase, reteplase, tenecteplase, or lanoteplase;
    the inhibitor of Factor Xa is apixaban, edoxaban, or rivaroxaban; and the inhibitor of thrombin is argatroban or melagatran.
    14. A molecular construct comprising, a pair of CH2-CH3 segments of an IgG.Fc;
    >0 a pair of effector elements, wherein each effector element is a tissue plasminogen activator or a drug bundle;
    a pair of targeting elements, wherein each targeting element is an antibody fragment specific for fibrin;
    optionally, a peptide extension that has the sequence of (G2-4S)2-8C, and is linked to the 25 C-terminus of one of the pair of CH2-CH3 segments; and optionally, a coupling arm that is linked to the C-terminus of the peptide extension via thiol-maleimide reaction occurred therebetween; wherein, when each effector element is the tissue plasminogen activator, then the pair of effector elements is linked to the N-termini of the pair of CH2-CH3 segments, and the pair of
    102
    2016316202 26 Feb 2018 targeting elements is linked to the N-termini of the pair of CH2-CH3 segments, or vice versa, or when each effector element is the drug bundle, then the pair of effector elements is linked to the C-termini of the pair of CH2-CH3 segments, and the pair of targeting elements 5 is linked to the N-termini of the pair of CH2-CH3 segments; wherein the drug bundle comprises, a center core that is a compound having a plurality of amine groups or is a polypeptide comprising a plurality of lysine (K) residues;
    a plurality of linking arms, each having one terminus linked to the center core by
    0 reacting with one of the amine groups or one of the K residues, and carrying, a maleimide, an N-hydroxysuccinimidyl (NHS), an azide, an alkyne, a tetrazine or a strained alkyne group at the free terminus thereof; and a plurality of molecules of an inhibitor of Factor Xa or an inhibitor of thrombin, wherein each of the molecules is linked to the center core via connecting through the linking 5 arm by reacting with the maleimide, the NHS, the azide, the alkyne, the tetrazine or the strained alkyne group, and the drug bundle is linked to the coupling arm via iEDDA reaction, SPAAC reaction, or CuAAC reaction occurred therebetween.
    15. The molecular construct of claim 14, wherein the pair of CH2-CH3 segments is derived from human y1 ory4 immunoglobulin.
    Ό 16. The molecular construct of claim 14, wherein the pair of targeting elements is in the form of an antigen-binding fragment (Fab) and is linked to the N-termini of the pair of CH2-CH3 segments, so that the molecular construct adopts an IgG configuration.
    17. The molecular construct of claim 14, wherein the inhibitor of Factor Xa is apixaban, edoxaban, or rivaroxaban;
    25 the inhibitor of thrombin is argatroban or melagatran; and the tissue plasminogen activator is alteplase, reteplase, tenecteplase, or lanoteplase.
    18. The molecular construct of claim 9, wherein the second center core is a polypeptide.
    103
    2016316202 26 Feb 2018
    19. The molecular construct of claim 18 wherein the polypeptide comprises, (1) a plurality of K residues, wherein the number of the K residues ranges from 2 to 15, and each K residue and its next K residue are separated by a filler sequence comprising G and S residues; or (2) the sequence of (Xaa-K)n, wherein Xaa is a PEGylated amino acid having 2 to 12 repeats of
    5 EG unit, and n is an integral from 2 to 15.
    20. The molecular construct of claim 19, wherein the amino acid residue at the N- or C-terminus of the second center core has the azide or the alkyne group; or the amino acid residue at the N- or C-terminus of the second center core is a cysteine residue, and the thiol group of the cysteine residue is linked with the second coupling arm having the azide, the
    10 alkyne, the tetrazine, the cyclooctene, or the cyclooctyne group at the free terminus of the second coupling arm.
    104
    WO 2017/036255
    PCT/CN2016/090296
    1/21
    FIG. 1C
    WO 2017/036255
    PCT/CN2016/090296
    2/21
    FIG. ID
    FIG. IE
    FIG. IF
    WO 2017/036255
    PCT/CN2016/090296
    3/21
    FIG. 1G
    FIG. 1H
    FIG. II
    WO 2017/036255 . . PCT/CN2016/090296
  4. 4/21 mj
    FIG. 1J
    WK
    FIG. IK
    FIG. 2
    WO 2017/036255
    PCT/CN2016/090296
  5. 5/21 i .152 ί
    •t t Λ fWVV { ί “
    130a \
    a 156 2
    I30a 230a
    FIG. 3A
    FIG. 3B
    WO 2017/036255
    PCT/CN2016/090296
  6. 6/21
    100C 110a |62 / r ? ™1 Z'^'X ί Xv^X jWsaQ J ( 1 > i' 120 130b
    100B
    I )\AAA^V\AAi Ezwvd/ ..-4
    X7 T LdJ
    FIG. 3C
    X.
    Λ A O J·
    FIG. 3D
    WO 2017/036255
    PCT/CN2016/090296
  7. 7/21
    FIG. 4
    WO 2017/036255
    PCT/CN2016/090296
  8. 8/21
    FIG. 5A
    320 420
    FIG. 5B
    FIG. 6
    WO 2017/036255
    PCT/CN2016/090296
  9. 9/21
    FIG. 7A
    600
    700B
    640
    FIG. 7B
    WO 2017/036255
    PCT/CN2016/090296
  10. 10/21
    1200A.
    - j w / --A.
    z” i CH3 |
    1 CH3 k.
    / yf
    V
    FIG. 8A FIG. 8B
    WO 2017/036255
    PCT/CN2016/090296
  11. 11/21
    1200C
    FIG. 8C
    WO 2017/036255
    PCT/CN2016/090296
  12. 12/21 »»X
    FIG. 9A FIG. 9B
    WO 2017/036255
    PCT/CN2016/090296
  13. 13/21
    Intensity χ 104
    FIG. 10
    1100 1200 1300 1400 1500 m/z
    FIG. 11
    WO 2017/036255
    PCT/CN2016/090296
  14. 14/21 intensity
    1378.61
    FIG. 12
    FIG. 13A
    WO 2017/036255
    PCT/CN2016/090296
  15. 15/21
    Intensity xlO4
    23000 25000 27000 29000 31000 m/z
    FIG. 13B
    Fibrinogen Fibrin
    Coated antigen
    FIG. 13C
    WO 2017/036255
    PCT/CN2016/090296
  16. 16/21
    Output/input titer ratio
    FIG. 14A
    1.5n
    Fibrinogen Fibrin
    FIG. 14B
    WO 2017/036255
    PCT/CN2016/090296
  17. 17/21
    FIG. 15A
    FIG. 15B
    WO 2017/036255
    PCT/CN2016/090296
  18. 18/21
    FIG. 16
    170
    130
    FIG. 17
    WO 2017/036255
    PCT/CN2016/090296
  19. 19/21
    FIG. 18
    FIG. 19
    WO 2017/036255
    PCT/CN2016/090296
  20. 20/21
    FIG. 22
    FIG. 23
    WO 2017/036255
    PCT/CN2016/090296
  21. 21/21 i Fibrin
    2 ___ □ Fibrinogen
    OD405
    FIG. 24
    16EAP0020CPT-seql
    SEQUENCE LISTING <110> Immunwork Inc.
    <120> MOLECULAR CONSTRUCTS FOR INHIBITING THE FORMATION OF BLOOD CLOT AND/OR TREATING THROMBOSIS <130> P2955-PCT <150> US 62/308,349 <151> 2016-03-15 <150> PCT/CN2016/071184 <151> 2016-01-18 <150> US 62/213,012 <151> 2015-09-01 <160> 35 <170> BiSSAP 1.3 <210> 1 <211> 4 <212> PRT <213> Artificial Sequence <220>
    <223> filler sequence-1 <400> 1
    Gly Gly Gly Ser <210> 2 <211> 4 <212> PRT <213> Artificial Sequence <220>
    <223> filler sequence-2 <400> 2
    Gly Ser Gly Ser <210> 3 <211> 4 <212> PRT <213> Artificial Sequence <220>
    <223> filler sequence-3 <400> 3
    Gly Gly Ser Gly <210> 4 <211> 5 <212> PRT <213> Artificial Sequence <220>
    <223> filler sequence-4 <400> 4
    Gly Ser Gly Gly Ser
    1 5
    Page 1
    16EAP0020CPT-seql <210> 5 <211> 5 <212> PRT <213> Artificial Sequence <220>
    <223> filler sequence-5 <400> 5
    Ser Gly Gly Ser Gly
    1 5 <210> 6 <211> 5 <212> PRT <213> Artificial Sequence <220>
    <223> filler sequence-6 <400> 6
    Gly Gly Gly Gly Ser
    1 5 <210> 7 <211> 6 <212> PRT <213> Artificial Sequence <220>
    <223> filler sequence-7 <400> 7
    Gly Gly Ser Gly Gly Ser
    1 5 <210> 8 <211> 7 <212> PRT <213> Artificial Sequence <220>
    <223> filler sequence-8 <400> 8
    Gly Gly Ser Gly Gly Ser Gly 1 5 <210> 9 <211> 8 <212> PRT <213> Artificial Sequence <220>
    <223> filler sequence-9 <400> 9
    Ser Gly Ser Gly Gly Ser Gly Ser 1 5 <210> 10 <211> 9 <212> PRT <213> Artificial Sequence <220>
    <223> filler sequence-10
    Page 2
    16EAP0020CPT-seql <400> 10
    Gly Ser Gly Gly Ser Gly Ser Gly Ser 1 5 <210> 11 <211> 10 <212> PRT <213> Artificial Sequence <220>
    <223> filler sequence-11 <400> 11
    Ser Gly Gly Ser Gly Gly Ser Gly Ser 1 5
    Gly <210> 12 <211> 11 <212> PRT <213> Artificial Sequence <220>
    <223> filler sequence-12 <400> 12
    Gly Gly Ser Gly Gly Ser Gly Gly Ser
    1 5
    Gly Ser <210> 13 <211> 12 <212> PRT <213> Artificial Sequence <220>
    <223> filler sequence-13 <400> 13
    Ser Gly Gly Ser Gly Gly Ser Gly Ser
    1 5
    Gly Gly Ser <210> 14 <211> 13 <212> PRT <213> Artificial Sequence <220>
    <223> filler sequence-14 <400> 14
    Gly Gly Gly Gly Ser Gly Gly Ser 1 5
    Gly Gly Gly Gly Ser <210> 15 <211> 14 <212> PRT <213> Artificial Sequence <220>
    <223> filler sequence-15 <400> 15
    Gly Gly Gly Ser Gly Ser Gly Ser Gly
    1 5
    Ser Gly Gly Gly Ser <210> 16 <211> 15 <212> PRT <213> Artificial Sequence
    Page 3
    16EAP0020CPT-seql <220>
    <223> filler sequence-16 <400> 16
    Ser Gly Ser Gly Gly Gly Gly Gly Ser Gly Gly Ser Gly Ser Gly 1 5 10 15 <210> 17 <211> 16 <212> PRT <213> Artificial Sequence <220>
    <221> MOD_RES <222> 1 <223> ACETYLATION <220>
    <223> polypeptide core <400> 17
    Cys Gly Gly Ser Gly Gly Ser Gly Gly Ser Lys Gly Ser Gly Ser Lys
    1 5 10 15 <210> 18 <211> 19 <212> PRT <213> Artificial Sequence <220>
    <221> MOD_RES <222> 1 <223> ACETYLATION <220>
    <223> polypeptitde core-1 <400> 18
    Cys Gly Gly Ser Gly Gly Ser Gly Gly Ser Lys Gly Ser Gly Ser Lys
    1 5 10 15
    Gly Ser Lys <210> 19 <211> 31 <212> PRT <213> Artificial Sequence <220>
    <221> MOD_RES <222> 1 <223> ACETYLATION <220>
    <223> polypeptide core <400> 19
    Cys 1 Gly Ser Lys Gly 5 Ser Lys Gly Ser Lys Gly 10 Ser Lys Gly Ser Lys 15 Gly Ser Lys Gly Ser Lys Gly Ser Lys Gly Ser Lys Gly Ser Lys 20 25 30
    <210> 20 <211> 16 <212> PRT
    Page 4
    16EAP0020CPT-seql <213> Artificial Sequence <220>
    <221> MOD_RES <222> 1 <223> Xaa is homopropargylglycine <220>
    <221> MOD_RES <222> 1 <223> ACETYLATION <220>
    <223> polypeptide core <400> 20
    Xaa Gly Gly Ser Gly Gly Ser Gly Gly Ser Lys Gly Ser Gly Ser Lys
    1 5 10 15 <210> 21 <211> 19 <212> PRT <213> Artificial Sequence <220>
    <221> MOD_RES <222> 1 <223> Xaa is homopropargylglycine <220>
    <221> MOD_RES <222> 1 <223> ACETYLATION <220>
    <223> polypeptide core <400> 21
    Xaa Gly Gly Ser Gly Gly Ser Gly
    1 5
    Gly Ser Lys
    Gly Ser Lys Gly Ser Gly Ser Lys
    10 15 <210> 22 <211> 19 <212> PRT <213> Artificial Sequence <220>
    <221> MOD_RES <222> 1 <223> Xaa is L-azidohomoalanine <220>
    <221> MOD_RES <222> 1 <223> ACETYLATION <220>
    <223> polypeptide core <400> 22
    Xaa Gly Gly Ser Gly Gly Ser Gly Gly Ser Lys Gly Ser Gly Ser Lys
    1 5 10 15
    Gly Ser Lys
    Page 5
    16EAP0020CPT-seql <210> 23 <211> 21 <212> PRT <213> Artificial Sequence <220>
    <221> MOD_RES <222> 1 <223> Xaa is homopropargylglycine <220>
    <221> MOD_RES <222> 1 <223> ACETYLATION <220>
    <223> polypeptide core <400> 23
    Xaa Gly Gly Ser Gly Gly Ser Gly Gly Ser Lys Gly Ser Gly Ser Lys 1 5 10 15
    Gly Ser Gly Ser Cys <210> 24 <211> 7 <212> PRT <213> Artificial Sequence <220>
    <221> MOD_RES <222> 1 <223> ACETYLATION <220>
    <223> polypeptide core <220>
    <221> MOD_RES <222> 2,4,6 <223> Xaa is PEGylated amino acid with two EG units <400> 24
    Cys Xaa Lys Xaa Lys Xaa Lys
    1 5 <210> 25 <211> 11 <212> PRT <213> Artificial Sequence <220>
    <221> MOD_RES <222> 1 <223> ACETYLATION <220>
    <223> polypeptide core <220>
    <221> MOD_RES <222> 2,4,6,8,10 <223> Xaa is PEGylated amino acid with six EG units <400> 25
    Cys Xaa Lys Xaa Lys Xaa Lys Xaa Lys Xaa Lys
    1 5 10
    Page 6
    16EAP0020CPT-seql <210> 26 <211> 16 <212> PRT <213> Artificial Sequence <220>
    <223> polypeptide core-2 <400> 26
    Cys Gly Ser Lys Gly Ser Lys Gly Ser Lys Gly Ser Lys Gly Ser Lys
    1 5 10 15 <210> 27 <211> 250 <212> PRT <213> Artificial Sequence <220>
    <223> anti-fibrin scFv 102-10 <400> 27
    Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Gly Lys Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Lys Tyr 20 25 30 Ile Ala Trp Phe Gln His Lys Pro Gly Lys Gly Pro Arg Leu Leu Ile 35 40 45 His Tyr Thr Ser Thr Leu Gln Pro Gly Ile Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Arg Asp Tyr Ser Phe Ser Ile Ser Asn Leu Glu Pro 65 70 75 80 Glu Asp Leu Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Asn Leu Thr Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Gly Ser Thr Ser 100 105 110 Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Gln Ile 115 120 125 Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val 130 135 140 Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Gly Met 145 150 155 160 Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp 165 170 175 Ile Asn Thr Tyr Thr Gly Glu Ala Thr Tyr Ala Asp Asp Phe Lys Gly 180 185 190 Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Asn Thr Ala Tyr Val Gln 195 200 205 Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg 210 215 220 Leu Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Gly 225 230 235 240 Gly Gly Gly Ser Gly Gly Gly Gly Ser Cys 245 250
    <210> 28 <211> 366 <212> PRT <213> Artificial Sequence <220>
    <223> reteplase-Cys <400> 28
    Ser Tyr Gln Gly Asn Ser Asp Cys Tyr Phe Gly Asn Gly Ser Ala Tyr
    1 5 10 15
    Page 7
    16EAP0020CPT-seql
    Arg Gly Thr His 20 Ser Leu Thr Glu Ser 25 Gly Ala Ser Cys Leu 30 Pro Trp Asn Ser Met Ile Leu Ile Gly Lys Val Tyr Thr Ala Gln Asn Pro Ser 35 40 45 Ala Gln Ala Leu Gly Leu Gly Lys His Asn Tyr Cys Arg Asn Pro Asp 50 55 60 Gly Asp Ala Lys Pro Trp Cys His Val Leu Lys Asn Arg Arg Leu Thr 65 70 75 80 Trp Glu Tyr Cys Asp Val Pro Ser Cys Ser Thr Cys Gly Leu Arg Gln 85 90 95 Tyr Ser Gln Pro Gln Phe Arg Ile Lys Gly Gly Leu Phe Ala Asp Ile 100 105 110 Ala Ser His Pro Trp Gln Ala Ala Ile Phe Ala Lys His Arg Arg Ser 115 120 125 Pro Gly Glu Arg Phe Leu Cys Gly Gly Ile Leu Ile Ser Ser Cys Trp 130 135 140 Ile Leu Ser Ala Ala His Cys Phe Gln Glu Arg Phe Pro Pro His His 145 150 155 160 Leu Thr Val Ile Leu Gly Arg Thr Tyr Arg Val Val Pro Gly Glu Glu 165 170 175 Glu Gln Lys Phe Glu Val Glu Lys Tyr Ile Val His Lys Glu Phe Asp 180 185 190 Asp Asp Thr Tyr Asp Asn Asp Ile Ala Leu Leu Gln Leu Lys Ser Asp 195 200 205 Ser Ser Arg Cys Ala Gln Glu Ser Ser Val Val Arg Thr Val Cys Leu 210 215 220 Pro Pro Ala Asp Leu Gln Leu Pro Asp Trp Thr Glu Cys Glu Leu Ser 225 230 235 240 Gly Tyr Gly Lys His Glu Ala Leu Ser Pro Phe Tyr Ser Glu Arg Leu 245 250 255 Lys Glu Ala His Val Arg Leu Tyr Pro Ser Ser Arg Cys Thr Ser Gln 260 265 270 His Leu Leu Asn Arg Thr Val Thr Asp Asn Met Leu Cys Ala Gly Asp 275 280 285 Thr Arg Ser Gly Gly Pro Gln Ala Asn Leu His Asp Ala Cys Gln Gly 290 295 300 Asp Ser Gly Gly Pro Leu Val Cys Leu Asn Asp Gly Arg Met Thr Leu 305 310 315 320 Val Gly Ile Ile Ser Trp Gly Leu Gly Cys Gly Gln Lys Asp Val Pro 325 330 335 Gly Val Tyr Thr Lys Val Thr Asn Tyr Leu Asp Trp Ile Arg Asp Asn 340 345 350 Met Arg Pro Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Cys 355 360 365
    <210> 29 <211> 244 <212> PRT <213> Artificial Sequence <220>
    <223> Phage-displayed anti-fibrin scFv D10 <400> 29
    Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Gly Phe Tyr 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Ser Tyr Pro Ser Gly Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Asp Tyr Pro Ile 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Gly Ser Thr Ser 100 105 110
    Page 8
    16EAP0020CPT-seql
    Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Val 115 120 125 Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu 130 135 140 Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ile Asn Asp Phe Ser Ile 145 150 155 160 His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Gly 165 170 175 Ile Trp Pro Tyr Gly Gly Tyr Thr Phe Tyr Ala Asp Ser Val Lys Gly 180 185 190 Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu Arg 195 200 205 Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 210 215 220 Phe Gly Tyr Tyr Ser Phe Gly Asp Tyr Trp Gly Gln Gly Thr Leu Val 225 230 235 240 Thr Val Ser Ser
    <210> 30 <211> 599 <212> PRT <213> Artificial Sequence <220>
    <223> 2-chain IgG4.Fc fusion protein containing reteplase <400> 30
    Ser Tyr Gln Gly Asn Ser Asp Cys Tyr Phe Gly Asn Gly Ser Ala Tyr 1 5 10 15 Arg Gly Thr His Ser Leu Thr Glu Ser Gly Ala Ser Cys Leu Pro Trp 20 25 30 Asn Ser Met Ile Leu Ile Gly Lys Val Tyr Thr Ala Gln Asn Pro Ser 35 40 45 Ala Gln Ala Leu Gly Leu Gly Lys His Asn Tyr Cys Arg Asn Pro Asp 50 55 60 Gly Asp Ala Lys Pro Trp Cys His Val Leu Lys Asn Arg Arg Leu Thr 65 70 75 80 Trp Glu Tyr Cys Asp Val Pro Ser Cys Ser Thr Cys Gly Leu Arg Gln 85 90 95 Tyr Ser Gln Pro Gln Phe Arg Ile Lys Gly Gly Leu Phe Ala Asp Ile 100 105 110 Ala Ser His Pro Trp Gln Ala Ala Ile Phe Ala Lys His Arg Arg Ser 115 120 125 Pro Gly Glu Arg Phe Leu Cys Gly Gly Ile Leu Ile Ser Ser Cys Trp 130 135 140 Ile Leu Ser Ala Ala His Cys Phe Gln Glu Arg Phe Pro Pro His His 145 150 155 160 Leu Thr Val Ile Leu Gly Arg Thr Tyr Arg Val Val Pro Gly Glu Glu 165 170 175 Glu Gln Lys Phe Glu Val Glu Lys Tyr Ile Val His Lys Glu Phe Asp 180 185 190 Asp Asp Thr Tyr Asp Asn Asp Ile Ala Leu Leu Gln Leu Lys Ser Asp 195 200 205 Ser Ser Arg Cys Ala Gln Glu Ser Ser Val Val Arg Thr Val Cys Leu 210 215 220 Pro Pro Ala Asp Leu Gln Leu Pro Asp Trp Thr Glu Cys Glu Leu Ser 225 230 235 240 Gly Tyr Gly Lys His Glu Ala Leu Ser Pro Phe Tyr Ser Glu Arg Leu 245 250 255 Lys Glu Ala His Val Arg Leu Tyr Pro Ser Ser Arg Cys Thr Ser Gln 260 265 270 His Leu Leu Asn Arg Thr Val Thr Asp Asn Met Leu Cys Ala Gly Asp 275 280 285 Thr Arg Ser Gly Gly Pro Gln Ala Asn Leu His Asp Ala Cys Gln Gly 290 295 300 Asp Ser Gly Gly Pro Leu Val Cys Leu Asn Asp Gly Arg Met Thr Leu 305 310 315 320
    Page 9
    16EAP0020CPT-seql
    Val Gly Ile Ile Ser 325 Trp Gly Leu Gly Cys 330 Gly Gln Lys Asp Val 335 Pro Gly Val Tyr Thr Lys Val Thr Asn Tyr Leu Asp Trp Ile Arg Asp Asn 340 345 350 Met Arg Pro Ala Ser Gly Gly Ser Pro Pro Cys Pro Ser Cys Pro Ala 355 360 365 Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 370 375 380 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 385 390 395 400 Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val 405 410 415 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 420 425 430 Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 435 440 445 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly 450 455 460 Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 465 470 475 480 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr 485 490 495 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 500 505 510 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 515 520 525 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 530 535 540 Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe 545 550 555 560 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 565 570 575 Ser Leu Ser Leu Ser Leu Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly 580 585 590 Gly Ser Gly Gly Gly Gly Ser
    595 <210> 31 <211> 838 <212> PRT <213> Artificial Sequence <220>
    <223> (reteplase)-hIgG4.Fc-(scFv α fibrin 102-10) <400> 31
    Ser Tyr Gln Gly Asn Ser Asp Cys Tyr Phe Gly Asn Gly Ser Ala Tyr 1 5 10 15 Arg Gly Thr His Ser Leu Thr Glu Ser Gly Ala Ser Cys Leu Pro Trp 20 25 30 Asn Ser Met Ile Leu Ile Gly Lys Val Tyr Thr Ala Gln Asn Pro Ser 35 40 45 Ala Gln Ala Leu Gly Leu Gly Lys His Asn Tyr Cys Arg Asn Pro Asp 50 55 60 Gly Asp Ala Lys Pro Trp Cys His Val Leu Lys Asn Arg Arg Leu Thr 65 70 75 80 Trp Glu Tyr Cys Asp Val Pro Ser Cys Ser Thr Cys Gly Leu Arg Gln 85 90 95 Tyr Ser Gln Pro Gln Phe Arg Ile Lys Gly Gly Leu Phe Ala Asp Ile 100 105 110 Ala Ser His Pro Trp Gln Ala Ala Ile Phe Ala Lys His Arg Arg Ser 115 120 125 Pro Gly Glu Arg Phe Leu Cys Gly Gly Ile Leu Ile Ser Ser Cys Trp 130 135 140 Ile Leu Ser Ala Ala His Cys Phe Gln Glu Arg Phe Pro Pro His His 145 150 155 160 Leu Thr Val Ile Leu Gly Arg Thr Tyr Arg Val Val Pro Gly Glu Glu 165 170 175
    Page 10
    16EAP0020CPT-seql
    Glu Gln Lys Phe 180 Glu Val Glu Lys Tyr 185 Ile Val His Lys Glu 190 Phe Asp Asp Asp Thr Tyr Asp Asn Asp Ile Ala Leu Leu Gln Leu Lys Ser Asp 195 200 205 Ser Ser Arg Cys Ala Gln Glu Ser Ser Val Val Arg Thr Val Cys Leu 210 215 220 Pro Pro Ala Asp Leu Gln Leu Pro Asp Trp Thr Glu Cys Glu Leu Ser 225 230 235 240 Gly Tyr Gly Lys His Glu Ala Leu Ser Pro Phe Tyr Ser Glu Arg Leu 245 250 255 Lys Glu Ala His Val Arg Leu Tyr Pro Ser Ser Arg Cys Thr Ser Gln 260 265 270 His Leu Leu Asn Arg Thr Val Thr Asp Asn Met Leu Cys Ala Gly Asp 275 280 285 Thr Arg Ser Gly Gly Pro Gln Ala Asn Leu His Asp Ala Cys Gln Gly 290 295 300 Asp Ser Gly Gly Pro Leu Val Cys Leu Asn Asp Gly Arg Met Thr Leu 305 310 315 320 Val Gly Ile Ile Ser Trp Gly Leu Gly Cys Gly Gln Lys Asp Val Pro 325 330 335 Gly Val Tyr Thr Lys Val Thr Asn Tyr Leu Asp Trp Ile Arg Asp Asn 340 345 350 Met Arg Pro Ala Ser Gly Gly Ser Pro Pro Cys Pro Ser Cys Pro Ala 355 360 365 Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 370 375 380 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 385 390 395 400 Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val 405 410 415 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 420 425 430 Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 435 440 445 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly 450 455 460 Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 465 470 475 480 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr 485 490 495 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 500 505 510 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 515 520 525 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 530 535 540 Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe 545 550 555 560 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 565 570 575 Ser Leu Ser Leu Ser Leu Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly 580 585 590 Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser 595 600 605 Ser Leu Ser Ala Ser Leu Gly Gly Lys Val Thr Ile Thr Cys Lys Ala 610 615 620 Ser Gln Asp Ile Asn Lys Tyr Ile Ala Trp Phe Gln His Lys Pro Gly 625 630 635 640 Lys Gly Pro Arg Leu Leu Ile His Tyr Thr Ser Thr Leu Gln Pro Gly 645 650 655 Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Arg Asp Tyr Ser Phe 660 665 670 Ser Ile Ser Asn Leu Glu Pro Glu Asp Leu Ala Thr Tyr Tyr Cys Leu 675 680 685 Gln Tyr Asp Asn Leu Thr Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu 690 695 700 Ile Lys Arg Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu 705 710 715 720
    Page 11
    16EAP0020CPT-seql
    Gly Ser Thr Lys Gly Gln 725 Ile Gln Leu Val 730 Gln Ser Gly Pro Glu 735 Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr 740 745 750 Thr Phe Thr Asn Tyr Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys 755 760 765 Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Tyr Thr Gly Glu Ala Thr 770 775 780 Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser 785 790 795 800 Ala Asn Thr Ala Tyr Val Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr 805 810 815 Ala Thr Tyr Phe Cys Ala Arg Leu Met Asp Tyr Trp Gly Gln Gly Thr 820 825 830 Ser Val Thr Val Ser Ser
    835 <210> 32 <211> 611 <212> PRT <213> Artificial Sequence <220>
    <223> (reteplase)-(scFv α fibrin 102-10) <400> 32
    Ser Tyr Gln Gly Asn Ser Asp Cys Tyr Phe Gly Asn Gly Ser Ala Tyr 1 5 10 15 Arg Gly Thr His Ser Leu Thr Glu Ser Gly Ala Ser Cys Leu Pro Trp 20 25 30 Asn Ser Met Ile Leu Ile Gly Lys Val Tyr Thr Ala Gln Asn Pro Ser 35 40 45 Ala Gln Ala Leu Gly Leu Gly Lys His Asn Tyr Cys Arg Asn Pro Asp 50 55 60 Gly Asp Ala Lys Pro Trp Cys His Val Leu Lys Asn Arg Arg Leu Thr 65 70 75 80 Trp Glu Tyr Cys Asp Val Pro Ser Cys Ser Thr Cys Gly Leu Arg Gln 85 90 95 Tyr Ser Gln Pro Gln Phe Arg Ile Lys Gly Gly Leu Phe Ala Asp Ile 100 105 110 Ala Ser His Pro Trp Gln Ala Ala Ile Phe Ala Lys His Arg Arg Ser 115 120 125 Pro Gly Glu Arg Phe Leu Cys Gly Gly Ile Leu Ile Ser Ser Cys Trp 130 135 140 Ile Leu Ser Ala Ala His Cys Phe Gln Glu Arg Phe Pro Pro His His 145 150 155 160 Leu Thr Val Ile Leu Gly Arg Thr Tyr Arg Val Val Pro Gly Glu Glu 165 170 175 Glu Gln Lys Phe Glu Val Glu Lys Tyr Ile Val His Lys Glu Phe Asp 180 185 190 Asp Asp Thr Tyr Asp Asn Asp Ile Ala Leu Leu Gln Leu Lys Ser Asp 195 200 205 Ser Ser Arg Cys Ala Gln Glu Ser Ser Val Val Arg Thr Val Cys Leu 210 215 220 Pro Pro Ala Asp Leu Gln Leu Pro Asp Trp Thr Glu Cys Glu Leu Ser 225 230 235 240 Gly Tyr Gly Lys His Glu Ala Leu Ser Pro Phe Tyr Ser Glu Arg Leu 245 250 255 Lys Glu Ala His Val Arg Leu Tyr Pro Ser Ser Arg Cys Thr Ser Gln 260 265 270 His Leu Leu Asn Arg Thr Val Thr Asp Asn Met Leu Cys Ala Gly Asp 275 280 285 Thr Arg Ser Gly Gly Pro Gln Ala Asn Leu His Asp Ala Cys Gln Gly 290 295 300 Asp Ser Gly Gly Pro Leu Val Cys Leu Asn Asp Gly Arg Met Thr Leu 305 310 315 320 Val Gly Ile Ile Ser Trp Gly Leu Gly Cys Gly Gln Lys Asp Val Pro 325 330 335
    Page 12
    16EAP0020CPT-seql
    Gly Val Tyr Thr 340 Lys Val Thr Asn Tyr 345 Leu Asp Trp Ile Arg 350 Asp Asn Met Arg Pro Ala Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 355 360 365 Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser 370 375 380 Ala Ser Leu Gly Gly Lys Val Thr Ile Thr Cys Lys Ala Ser Gln Asp 385 390 395 400 Ile Asn Lys Tyr Ile Ala Trp Phe Gln His Lys Pro Gly Lys Gly Pro 405 410 415 Arg Leu Leu Ile His Tyr Thr Ser Thr Leu Gln Pro Gly Ile Pro Ser 420 425 430 Arg Phe Ser Gly Ser Gly Ser Gly Arg Asp Tyr Ser Phe Ser Ile Ser 435 440 445 Asn Leu Glu Pro Glu Asp Leu Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp 450 455 460 Asn Leu Thr Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 465 470 475 480 Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr 485 490 495 Lys Gly Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro 500 505 510 Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr 515 520 525 Asn Tyr Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys 530 535 540 Trp Met Gly Trp Ile Asn Thr Tyr Thr Gly Glu Ala Thr Tyr Ala Asp 545 550 555 560 Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Asn Thr 565 570 575 Ala Tyr Val Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr 580 585 590 Phe Cys Ala Arg Leu Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr 595 600 605 Val Ser Ser
    610 <210> 33 <211> 771 <212> PRT <213> Artificial Sequence <220>
    <223> 2-chain IgG4.Fc fusion protein containing TNK-tPA <400> 33
    Ser Tyr Gln Val Ile Cys Arg Asp Glu Lys Thr Gln Met Ile Tyr Gln 1 5 10 15 Gln His Gln Ser Trp Leu Arg Pro Val Leu Arg Ser Asn Arg Val Glu 20 25 30 Tyr Cys Trp Cys Asn Ser Gly Arg Ala Gln Cys His Ser Val Pro Val 35 40 45 Lys Ser Cys Ser Glu Pro Arg Cys Phe Asn Gly Gly Thr Cys Gln Gln 50 55 60 Ala Leu Tyr Phe Ser Asp Phe Val Cys Gln Cys Pro Glu Gly Phe Ala 65 70 75 80 Gly Lys Cys Cys Glu Ile Asp Thr Arg Ala Thr Cys Tyr Glu Asp Gln 85 90 95 Gly Ile Ser Tyr Arg Gly Asn Trp Ser Thr Ala Glu Ser Gly Ala Glu 100 105 110 Cys Thr Gln Trp Asn Ser Ser Ala Leu Ala Gln Lys Pro Tyr Ser Gly 115 120 125 Arg Arg Pro Asp Ala Ile Arg Leu Gly Leu Gly Asn His Asn Tyr Cys 130 135 140 Arg Asn Pro Asp Arg Asp Ser Lys Pro Trp Cys Tyr Val Phe Lys Ala 145 150 155 160 Gly Lys Tyr Ser Ser Glu Phe Cys Ser Thr Pro Ala Cys Ser Glu Gly 165 170 175
    Page 13
    16EAP0020CPT-seql
    Asn Ser Asp Cys 180 Tyr Phe Gly Asn Gly Ser Ala Tyr Arg Gly Thr His 185 190 Ser Leu Thr Glu Ser Gly Ala Ser Cys Leu Pro Trp Asn Ser Met Ile 195 200 205 Leu Ile Gly Lys Val Tyr Thr Ala Gln Asn Pro Ser Ala Gln Ala Leu 210 215 220 Gly Leu Gly Lys His Asn Tyr Cys Arg Asn Pro Asp Gly Asp Ala Lys 225 230 235 240 Pro Trp Cys His Val Leu Lys Asn Arg Arg Leu Thr Trp Glu Tyr Cys 245 250 255 Asp Val Pro Ser Cys Ser Thr Cys Gly Leu Arg Gln Tyr Ser Gln Pro 260 265 270 Gln Phe Arg Ile Lys Gly Gly Leu Phe Ala Asp Ile Ala Ser His Pro 275 280 285 Trp Gln Ala Ala Ala Ala Ala Lys His Arg Arg Ser Pro Gly Glu Arg 290 295 300 Phe Leu Cys Gly Gly Ile Leu Ile Ser Ser Cys Trp Ile Leu Ser Ala 305 310 315 320 Ala His Cys Phe Gln Glu Arg Phe Pro Pro His His Leu Thr Val Ile 325 330 335 Leu Gly Arg Thr Tyr Arg Val Val Pro Gly Glu Glu Glu Gln Lys Phe 340 345 350 Glu Val Glu Lys Tyr Ile Val His Lys Glu Phe Asp Asp Asp Thr Tyr 355 360 365 Asp Asn Asp Ile Ala Leu Leu Gln Leu Lys Ser Asp Ser Ser Arg Cys 370 375 380 Ala Gln Glu Ser Ser Val Val Arg Thr Val Cys Leu Pro Pro Ala Asp 385 390 395 400 Leu Gln Leu Pro Asp Trp Thr Glu Cys Glu Leu Ser Gly Tyr Gly Lys 405 410 415 His Glu Ala Leu Ser Pro Phe Tyr Ser Glu Arg Leu Lys Glu Ala His 420 425 430 Val Arg Leu Tyr Pro Ser Ser Arg Cys Thr Ser Gln His Leu Leu Asn 435 440 445 Arg Thr Val Thr Asp Asn Met Leu Cys Ala Gly Asp Thr Arg Ser Gly 450 455 460 Gly Pro Gln Ala Asn Leu His Asp Ala Cys Gln Gly Asp Ser Gly Gly 465 470 475 480 Pro Leu Val Cys Leu Asn Asp Gly Arg Met Thr Leu Val Gly Ile Ile 485 490 495 Ser Trp Gly Leu Gly Cys Gly Gln Lys Asp Val Pro Gly Val Tyr Thr 500 505 510 Lys Val Thr Asn Tyr Leu Asp Trp Ile Arg Asp Asn Met Arg Pro Ala 515 520 525 Ser Gly Gly Ser Pro Pro Cys Pro Ser Cys Pro Ala Pro Glu Phe Leu 530 535 540 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 545 550 555 560 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 565 570 575 Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu 580 585 590 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr 595 600 605 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 610 615 620 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser 625 630 635 640 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 645 650 655 Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val 660 665 670 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 675 680 685 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 690 695 700 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr 705 710 715 720
    Page 14
    16EAP0020CPT-seql
    Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val 725 730 735 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 740 745 750 Ser Leu Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 755 760 765
    Gly Gly Ser
    770 <210> 34 <211> 1015 <212> PRT <213> Artificial Sequence <220>
    <223> (TNK-tPA)-hIgG4.Fc-(scFv α fibrin D10) <400> 34
    Ser 1 Tyr Gln Val Ile Cys 5 Arg Asp Glu Lys Thr 10 Gln Met Ile Tyr 15 Gln Gln His Gln Ser Trp Leu Arg Pro Val Leu Arg Ser Asn Arg Val Glu 20 25 30 Tyr Cys Trp Cys Asn Ser Gly Arg Ala Gln Cys His Ser Val Pro Val 35 40 45 Lys Ser Cys Ser Glu Pro Arg Cys Phe Asn Gly Gly Thr Cys Gln Gln 50 55 60 Ala Leu Tyr Phe Ser Asp Phe Val Cys Gln Cys Pro Glu Gly Phe Ala 65 70 75 80 Gly Lys Cys Cys Glu Ile Asp Thr Arg Ala Thr Cys Tyr Glu Asp Gln 85 90 95 Gly Ile Ser Tyr Arg Gly Asn Trp Ser Thr Ala Glu Ser Gly Ala Glu 100 105 110 Cys Thr Gln Trp Asn Ser Ser Ala Leu Ala Gln Lys Pro Tyr Ser Gly 115 120 125 Arg Arg Pro Asp Ala Ile Arg Leu Gly Leu Gly Asn His Asn Tyr Cys 130 135 140 Arg Asn Pro Asp Arg Asp Ser Lys Pro Trp Cys Tyr Val Phe Lys Ala 145 150 155 160 Gly Lys Tyr Ser Ser Glu Phe Cys Ser Thr Pro Ala Cys Ser Glu Gly 165 170 175 Asn Ser Asp Cys Tyr Phe Gly Asn Gly Ser Ala Tyr Arg Gly Thr His 180 185 190 Ser Leu Thr Glu Ser Gly Ala Ser Cys Leu Pro Trp Asn Ser Met Ile 195 200 205 Leu Ile Gly Lys Val Tyr Thr Ala Gln Asn Pro Ser Ala Gln Ala Leu 210 215 220 Gly Leu Gly Lys His Asn Tyr Cys Arg Asn Pro Asp Gly Asp Ala Lys 225 230 235 240 Pro Trp Cys His Val Leu Lys Asn Arg Arg Leu Thr Trp Glu Tyr Cys 245 250 255 Asp Val Pro Ser Cys Ser Thr Cys Gly Leu Arg Gln Tyr Ser Gln Pro 260 265 270 Gln Phe Arg Ile Lys Gly Gly Leu Phe Ala Asp Ile Ala Ser His Pro 275 280 285 Trp Gln Ala Ala Ala Ala Ala Lys His Arg Arg Ser Pro Gly Glu Arg 290 295 300 Phe Leu Cys Gly Gly Ile Leu Ile Ser Ser Cys Trp Ile Leu Ser Ala 305 310 315 320 Ala His Cys Phe Gln Glu Arg Phe Pro Pro His His Leu Thr Val Ile 325 330 335 Leu Gly Arg Thr Tyr Arg Val Val Pro Gly Glu Glu Glu Gln Lys Phe 340 345 350 Glu Val Glu Lys Tyr Ile Val His Lys Glu Phe Asp Asp Asp Thr Tyr 355 360 365 Asp Asn Asp Ile Ala Leu Leu Gln Leu Lys Ser Asp Ser Ser Arg Cys 370 375 380 Ala Gln Glu Ser Ser Val Val Arg Thr Val Cys Leu Pro Pro Ala Asp 385 390 395 400
    Page 15
    16EAP0020CPT-seql
    Leu Gln Leu Pro Asp 405 Trp Thr Glu Cys Glu 410 Leu Ser Gly Tyr Gly 415 Lys His Glu Ala Leu Ser Pro Phe Tyr Ser Glu Arg Leu Lys Glu Ala His 420 425 430 Val Arg Leu Tyr Pro Ser Ser Arg Cys Thr Ser Gln His Leu Leu Asn 435 440 445 Arg Thr Val Thr Asp Asn Met Leu Cys Ala Gly Asp Thr Arg Ser Gly 450 455 460 Gly Pro Gln Ala Asn Leu His Asp Ala Cys Gln Gly Asp Ser Gly Gly 465 470 475 480 Pro Leu Val Cys Leu Asn Asp Gly Arg Met Thr Leu Val Gly Ile Ile 485 490 495 Ser Trp Gly Leu Gly Cys Gly Gln Lys Asp Val Pro Gly Val Tyr Thr 500 505 510 Lys Val Thr Asn Tyr Leu Asp Trp Ile Arg Asp Asn Met Arg Pro Ala 515 520 525 Ser Gly Gly Ser Pro Pro Cys Pro Ser Cys Pro Ala Pro Glu Phe Leu 530 535 540 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 545 550 555 560 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 565 570 575 Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu 580 585 590 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr 595 600 605 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 610 615 620 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser 625 630 635 640 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 645 650 655 Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val 660 665 670 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 675 680 685 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 690 695 700 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr 705 710 715 720 Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val 725 730 735 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 740 745 750 Ser Leu Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 755 760 765 Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala 770 775 780 Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val 785 790 795 800 Gly Phe Tyr Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys 805 810 815 Leu Leu Ile Ser Tyr Pro Ser Gly Leu Tyr Ser Gly Val Pro Ser Arg 820 825 830 Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser 835 840 845 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Asp 850 855 860 Tyr Pro Ile Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Gly 865 870 875 880 Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys 885 890 895 Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly 900 905 910 Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ile Asn Asp 915 920 925 Phe Ser Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp 930 935 940
    Page 16
    16EAP0020CPT-seql
    Val Ala Gly Ile Trp Pro Tyr Gly Gly Tyr Thr Phe Tyr Ala Asp Ser 945 950 955 960 Val Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala 965 970 975 Tyr Leu Arg Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr 980 985 990 Cys Ala Arg Phe Gly Tyr Tyr Ser Phe Gly Asp Tyr Trp Gly Gln Gly 995 1000 1005 Thr Leu Val Thr Val Ser Ser
    1010 1015 <210> 35 <211> 788 <212> PRT <213> Artificial Sequence <220>
    <223> (TNK-tPA)-(scFv α fibrin) <400> 35
    Ser Tyr Gln Val Ile Cys Arg Asp Glu Lys Thr Gln Met Ile Tyr Gln 1 5 10 15 Gln His Gln Ser Trp Leu Arg Pro Val Leu Arg Ser Asn Arg Val Glu 20 25 30 Tyr Cys Trp Cys Asn Ser Gly Arg Ala Gln Cys His Ser Val Pro Val 35 40 45 Lys Ser Cys Ser Glu Pro Arg Cys Phe Asn Gly Gly Thr Cys Gln Gln 50 55 60 Ala Leu Tyr Phe Ser Asp Phe Val Cys Gln Cys Pro Glu Gly Phe Ala 65 70 75 80 Gly Lys Cys Cys Glu Ile Asp Thr Arg Ala Thr Cys Tyr Glu Asp Gln 85 90 95 Gly Ile Ser Tyr Arg Gly Asn Trp Ser Thr Ala Glu Ser Gly Ala Glu 100 105 110 Cys Thr Gln Trp Asn Ser Ser Ala Leu Ala Gln Lys Pro Tyr Ser Gly 115 120 125 Arg Arg Pro Asp Ala Ile Arg Leu Gly Leu Gly Asn His Asn Tyr Cys 130 135 140 Arg Asn Pro Asp Arg Asp Ser Lys Pro Trp Cys Tyr Val Phe Lys Ala 145 150 155 160 Gly Lys Tyr Ser Ser Glu Phe Cys Ser Thr Pro Ala Cys Ser Glu Gly 165 170 175 Asn Ser Asp Cys Tyr Phe Gly Asn Gly Ser Ala Tyr Arg Gly Thr His 180 185 190 Ser Leu Thr Glu Ser Gly Ala Ser Cys Leu Pro Trp Asn Ser Met Ile 195 200 205 Leu Ile Gly Lys Val Tyr Thr Ala Gln Asn Pro Ser Ala Gln Ala Leu 210 215 220 Gly Leu Gly Lys His Asn Tyr Cys Arg Asn Pro Asp Gly Asp Ala Lys 225 230 235 240 Pro Trp Cys His Val Leu Lys Asn Arg Arg Leu Thr Trp Glu Tyr Cys 245 250 255 Asp Val Pro Ser Cys Ser Thr Cys Gly Leu Arg Gln Tyr Ser Gln Pro 260 265 270 Gln Phe Arg Ile Lys Gly Gly Leu Phe Ala Asp Ile Ala Ser His Pro 275 280 285 Trp Gln Ala Ala Ala Ala Ala Lys His Arg Arg Ser Pro Gly Glu Arg 290 295 300 Phe Leu Cys Gly Gly Ile Leu Ile Ser Ser Cys Trp Ile Leu Ser Ala 305 310 315 320 Ala His Cys Phe Gln Glu Arg Phe Pro Pro His His Leu Thr Val Ile 325 330 335 Leu Gly Arg Thr Tyr Arg Val Val Pro Gly Glu Glu Glu Gln Lys Phe 340 345 350 Glu Val Glu Lys Tyr Ile Val His Lys Glu Phe Asp Asp Asp Thr Tyr 355 360 365 Asp Asn Asp Ile Ala Leu Leu Gln Leu Lys Ser Asp Ser Ser Arg Cys 370 375 380
    Page 17
    16EAP0020CPT-seql Ala Gln Glu Ser Ser Val Val Arg Thr Val Cys Leu Pro Pro Ala Asp 385 390 395 400 Leu Gln Leu Pro Asp Trp Thr Glu Cys Glu Leu Ser Gly Tyr Gly Lys 405 410 415 His Glu Ala Leu Ser Pro Phe Tyr Ser Glu Arg Leu Lys Glu Ala His 420 425 430 Val Arg Leu Tyr Pro Ser Ser Arg Cys Thr Ser Gln His Leu Leu Asn 435 440 445 Arg Thr Val Thr Asp Asn Met Leu Cys Ala Gly Asp Thr Arg Ser Gly 450 455 460 Gly Pro Gln Ala Asn Leu His Asp Ala Cys Gln Gly Asp Ser Gly Gly 465 470 475 480 Pro Leu Val Cys Leu Asn Asp Gly Arg Met Thr Leu Val Gly Ile Ile 485 490 495 Ser Trp Gly Leu Gly Cys Gly Gln Lys Asp Val Pro Gly Val Tyr Thr 500 505 510 Lys Val Thr Asn Tyr Leu Asp Trp Ile Arg Asp Asn Met Arg Pro Ala 515 520 525 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 530 535 540 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 545 550 555 560 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Gly Phe Tyr 565 570 575 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 580 585 590 Ser Tyr Pro Ser Gly Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 595 600 605 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 610 615 620 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Asp Tyr Pro Ile 625 630 635 640 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Gly Ser Thr Ser 645 650 655 Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Val 660 665 670 Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu 675 680 685 Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ile Asn Asp Phe Ser Ile 690 695 700 His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Gly 705 710 715 720 Ile Trp Pro Tyr Gly Gly Tyr Thr Phe Tyr Ala Asp Ser Val Lys Gly 725 730 735 Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu Arg 740 745 750 Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 755 760 765 Phe Gly Tyr Tyr Ser Phe Gly Asp Tyr Trp Gly Gln Gly Thr Leu Val 770 775 780 Thr Val Ser Ser 785
    Page 18
AU2016316202A 2015-09-01 2016-07-18 Molecular constructs for preventing the formation of blood clot and/or treating thrombosis Active AU2016316202B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562213012P 2015-09-01 2015-09-01
US62/213,012 2015-09-01
AUPCT/CN2016/071184 2016-01-18
PCT/CN2016/071184 WO2016112870A1 (en) 2015-01-16 2016-01-18 Molecular constructs with targeting and effector elements
US201662308349P 2016-03-15 2016-03-15
US62/308,349 2016-03-15
PCT/CN2016/090296 WO2017036255A1 (en) 2015-09-01 2016-07-18 Molecular constructs for preventing the formation of blood clot and/or treating thrombosis

Publications (3)

Publication Number Publication Date
AU2016316202A1 AU2016316202A1 (en) 2018-03-22
AU2016316202A8 AU2016316202A8 (en) 2018-04-05
AU2016316202B2 true AU2016316202B2 (en) 2018-11-15

Family

ID=58098078

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016316202A Active AU2016316202B2 (en) 2015-09-01 2016-07-18 Molecular constructs for preventing the formation of blood clot and/or treating thrombosis
AU2016316281A Active AU2016316281B2 (en) 2015-09-01 2016-09-01 Molecular constructs for treating rejection reaction in transplantation

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016316281A Active AU2016316281B2 (en) 2015-09-01 2016-09-01 Molecular constructs for treating rejection reaction in transplantation

Country Status (10)

Country Link
US (3) US9623118B2 (en)
EP (1) EP3344285A4 (en)
JP (2) JP2018527350A (en)
CN (2) CN108431045B (en)
AU (2) AU2016316202B2 (en)
CA (2) CA2996652A1 (en)
HK (1) HK1254280A1 (en)
IL (2) IL257750A (en)
TW (5) TWI617319B (en)
WO (2) WO2017036255A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3081058C (en) * 2015-01-16 2024-02-20 Academia Sinica Linker units and their uses in configuring pharmaceutical molecules
JP7011764B2 (en) 2016-07-07 2022-01-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Antibody adjuvant complex
CN110520436A (en) * 2017-03-15 2019-11-29 潘迪恩治疗公司 Target immunological tolerance
CA3056290C (en) * 2017-03-16 2021-09-28 Immunwork Inc. Linker units and molecular constructs comprising same
JP2020521452A (en) * 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド Targeted tolerance
EP3684414A4 (en) * 2017-09-19 2021-06-09 Immunwork Inc. Pharmaceutical constructs with enhanced binding affinity with albumin
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
AU2019382515B2 (en) * 2018-11-21 2023-11-23 Immunwork Inc. Polypeptide for treating pathological blood clots
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
JP7028904B2 (en) * 2019-03-21 2022-03-02 アカデミア シニカ Synthetic peptides, pharmaceutical compositions comprising them and their use in the treatment of thromboembolism-related diseases
BR112021023345A2 (en) 2019-05-20 2022-02-01 Pandion Operations Inc Targeted immunotolerance in madcam
CN113248436A (en) * 2021-04-13 2021-08-13 南京工业大学 Novel cross-linked molecule for protein targeted transportation and preparation method and application thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432260A (en) * 1991-05-03 1995-07-11 Washington University High affinity mannose receptor ligands
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
NZ509430A (en) * 1998-08-28 2002-04-26 Genentech Inc Antibodies reactive with blood coagulation factors IX/IXa Gla domain to treat thrombotic disorders
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
RU2263118C2 (en) * 1999-08-09 2005-10-27 Лексиген Фармасьютикэлс Корп. Complexes of antibodies with some cytokines
AR036993A1 (en) * 2001-04-02 2004-10-20 Wyeth Corp USE OF AGENTS THAT MODULATE THE INTERACTION BETWEEN PD-1 AND ITS LINKS IN THE SUBMODULATION OF IMMUNOLOGICAL ANSWERS
US8298532B2 (en) * 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
JP2009525986A (en) * 2006-02-03 2009-07-16 メディミューン，エルエルシー Protein preparation
EP2076557A4 (en) * 2006-08-11 2012-08-29 Starpharma Pty Ltd Polylysine dendrimer contrast agent
CN100467022C (en) * 2007-04-13 2009-03-11 天津市炜杰科技有限公司 Application of 21(S) argatroban
EP2385065A1 (en) * 2007-11-01 2011-11-09 Perseid Therapeutics LLC Immunosuppressive polypeptides and nucleic acids
WO2010039496A2 (en) * 2008-09-23 2010-04-08 The Regents Of The University Of California Nanocarriers for drug delivery
JP2012515556A (en) * 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド Stabilized Fc polypeptides with reduced effector function and methods of use
PL2396036T3 (en) * 2009-02-13 2017-12-29 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US20130131573A1 (en) * 2009-08-18 2013-05-23 William H. Hildebrand Selective anti-hla antibody removal device and methods of production and use thereof
WO2011029008A2 (en) * 2009-09-04 2011-03-10 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Synbodies to akt1
EP2488208B1 (en) * 2009-10-14 2018-11-21 The Governors of the University of Alberta Compounds having peptides conjugated to bone targeting moieties and methods of making and using thereof
IN2012DN03177A (en) * 2009-12-04 2015-09-25 Immunomedics Inc
AR082205A1 (en) * 2010-07-12 2012-11-21 Covx Technologies Ireland Ltd CONJUGATES OF MULTIFUNCTIONAL ANTIBODIES
WO2012088302A2 (en) * 2010-12-22 2012-06-28 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
AU2012316859A1 (en) * 2011-09-29 2014-04-17 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
WO2013123591A1 (en) * 2012-02-20 2013-08-29 National Research Council Of Canada Multimerized single domain antibody ligands of prothrombin as inhibitors of blood and extravascular coagulation
PT2850106T (en) * 2012-05-18 2022-07-18 Aptevo Res & Development Llc Bispecific scfv immunofusion (bif)
KR102182800B1 (en) * 2012-08-31 2020-11-25 서트로 바이오파마, 인크. Modified amino acids comprising an azido group
EP2963059B1 (en) 2013-02-28 2018-04-04 National Cancer Center Antibody against insoluble fibrin
MX368665B (en) * 2013-03-15 2019-10-10 Abbvie Biotherapeutics Inc Fc variants.
CA3081058C (en) * 2015-01-16 2024-02-20 Academia Sinica Linker units and their uses in configuring pharmaceutical molecules
CN107847588B (en) * 2015-05-20 2021-12-28 免疫功坊股份有限公司 Molecular construct with targeting and effector moieties and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IAN W. HAMLEY, "PEG-Peptide Conjugates", BIOMACROMOLECULES, US, (2014-05-12), vol. 15, no. 5, doi:10.1021/bm500246w, ISSN 1525-7797, pages 1543 - 1559 *
LI, WENLI et al., "New advances in bispecific antibodies for cancer therapy.", CHEMISTRY OF LIFE, (2010-12-31), vol. 30, no. 6, pages 827 -832 *

Also Published As

Publication number Publication date
CA2996653A1 (en) 2017-03-09
TW201711704A (en) 2017-04-01
TWI608018B (en) 2017-12-11
TWI614268B (en) 2018-02-11
HK1254280A1 (en) 2019-07-19
TWI617319B (en) 2018-03-11
TWI603980B (en) 2017-11-01
CN108271357A (en) 2018-07-10
AU2016316281A1 (en) 2018-03-22
US20170056521A1 (en) 2017-03-02
TWI599372B (en) 2017-09-21
US9623118B2 (en) 2017-04-18
IL257750A (en) 2018-06-28
CA2996652A1 (en) 2017-03-09
US20170056517A1 (en) 2017-03-02
AU2016316202A8 (en) 2018-04-05
JP6709844B2 (en) 2020-06-17
CN108431045A (en) 2018-08-21
TW201712039A (en) 2017-04-01
EP3344285A1 (en) 2018-07-11
WO2017036255A1 (en) 2017-03-09
US10300104B2 (en) 2019-05-28
EP3344285A4 (en) 2019-10-09
IL257751A (en) 2018-04-30
JP2018531904A (en) 2018-11-01
CA2996653C (en) 2022-08-16
TW201710297A (en) 2017-03-16
US10293018B2 (en) 2019-05-21
JP2018527350A (en) 2018-09-20
AU2016316281B2 (en) 2018-11-15
US20170056520A1 (en) 2017-03-02
WO2017036407A1 (en) 2017-03-09
CN108431045B (en) 2022-05-13
CN108271357B (en) 2022-06-07
AU2016316202A1 (en) 2018-03-22
TW201710298A (en) 2017-03-16
IL257751B (en) 2021-07-29
TW201711703A (en) 2017-04-01

Similar Documents

Publication Publication Date Title
US10383947B2 (en) Pharmaceuticals in joint-linker configurations for treating pathological blood clots
AU2016316202B2 (en) Molecular constructs for preventing the formation of blood clot and/or treating thrombosis
AU2016264649B2 (en) Molecular constructs with targeting and effector elements and their applications
KR102361890B1 (en) Linker unit and molecular structure comprising same
JP2015535523A (en) Aprotinin-derived polypeptide-antibody conjugate
AU2018336482B2 (en) Pharmaceutical constructs with enhanced binding affinity with albumin
EP3344659A1 (en) Molecular constructs for preventing the formation of blood clot and/or treating thrombosis
US20180055946A1 (en) Versatile peptide-based multi-arm linkers for constructing pharmaceutical molecules
TW202237667A (en) Her-2 targeted bispecific compositions and methods for making and using the same
WO2021263058A1 (en) Her-2 targeted bispecific compositions and methods for making and using the same

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 32 , NO 11 , PAGE(S) 1561 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME IMMUNWORK INC., APPLICATION NO. 2016316202, UNDER INID (31) CORRECT THE NUMBER TO READ 62/213,012

FGA Letters patent sealed or granted (standard patent)